KOL | Harry Roger BüllerDepartment of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ... |
Kol Lebenslauf für Harry Roger Büller
| Year | |
|---|---|
| 2022 | Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands |
| 2021 | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.). Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.). |
| 2020 | From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.) Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands |
| 2019 | Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands |
| 2018 | Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| 2017 | Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands. From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy. |
| 2016 | Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands |
| 2015 | Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands |
| 2014 | From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.). Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and |
| 2013 | Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands Academic Medical Center, Amsterdam (H.R.B.) |
| 2012 | Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.) Vascular Medicine, AMC, Amsterdam, the Netherlands |
| 2011 | Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, From the Academic Medical Center and Slotervaart Hospital, Amsterdam |
Harry Roger Büller: Einflussstatistik
Bericht ausführen
| Concept | World rank |
|---|---|
| bleeding clinically | #1 |
| activecontrol placebo | #1 |
| heparin acenocoumarol | #1 |
| pvo ctscan | #1 |
| initial treatment patients | #1 |
| standard therapy months | #1 |
| residual thrombotic mass | #1 |
| deficiency proteins | #1 |
| einsteindvt | #1 |
| revascularisation procedures patients | #1 |
| efficacy vte | #1 |
| tb402 12 kg1 | #1 |
| cdr ddimer test | #1 |
| treatment cumulative incidence | #1 |
| sensitivity 100 percent | #1 |
| aged nadroparin | #1 |
| category fxainhibitors | #1 |
| tb402 50 | #1 |
| ufh grade 1a | #1 |
| vte study | #1 |
| treated vka | #1 |
| crptest | #1 |
| patients malignancy | #1 |
| riskstroponin | #1 |
| enoxaparin initial treatment | #1 |
| normal dimer | #1 |
| women edoxaban | #1 |
| presentation 1 week | #1 |
| carriers thrombophilic defects | #1 |
| doacs cirrhosis patients | #1 |
| idraparinux standard therapy | #1 |
| wells rule exclusion | #1 |
| apixaban randomized patients | #1 |
| normal venogram | #1 |
| animal female heparin | #1 |
| wells cdr | #1 |
| initial heparin patients | #1 |
| standard treatment idraparinux | #1 |
| warfarin cstatistic | #1 |
| anticoagulant fondaparinux | #1 |
| reduceddose noacs stroke | #1 |
| dimer clinical | #1 |
| ddimer test patients | #1 |
| elevated ctni patients | #1 |
| elevated fviii | #1 |
| coagulationinhibiting | #1 |
| d‐dimer test | #1 |
| strategies diagnostic management | #1 |
| symptomatic venous | #1 |
| echocardiography normotensive patients | #1 |
| 2 diagnostic management | #1 |
| 95ci tb402 | #1 |
| presenting location vte | #1 |
| pulmonary embolism tests | #1 |
| suspected symptomatic | #1 |
| principal safety | #1 |
| undvt | #1 |
| gentamicin patients netilmicin | #1 |
| strategy abdominal pelvic | #1 |
| simplified rule proportion | #1 |
| thromboembolism relatives | #1 |
| cstatistic major bleeding | #1 |
| patients tb402 | #1 |
| levels procoagulant factors | #1 |
| pulmonary angiography ultrasonography | #1 |
| embolism sensitivity | #1 |
| cdrscore combination | #1 |
| puerperium diagnostic suspicion | #1 |
| 378 patients edoxaban | #1 |
| questionnaires thrombosis | #1 |
| idraparinux versus | #1 |
| malignancy achieved inr | #1 |
| constans score | #1 |
| management study | #1 |
| hyperhomocysteinemia relatives | #1 |
| fviii venous thromboembolism | #1 |
| chest perfusion scintigraphy | #1 |
| dvt 56 | #1 |
| elevated fviii age | #1 |
| gastrointestinal cancer edoxaban | #1 |
| months standard therapy | #1 |
| coagulation factors markers | #1 |
| pulmonary embolism life | #1 |
| fetal loss miscarriage | #1 |
| perfusion scan | #1 |
| patients retropubic prostatectomy | #1 |
| prophylaxis idraparinux | #1 |
| suspected perfusion scan | #1 |
| neoplasms heparin | #1 |
| failure cip | #1 |
| prediction models recurrence | #1 |
| efficacy heparin therapy | #1 |
| departments pharmacological prophylaxis | #1 |
| 95 3633 patients | #1 |
| asymptomatic extension | #1 |
| presenting location women | #1 |
| initial treatment dvt | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| recurrence bleeding risk | #1 |
| amplify trial apixaban | #1 |
| suspected deep | #1 |
| venous thrombosis mutations | #1 |
| uedvt clinical | #1 |
| lmwh plasma levels | #1 |
| combined training gps | #1 |
| reported incidence vte | #1 |
| 8h flight | #1 |
| fviii homocysteine | #1 |
| dimer test | #1 |
| pulmonary embolism basis | #1 |
| warfarin cancer patients | #1 |
| ventilation lung scanning | #1 |
| low levels ft4 | #1 |
| doac recipients | #1 |
| ecq ankle brachial | #1 |
| incidental symptomatic vte | #1 |
| dose daily edoxaban | #1 |
| lmwh immobilization | #1 |
| patients examiner | #1 |
| obese hemophilic patients | #1 |
| presence venous thrombosis | #1 |
| normotensive patients studies | #1 |
| efficiency subgroups | #1 |
| patients unexplained dvt | #1 |
| patients clinical probability | #1 |
| venous thrombosis recurrence | #1 |
| relative risks carriers | #1 |
| dvt 3 | #1 |
| messages justification | #1 |
| perelated death classification | #1 |
| recurrent vte statin | #1 |
| enoxaparin primary efficacy | #1 |
| anticoagulants double | #1 |
| impedance thrombophlebitis | #1 |
| ultrasonography leg veins | #1 |
| evaluable patients apixaban | #1 |
| 95 intracranial | #1 |
| withheld | #1 |
| tsh antitpo | #1 |
| scenarioanalysis | #1 |
| thiazoles venous | #1 |
| clinical probability exclusion | #1 |
| achieved inr patients | #1 |
| 547253 | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| nadroparin patients | #1 |
| relatives antithrombin | #1 |
| time recombinant | #1 |
| oral administration bsf | #1 |
| vkas lmwh | #1 |
| quantitative ddimer testing | #1 |
| patients laalleles | #1 |
| pyridines recurrence | #1 |
| cancer patients uedvt | #1 |
| —brachial | #1 |
| rnapc2 groups placebo | #1 |
| dalteparin major bleeding | #1 |
| pulmonary angiography strategies | #1 |
| proportion 75 years | #1 |
| aptt org | #1 |
| embolism radionuclide | #1 |
| cart lower levels | #1 |
| realtime bmode ultrasonography | #1 |
| lmwhmediated | #1 |
| types major bleeding | #1 |
| international thrombosis experts | #1 |
| vitamin antagonists treatment | #1 |
| normal levels fviii | #1 |
| departments orthopedic surgery | #1 |
| factual hemorrhage heparin | #1 |
| idraparinux vte | #1 |
| patients mismatched scan | #1 |
| strategies abdominal pelvic | #1 |
| positive vte | #1 |
| ivte | #1 |
| standardintensity vkas doacs | #1 |
| hokusaivte study | #1 |
| hokusaivte trial | #1 |
| edoxaban risk factors | #1 |
| 3 rfviia | #1 |
| early discharge strategies | #1 |
| diagnostic strategy primary | #1 |
| elevated fviii patients | #1 |
| cip diagnostic management | #1 |
| recurrent vte doacs | #1 |
| idraparinux placebo | #1 |
| timerequirement | #1 |
| vka recipients | #1 |
| vka share | #1 |
| falsenormal | #1 |
| uedvt recurrent vte | #1 |
| travel venous thromboembolism | #1 |
| calfvein thrombi | #1 |
| submassive elevated ctni | #1 |
| absolute thrombotic risk | #1 |
| local radiologist experts | #1 |
| death vte studies | #1 |
| category perelated death | #1 |
| vitamin antagonists time | #1 |
| oral rivaroxaban treatment | #1 |
| patients deep | #1 |
| uesvt recurrent vte | #1 |
| wells rules | #1 |
| severe presentation patients | #1 |
| s1p1activation | #1 |
| pulmonary angiography study | #1 |
| ldf diagnosis | #1 |
| method factor | #1 |
| 123362 | #1 |
| sustained antithrombotic effects | #1 |
| nadroparin aspirin | #1 |
| normal ddimer result | #1 |
| enoxaparin vkas treatment | #1 |
| botticelli dvt dose‐ranging | #1 |
| patients reduceddose noacs | #1 |
| venous thrombosis pregnancy | #1 |
| uesvt uedvt | #1 |
| ifngamma pselectin | #1 |
| adjunct thrombolysis | #1 |
| extended treatment edoxaban | #1 |
| early time recurrence | #1 |
| cus strategies | #1 |
| prolactin venous thrombosis | #1 |
| quantitative dimer | #1 |
| lmwh users incidence | #1 |
| upper extremity uedvt | #1 |
| embolism wells | #1 |
| acenocoumarol efficacy | #1 |
| protein levels mortality | #1 |
| cancer clinical presentation | #1 |
| abelacimab | #1 |
| presentation major | #1 |
| venous thrombosis vwf | #1 |
| rule exclusion | #1 |
| annual incidence patients | #1 |
| combination nonhigh cdr | #1 |
| d‐dimer level | #1 |
| tb402 enoxaparin | #1 |
| patients acute recurrent | #1 |
| daily dalteparin treatment | #1 |
| fviii concentration | #1 |
| controlledstudy | #1 |
| fviii normal levels | #1 |
| simplified geneva score | #1 |
| selective ddimer thresholds | #1 |
| outcome clinically | #1 |
| orthopedic surgery netherlands | #1 |
| subsequent diagnosis malignancy | #1 |
| safety clinical utility | #1 |
| cdrscore | #1 |
| rfviia fondaparinux | #1 |
| older patients cdr | #1 |
| cdr dimer | #1 |
| clinical uedvt | #1 |
| patients uedvt uesvt | #1 |
| probability lung scan | #1 |
| excluding pulmonary | #1 |
| lmwh venous thrombosis | #1 |
| doacs anatomical extent | #1 |
| molecular weight fondaparinux | #1 |
| evaluable patients 95 | #1 |
| safety idraparinux | #1 |
| noncarriers annual incidence | #1 |
| compression ultrasonography patients | #1 |
| khorana | #1 |
| ultrasound compression ultrasound | #1 |
| patients compression ultrasonography | #1 |
| included patients study | #1 |
| single‐detector row | #1 |
| subcutaneous nadroparin placebo | #1 |
| clinically suspected cancer | #1 |
| followup overt cancer | #1 |
| preference doacs | #1 |
| pharmacological methods prophylaxis | #1 |
| scan pulmonary embolism | #1 |
| 6 months avidin | #1 |
| vte arterial | #1 |
| ivte clinical practice | #1 |
| 0·620·74 | #1 |
| ddimer levels cdr | #1 |
| successful attenuation | #1 |
| fviii hyperhomocysteinemia | #1 |
| 023 relatives | #1 |
| placebo rnapc2 | #1 |
| ankle brachial prevalence | #1 |
| compression ultrasound dvt | #1 |
| practiceassistants | #1 |
| pvo qscan | #1 |
| preferred oral anticoagulant | #1 |
| netherlands vka | #1 |
| org heparin | #1 |
| 9 incidence | #1 |
| rabinov | #1 |
| original wells | #1 |
| beneficial lmwh | #1 |
| netherlands 5 years | #1 |
| uedvt terms | #1 |
| patients treatment duration | #1 |
| thrombophilia late loss | #1 |
| diagnosis deepvein thrombosis | #1 |
| relatives normal levels | #1 |
| cancer patients cvcs | #1 |
| incidence venous | #1 |
| tests venography | #1 |
| extended anticoagulation doacs | #1 |
| mutation arg506 | #1 |
| lowmolecularweight heparin 95 | #1 |
| vte airline pilots | #1 |
| failure rate efficiency | #1 |
| 5 years lmwh | #1 |
| timeperiod | #1 |
| edoxaban warfarin groups | #1 |
| plasma concentration fviii | #1 |
| elderly patients dvt | #1 |
| models development studies | #1 |
| heparinoid | #1 |
| deep vein thrombosis | #1 |
| death category | #1 |
| 3 idraparinux | #1 |
| control anticardiolipin antibodies | #1 |
| distal clots | #1 |
| alternative diagnoses patients | #1 |
| synthetic selective factor | #1 |
| vte location | #1 |
| cdr ddimer levels | #1 |
| heparins data | #1 |
| polyethylenglycolhirudin | #1 |
| elevated cardiac troponins | #1 |
| total vte patients | #1 |
| thrombo‐embolic events | #1 |
| matisse clinical trials | #1 |
| rfviia idraparinux | #1 |
| tinaquant assay comparison | #1 |
| fondaparinux unfractionated | #1 |
| probability ventilation | #1 |
| casedescription | #1 |
| qscan | #1 |
| diagnostic strategies patients | #1 |
| milliliter enoxaparin | #1 |
| xainhibitors | #1 |
| clinical decision rule | #1 |
| anticoagulants chemotherapy | #1 |
| exclusion pulmonary | #1 |
| intensity vkas doacs | #1 |
| idrabiotaparinux idraparinux | #1 |
| cdr normal | #1 |
| acute recurrent patients | #1 |
| heparin vitamin antagonist | #1 |
| women elevated levels | #1 |
| respondents 60 | #1 |
| ddimer test combination | #1 |
| edoxaban cancer patients | #1 |
| avws prevalence | #1 |
| symptomatic legs dvt | #1 |
| travellers thrombosis | #1 |
| diagnostic strategies strategies | #1 |
| ultrasonography diagnostic | #1 |
| cancer 145 patients | #1 |
| combination cdrs | #1 |
| 5mg apixaban | #1 |
| patients artificial graft | #1 |
| patients advanced prostate | #1 |
| vte risk day | #1 |
| strategies ultrasonography | #1 |
| 50 years combination | #1 |
| mutation relatives | #1 |
| heparins vitamin antagonists | #1 |
| compression ultrasonography presentation | #1 |
| rabinovpaulin | #1 |
| fetal loss stillbirth | #1 |
| baseline characteristics duration | #1 |
| cdr physicians | #1 |
| 12 kg1 enoxaparin | #1 |
| 7268 patients | #1 |
| idraparinux months | #1 |
| elderly outpatients combination | #1 |
| travel‐related venous thrombosis | #1 |
| intravenous injections lmwh | #1 |
| dose response apixaban | #1 |
| 7268 patients suspected | #1 |
| isolated deficiencies proteins | #1 |
| fviii women | #1 |
| rnapc2 groups | #1 |
| matisse trials | #1 |
| false normal | #1 |
| lmwh edoxaban | #1 |
| ldfr symptomatic legs | #1 |
| carriers relative risks | #1 |
| abdominal pelvic strategies | #1 |
| 5395 patients | #1 |
| death venous thromboembolism | #1 |
| test venography | #1 |
| sspe proximal | #1 |
| infections gentamicin | #1 |
| coagulation fibrinolytic proteins | #1 |
| intracranial clinical presentation | #1 |
| duration heparin treatment | #1 |
| sgs pretest probability | #1 |
| presentation category | #1 |
| hokusai‐vte trial | #1 |
| prothrombin 20210a mutation | #1 |
| relatives tafi levels | #1 |
| rnapc2 inhibition | #1 |
| pulmonary embolism metaanalysis | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| studies doac treatment | #1 |
| 12 months edoxaban | #1 |
| avidin idrabiotaparinux | #1 |
| treatment venous | #1 |
| fondaparinux rfviia injection | #1 |
| heparin initial | #1 |
| pulmonary embolism cdr | #1 |
| cancer edoxaban | #1 |
| outpatients symptomatic dvt | #1 |
| wellscdr | #1 |
| dalteparin 6 months | #1 |
| apixaban extended treatment | #1 |
| replacement vka | #1 |
| enoxaparin tb402 | #1 |
| oral anticoagulants phase | #1 |
| pulmonary embolism role | #1 |
| equinox study | #1 |
| safety outcome | #1 |
| dvt impedance plethysmography | #1 |
| local radiologist | #1 |
| mortality postthrombotic symptoms | #1 |
| pioped study study | #1 |
| scores occult cancer | #1 |
| leg ultrasonography patients | #1 |
| vka treatment treatment | #1 |
| plateletactivating antibodies risk | #1 |
| hokusai‐vte cancer study | #1 |
| pulmonary embolism idraparinux | #1 |
| initial heparin edoxaban | #1 |
| smoking graft patency | #1 |
| dimer result | #1 |
| previous surveys netherlands | #1 |
| aptt org 10172 | #1 |
| protecht shr | #1 |
| uesvt mortality | #1 |
| unexplained dvt patients | #1 |
| treat thrombosis | #1 |
| year prophylaxis | #1 |
| laalleles platelets | #1 |
| progression svt | #1 |
| ventilation scan chest | #1 |
| uesvt patients | #1 |
| bleeding rates quality | #1 |
| nondiagnostic lung scan | #1 |
| crp test patients | #1 |
| randomized studies efficacy | #1 |
| oral edoxaban dose | #1 |
| wells clinical | #1 |
| elevated levels fviii | #1 |
| wellsrule | #1 |
| vka netherlands | #1 |
| age∗10μg | #1 |
| individuals air travel | #1 |
| atherosclerosis hemophilia patients | #1 |
| vitamin anticoagulants | #1 |
| thromboembolism treated | #1 |
| severity clinical presentation | #1 |
| venous thrombus growth | #1 |
| procoagulant factors levels | #1 |
| simplified wells rule | #1 |
| 2630 pilots | #1 |
| bleeding risk lmwh | #1 |
| rivaroxaban replacement | #1 |
| recurrent dvt dvt | #1 |
| poc test patients | #1 |
| association travel | #1 |
| obstetric complications relatives | #1 |
| factor viii homocysteine | #1 |
| hokusai vte cancer | #1 |
| doacs initial heparin | #1 |
| cancer patients cancer | #1 |
| superficial thrombophlebitis incidence | #1 |
| ili score | #1 |
| rule cdr | #1 |
| postthrombotic symptoms patients | #1 |
| probability cdr | #1 |
| silent dvt | #1 |
| 53 amputations | #1 |
| loss subsequent pregnancy | #1 |
| united states rnapc2 | #1 |
| probability categories | #1 |
| increasing levels ft4 | #1 |
| individualized duration | #1 |
| popliteal veins sensitivity | #1 |
| nadroparin therapeutic dose | #1 |
| aged venous | #1 |
| standalone ddimer testing | #1 |
| excluded pulmonary | #1 |
| ddimer test result | #1 |
| idraparinux recurrent thromboembolism | #1 |
| 65±9years | #1 |
| longhaul flight | #1 |
| variable d‐dimer thresholds | #1 |
| proximal extent ipe | #1 |
| 208791 | #1 |
| clinical probability patients | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| rnapc2 united states | #1 |
| suspected cdr | #1 |
| 5‐snp scores | #1 |
| prevalence coagulation | #1 |
| ddimer result | #1 |
| relevant bleeding | #1 |
| cancer patients patients | #1 |
| ambulatory computers | #1 |
| edoxaban east asian | #1 |
| anticoagulants probability | #1 |
| screening carriers | #1 |
| age multiple comorbidities | #1 |
| subsequent symptomatic cancer | #1 |
| consensus strategy strategy | #1 |
| noacs prevention | #1 |
| hellp syndrome mutations | #1 |
| 25mg apixaban | #1 |
| limited screening 95 | #1 |
| pulmonary embolism fondaparinux | #1 |
| decisions duration | #1 |
| ufh grade | #1 |
| pvoq | #1 |
| vte occurred | #1 |
| heparin vitamin | #1 |
| heparins cancer spread | #1 |
| dvt 69 | #1 |
| p0424 | #1 |
| clinical presentation category | #1 |
| idraparinux 6 months | #1 |
| dalteparin vte treatment | #1 |
| thrice daily gentamicin | #1 |
| failure diagnostic management | #1 |
| survival fondaparinux | #1 |
| diagnostic management patients | #1 |
| hokusaivte trial patients | #1 |
| intravenous unfractionated | #1 |
| placebo 25mg apixaban | #1 |
| idraparinux 25 | #1 |
| patients khorana | #1 |
| adjusted dose ufh | #1 |
| progression vte | #1 |
| 500 org | #1 |
| apixaban conventional therapy | #1 |
| protein resistance control | #1 |
| predefined outcomes vte | #1 |
| beta thromboglobulin org | #1 |
| venous thromboembolism edoxaban | #1 |
| prescriptionbased | #1 |
| clinically relevant disease | #1 |
| tests pulmonary embolism | #1 |
| rnapc2 patients | #1 |
| platelets iqr | #1 |
| 36 papers | #1 |
| ctscanreading | #1 |
| ft4 level patients | #1 |
| scores riete score | #1 |
| tomography angiography vte | #1 |
| lmwh acute treatment | #1 |
| laalleles | #1 |
| reduceddose noacs | #1 |
| 0·2 3633 patients | #1 |
| vte difference | #1 |
| advanced malignancy | #1 |
| prevention topic guidelines | #1 |
| wellscdrscore | #1 |
| patients advanced malignancy | #1 |
| enoxaparin heparin treatment | #1 |
| fviii vte | #1 |
| thrombophlebitis tomography | #1 |
| xageneration | #1 |
| einstein dvt patients | #1 |
| ccus 4 | #1 |
| relevant major | #1 |
| idraparinux vitamin antagonist | #1 |
| vitamin antagonist patients | #1 |
| leg veins patients | #1 |
| factor viii relatives | #1 |
| relatives normal fviii | #1 |
| 560 pharmacies | #1 |
| prophylaxis crt | #1 |
| extended anticoagulation apixaban | #1 |
| heparins cancer patients | #1 |
| analysis hokusai | #1 |
| ipe expert radiologists | #1 |
| 5 avidin infusion | #1 |
| rate recurrent | #1 |
| 393 patients warfarin | #1 |
| carriers recurrence | #1 |
| combination ddimer testing | #1 |
| p0001 saline | #1 |
| recurrent thrombosis pts | #1 |
| dvt symptomatic | #1 |
| thrombosis vitamin | #1 |
| vte trial | #1 |
| administration lmwh | #1 |
| pregnancyrelated complications relatives | #1 |
| patients ivte | #1 |
| intestinal microbiota coagulation | #1 |
| smoking patency | #1 |
| major bleeding cancer | #1 |
| clinically suspected dvt | #1 |
| rivaroxaban dvt treatment | #1 |
| dose rnapc2 | #1 |
| long haul flights | #1 |
| level loss patency | #1 |
| 0·2 edoxabantreated | #1 |
| wells simplified | #1 |
| inr studies | #1 |
| controlled trials thrombophilia | #1 |
| ddimer test | #1 |
| embolism randomized | #1 |
| heparin org 10172 | #1 |
| ml1 ctpa | #1 |
| somittrial | #1 |
| bleeding einstein | #1 |
| lmwhs 95 | #1 |
| lmprovement | #1 |
| acenocoumarol heparin | #1 |
| rivaroxaban acute dvt | #1 |
| antithrombotic prescriptions adherence | #1 |
| vte procoagulant activity | #1 |
| double heterozygous carriers | #1 |
| relatives mutation | #1 |
| unexplained dvt | #1 |
| age recurrent vte | #1 |
| acute treatment lmwh | #1 |
| safety 60 dose | #1 |
| rule dimer | #1 |
| single dose tb402 | #1 |
| graft patency patency | #1 |
| baseline pvo | #1 |
| ultrasound strategies patients | #1 |
| prospective management study | #1 |
| fetal loss carriers | #1 |
| risk pulmonary embolism | #1 |
| avidin placebo | #1 |
| rfviia 3 | #1 |
| calf dvt ultrasound | #1 |
| edoxaban dalteparin | #1 |
| perelated death category | #1 |
| symptomatic recurrent vte | #1 |
| cstatistic model discrimination | #1 |
| endotoxemia tests | #1 |
| carriers pulmonary embolism | #1 |
| thromboembolism 3 | #1 |
| oral apixaban treatment | #1 |
| efficacy conventional treatment | #1 |
| heparin initial treatment | #1 |
| 3633 patients edoxabantreated | #1 |
| simple diagnostic strategy | #1 |
| fxainhibitors vka recipients | #1 |
| wound haematoma | #1 |
| doacs factor | #1 |
| 3633 patients edoxaban | #1 |
| influenza case patients | #1 |
| anticoagulant treatment patients | #1 |
| chest perfusion scan | #1 |
| quantitative ddimer tests | #1 |
| heparin survival | #1 |
| systematic search cteph | #1 |
| nonhigh cdr | #1 |
| rivaroxaban standard therapy | #1 |
| netherlands lmwh | #1 |
| einsteinextension | #1 |
| anticoagulation period | #1 |
| segmental subsegmental | #1 |
| tests prevalence abi | #1 |
| pulmonary embolism carriers | #1 |
| quantitative ddimer test | #1 |
| monoclonal antibodies apc | #1 |
| patients tests prevalence | #1 |
| proportion pulmonary embolism | #1 |
| threemonth incidence | #1 |
| elevated biomarkers hospital | #1 |
| abnormal ipg | #1 |
| enoxaparin vkas | #1 |
| recommendations dvt | #1 |
| embolism suspected | #1 |
| vte risk coc | #1 |
| fxainhibitors | #1 |
| 00515 | #1 |
| comparison vidas assay | #1 |
| compression ultrasonography detection | #1 |
| patency smokers | #1 |
| association protein levels | #1 |
| venous thrombosis hyperglycemia | #1 |
| 20210a mutation | #1 |
| current comprehensions | #1 |
| probabilityscan | #1 |
| non‐invasive diagnostic work‐up | #1 |
| extensive screening cancer | #1 |
| cdrs patients | #1 |
| thrombophilia patients doacs | #1 |
| feasibility venography | #1 |
| svt lmwh | #1 |
| org aptt | #1 |
| guideline adherence justification | #1 |
| thrombosis vte | #1 |
| intrinsic coagulation vivo | #1 |
| compression ultrasonography | #1 |
| standard therapy rivaroxaban | #1 |
| easier monitoring | #1 |
| antidote vitamin | #1 |
| respondents lmwh | #1 |
| therapeutic doses lmwh | #1 |
| recurrent vte immobilization | #1 |
| treatment experimental thrombosis | #1 |
| patients inherited thrombophilia | #1 |
| treatment idraparinux | #1 |
| idraparinux | #1 |
| lmwh delivery | #1 |
| desogestrelcontaining coagulation factors | #1 |
| ultrasonography dvt | #1 |
| pulmonary embolism studies | #1 |
| cvc crt | #1 |
| doubleheterozygotes | #1 |
| flebography | #1 |
| heparins inhibition | #1 |
| weight heparinoid | #1 |
| selective beta‐blocker treatment | #1 |
| chromogenic endotoxin | #1 |
| absolute annual incidences | #1 |
| wells rule primary | #1 |
| mdct expert radiologist | #1 |
| avidin vte | #1 |
| anticoagulant treatment vte | #1 |
| members symptomatic carriers | #1 |
| tb402 prevention | #1 |
| obese controls difference | #1 |
| coagulation clinical | #1 |
| outcome recurrent | #1 |
| 250 patients cancer | #1 |
| patients normal tests | #1 |
| ventricular dysfunction edoxaban | #1 |
| abnormal vaginal bleeding | #1 |
| venous thromboembolism episode | #1 |
| lowmolecularweight heparin category | #1 |
| bmi fondaparinux | #1 |
| venography feasibility | #1 |
| risk percentage points | #1 |
| axa activity 5 | #1 |
| cancer patients ufh | #1 |
| combination cdr | #1 |
| 15 lmwh | #1 |
| submassive incidence | #1 |
| 69 conclusions | #1 |
| 50 rivaroxaban | #1 |
| hemorrhage heparin | #1 |
| bleeding risk treatment | #1 |
| inherited thrombophilia patients | #1 |
| patients idraparinux | #1 |
| symptomatic pts | #1 |
| role exclusion | #1 |
| current practise | #1 |
| rtap lmwh | #1 |
| orthopedic thromboprophylaxis | #1 |
| vivo coagulation factor | #1 |
| study ecq | #1 |
| apc resistance tests | #1 |
| uesvt median | #1 |
| fxiaso enoxaparin | #1 |
| fibrinolysis levels | #1 |
| patients protein deficiencies | #1 |
| dvt anticoagulants | #1 |
| patients wells rule | #1 |
| probability normal | #1 |
| incidence ctni | #1 |
| acquired atiii deficiency | #1 |
| cancer patients cdr | #1 |
| prothrombin individuals | #1 |
| 750 μg l1 | #1 |
| recurrence major bleeding | #1 |
| standardintensity vkas | #1 |
| referral basis | #1 |
| patients antithrombotic prescriptions | #1 |
| pulmonary embolism | #1 |
| lmwh departments | #1 |
| rhir lmwh | #1 |
| doses 75 microg | #1 |
| clinically suspected uedvt | #1 |
| iii plg | #1 |
| category death | #1 |
| idraparinux patients | #1 |
| lowmolecularweight heparin treatment | #1 |
| survival lmwh | #1 |
| amplify trial | #1 |
| dvt costs | #1 |
| symptomatic recurrent | #1 |
| conventional therapy enoxaparin | #1 |
| lmwh replacement | #1 |
| reduceddose noacs warfarin | #1 |
| crt cvc | #1 |
| studies 3 months | #1 |
| combination cdrscore | #1 |
| ctscan qscan | #1 |
| edoxabantreated | #1 |
| vkas efficacy | #1 |
| uesvt | #1 |
| double reports | #1 |
| 95 elevated ctni | #1 |
| protein mortality | #1 |
| 97 compression ultrasonography | #1 |
| lmwh rtap | #1 |
| clinical probability risk | #1 |
| vte fatal | #1 |
| 2479 relatives | #1 |
| risk homozygous women | #1 |
| efficacy outcome | #1 |
| patients enoxaparin vkas | #1 |
| subcutaneous idraparinux | #1 |
| acenocoumarol initial treatment | #1 |
| major bleeds vka | #1 |
| normal ddimer concentration | #1 |
| inr range ttr | #1 |
| matisse dvt | #1 |
| patients initial heparin | #1 |
| presenting vte location | #1 |
| normal lung scan | #1 |
| study centre duration | #1 |
| deepvein thrombosis incidence | #1 |
| qscan 3 weeks | #1 |
| frequency venous thromboembolism | #1 |
| venous thromboembolism idraparinux | #1 |
| relatives elevated levels | #1 |
| extra hospital visits | #1 |
| specificity pulmonary embolism | #1 |
| venography tests | #1 |
| apc resistance factor | #1 |
| reocclusion antithrombotic drug | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| phase doacs | #1 |
| cancer cdr | #1 |
| proximal location ipe | #1 |
| studies ttr | #1 |
| ldf cus | #1 |
| women factor leiden | #1 |
| topic thrombophlebitis | #1 |
| subcutaneous length life | #1 |
| guidelines abi | #1 |
| rivaroxaban lmwh vka | #1 |
| gogh dvt trial | #1 |
| predefined outcomes | #1 |
| vte day | #1 |
| vte addition | #1 |
| enoxaparin difference | #2 |
| travel venous | #2 |
| computerized impedance | #2 |
| mutations cleavage sites | #2 |
| mutations propeptide | #2 |
| symptomatic outpatients | #2 |
| impedance plethysmography patients | #2 |
| absolute incidence | #2 |
| beta‐receptor blockade | #2 |
| major bleeding intermediate | #2 |
| ufh survival | #2 |
| model cancer patients | #2 |
| vte 1000 personyears | #2 |
| deficiencies proteins | #2 |
| fibrinolytic proteins | #2 |
| heparin effective | #2 |
| exclude pulmonary | #2 |
| suspected upper | #2 |
| serum tnf activity | #2 |
| exposure flights | #2 |
| nematode anticoagulant | #2 |
| referred patients secondary | #2 |
| statins recurrent vte | #2 |
| global public awareness | #2 |
| adapted ddimer thresholds | #2 |
| standardised time intervals | #2 |
| low‐molecular‐weight heparin | #2 |
| failure rate strategy | #2 |
| levels coagulation factors | #2 |
| recurrent deep | #2 |
| rfviia injection rfviia | #2 |
| pulmonary embolism asthma | #2 |
| ddimer assay | #2 |
| intrinsic cascade | #2 |
| major bleeding cindexes | #2 |
| central localization | #2 |
| exclusion pulmonary embolism | #2 |
| vitamin antagonist rivaroxaban | #2 |
| negative ageadjusted ddimer | #2 |
| embolism safely | #2 |
| raskob | #2 |
| heparin compounds | #2 |
| euro138 | #2 |
| 20210a mutations | #2 |
| test cancer | #2 |
| prolactin relation | #2 |
| comparator individuals 95 | #2 |
| fibrinolysis influenza | #2 |
| computed venous | #2 |
| relevant patient subgroups | #2 |
| limits cancer | #2 |
| lowmolecularweight heparin women | #2 |
| lmwh efficacy | #2 |
| outcome symptomatic | #2 |
| compression doppler | #2 |
| simplified wells | #2 |
| pulmonary embolism purpose | #2 |
| embolism deep | #2 |
| wells cdr cdr | #2 |
| pulmonary embolism efficacy | #2 |
| 17 apixaban | #2 |
| recurrence thromboembolism | #2 |
| clinical prediction model | #2 |
| apixaban lmwh vka | #2 |
| duration anticoagulant | #2 |
| treated anticoagulants | #2 |
| intermediate phenotype vte | #2 |
| 95 0·2 | #2 |
| subcutaneous length | #2 |
| secondary efficiency | #2 |
| angioplasty clopidogrel | #2 |
| levothyroxine exposure | #2 |
| patients abi measurement | #2 |
| biomarkers casecontrol studies | #2 |
| subsegmental emboli | #2 |
| idraparinux vitamin | #2 |
| pregnancy venous thrombosis | #2 |
| patients hemorr2hages | #2 |
| arterial thrombotic disease | #2 |
| venographically | #2 |
| coagulation factors prolactin | #2 |
| uedvt performance | #2 |
| extended constans score | #2 |
| incidental vte | #2 |
| amuse strategy | #2 |
| thrombophilic defects risk | #2 |
| patients prior vte | #2 |
| thrombophilic disorders | #2 |
| anticoagulated patients permanent | #2 |
| nonpermanent heart failure | #2 |
| blood coagulation rnapc2 | #2 |
| alife study | #2 |
| endotoxininduced activation coagulation | #2 |
| impedance plethysmography diagnosis | #2 |
| scan normal | #2 |
| prothrombin pulmonary embolism | #2 |
| vein compressibility | #2 |
| decision rule | #2 |
| uptake noacs | #2 |
| normohomocysteinemic relatives | #2 |
| factor iia | #2 |
| risk anticoagulation therapy | #2 |
| uedvt efficiency | #2 |
| treated edoxaban | #2 |
| surgical casts | #2 |
| venous thrombophlebitis | #2 |
| thrombosis normal | #2 |
| ageadjusted ddimer testing | #2 |
| gauge plethysmography | #2 |
| efficiency strategy | #2 |
| c1173t dimorphism | #2 |
| age‐adjusted d‐dimer testing | #2 |
| n832 | #2 |
| oral direct inhibitors | #2 |
| common alternative diagnoses | #2 |
| pentasaccharide fondaparinux | #2 |
| heparin nadroparin | #2 |
| acquired antithrombin | #2 |
| administration rviia | #2 |
| vidas assay | #2 |
| patients khorana score | #2 |
| concomitant thrombophilic | #2 |
| vitamin antagonists quality | #2 |
| simplired test | #2 |
| amadeus study | #2 |
| women therapeutic doses | #2 |
| bleeding complications treatment | #2 |
| lmwh users | #2 |
| 8 wk risk | #2 |
| principal safety outcome | #2 |
| life treatment duration | #2 |
| tinaquant vidas | #2 |
| major bleeding recurrent | #2 |
| gcpg | #2 |
| clinical probability estimate | #2 |
| thromboinflammation cardiovascular disease | #2 |
| resource utilisation treatment | #2 |
| cdr variables cdr | #2 |
| blood coagulation inhibition | #2 |
| hellp syndrome prevalence | #2 |
| healthcare settings findings | #2 |
| death vte | #2 |
| incidental venous | #2 |
| major clinically | #2 |
| n1423 | #2 |
| vte elevated fviii | #2 |
| 95 cancer patients | #2 |
| crd42017056309 | #2 |
| pharmacological strategies | #2 |
| patients peripheral graft | #2 |
| heparin treatment influenza | #2 |
| fvl carriers carriers | #2 |
| patients low probability | #2 |
| enoxaparin warfarin | #2 |
| score dimer | #2 |
| pregnancy coc | #2 |
| suspected pulmonary | #2 |
| venous | #2 |
| 95 comparator individuals | #2 |
| mdct reference standard | #2 |
| rule proportion | #2 |
| presentation dvt | #2 |
| venous thromboembolism enoxaparin | #2 |
| current clinical challenges | #2 |
| pravastatin therapy children | #2 |
| diagnostic lung | #2 |
| primary healthcare secondary | #2 |
| mutation 35 | #2 |
| inflammation neutrophils thrombosis | #2 |
| clinical pretest probability | #2 |
| rivaroxaban thiazoles | #2 |
| months 25 | #2 |
| years 36 | #2 |
| sr34006 | #2 |
| duration anticoagulant treatment | #2 |
| efficiency original score | #2 |
| normal ddimer test | #2 |
| fviii increased risk | #2 |
| primary efficacy outcome | #2 |
| primary hospitalbased strategies | #2 |
| relation coagulation factors | #2 |
| influenza prothrombotic state | #2 |
| protein rnapc2 | #2 |
| suspected pulmonary embolism | #2 |
| safety pravastatin therapy | #2 |
| heparin administered | #2 |
| hokusai vte | #2 |
| wells cdr patients | #2 |
| secondary strategies | #2 |
| patients oral factor | #2 |
| sspe patients patients | #2 |
| plasmin activity inhibition | #2 |
| coumarin sensitivity | #2 |
| efficiency diagnostic strategies | #2 |
| hmb primary outcome | #2 |
| antagonists vka | #2 |
| 3306 patients | #2 |
| hemorr2hages atria scores | #2 |
| thyroid hormone coagulation | #2 |
| hospitalbased strategies | #2 |
| screening fvl | #2 |
| lower clinical utility | #2 |
| uedvt cancer patients | #2 |
| graft occlusion patients | #2 |
| analysis venous | #2 |
| interleukin‐10 response | #2 |
| major bleeding edoxaban | #2 |
| rule combined | #2 |
| influenza coagulation | #2 |
| 6 months scores | #2 |
| rnapc2 doses | #2 |
| embolism primary | #2 |
| hyperglycemia diagnosis | #2 |
| ate cancer patients | #2 |
| employees longhaul flight | #2 |
| mild risk factor | #2 |
| cdr wells cdr | #2 |
| events severe | #2 |
| single administration tb402 | #2 |
| plasma concentrations endotoxin | #2 |
| hasbled score hemorr2hages | #2 |
| clinically suspected | #2 |
| endogenous activated protein | #2 |
| khorana protecht | #2 |
| ddimer determination | #2 |
| vte 12 | #2 |
| risk khorana | #2 |
| cancer addition | #2 |
| cha2ds2vasc nri | #2 |
| recombinant nematode | #2 |
| f5 r506q | #2 |
| regression pravastatin | #2 |
| measurement ankle brachial | #2 |
| risk deep | #2 |
| nct00633893 | #2 |
| medscape | #2 |
| thromboembolism thrombophilia | #2 |
| composite scores area | #2 |
| received edoxaban | #2 |
| rivaroxaban 30 bid | #2 |
| performance constans rule | #2 |
| apixaban enoxaparin warfarin | #2 |
| warfarintreated | #2 |
| treatment ttr | #2 |
| recurrent vte risk | #2 |
| coagulation fibrinolytic | #2 |
| rnapc2 | #2 |
| recombinant hirudin cgp | #2 |
| undiagnosed malignancy | #2 |
| bleeding edoxaban | #2 |
| ultrasonography patients | #2 |
| dimer thresholds | #2 |
| 95 dvt | #2 |
| 8292 patients | #2 |
| crnm bleeds | #2 |
| brain metastases doacs | #2 |
| ventilation scanning | #2 |
| incidence recurrent | #2 |
| treatment deep | #2 |
| bleeding rate patients | #2 |
| vte svt | #2 |
| quality warfarin treatment | #2 |
| bleeding occurred | #2 |
| cancer recurrent vte | #2 |
| annual incidences | #2 |
| fibrinolysis pentoxifylline | #2 |
| vte orthopedic surgery | #2 |
| plasma d‐dimer concentration | #2 |
| ufh 6 months | #2 |
| sustained antithrombotic | #2 |
| hokusai vtecancer study | #2 |
| simplified wells specificity | #3 |
| atria hemorr2hages | #3 |
| dose reduction edoxaban | #3 |
| tfindependent | #3 |
| diagnosis pulmonary | #3 |
| nadroparin placebo | #3 |
| proximalvein thrombosis | #3 |
| selectine | #3 |
| 12month study period | #3 |
| cancer active cancer | #3 |
| venous thrombosis cancer | #3 |
| inhibition blood coagulation | #3 |
| venous thrombosis positive | #3 |
| vte venous thrombosis | #3 |
| gestalt 95 | #3 |
| placebo n4 | #3 |
| diagnosis deep | #3 |
| cdr combination | #3 |
| topic heparin heparin | #3 |
| venous arterial | #3 |
| 3633 patients | #3 |
| pulmonary embolism‐related death | #3 |
| treatment vitamin antagonists | #3 |
| nct00643201 | #3 |
| factor viiic | #3 |
| idiopathic venous | #3 |
| treatment low | #3 |
| fxiaso | #3 |
| patients 6 months | #3 |
| tinaquant assay | #3 |
| thromboembolism low | #3 |
| heparin edoxaban | #3 |
| mechanisms heparin | #3 |
| influence heparins | #3 |
| vte 3 | #3 |
| bleeding major | #3 |
| vte performance | #3 |
| approaches primary | #3 |
| lmwh | #3 |
| clinical models patients | #3 |
| impedance predictive | #3 |
| ctnt risk stratification | #3 |
| detection dvt | #3 |
| treatment vte recurrence | #3 |
| safely | #3 |
| healthy donor fmt | #3 |
| 02011 | #3 |
| definition perelated death | #3 |
| compensated dic | #3 |
| therapy venous | #3 |
| tb‐402 | #3 |
| safely excluded | #3 |
| predictable pharmacokinetics | #3 |
| patients ft4 level | #3 |
| wells rule dvt | #3 |
| patients wells | #3 |
| outpatient treatment dvt | #3 |
| baseline values placebo | #3 |
| studies cus strategies | #3 |
| introduction mdct | #3 |
| “gestalt | #3 |
| pulmonary embolism primary | #3 |
| ultrasonography strategies | #3 |
| subcutaneous fondaparinux | #3 |
| 6575 years | #3 |
| negative predictive proportion | #3 |
| primary wells rule | #3 |
| cohort study employees | #3 |
| einstein patients | #3 |
| factors prothrombin | #3 |
| dimer blood | #3 |
| protein thrombophilia | #3 |
| dvt major | #3 |
| travel venous thrombosis | #3 |
| deep vein | #3 |
| activecontrol | #3 |
| antithrombin iii concentrate | #3 |
| failurerate | #3 |
| cancer randomised trials | #3 |
| recombinant hirudin rhir | #3 |
| svt vte | #3 |
| dvt einstein | #3 |
| patients 6575 years | #3 |
| crt cancer patients | #3 |
| alternative diagnoses | #3 |
| venous thromboembolism apixaban | #3 |
| pulmonary embolism models | #3 |
| dvt systematic differences | #3 |
| thromboembolism background | #3 |
| apc protective | #3 |
| einstein studies | #3 |
| incidence total vte | #3 |
| bleeding 3 | #3 |
| treatment vka | #3 |
| patients ultrasonography | #3 |
| thombosis | #3 |
| gestalt probability | #3 |
| hokusai‐vte | #3 |
| mutation venous | #3 |
| wells rule gestalt | #3 |
| dalteparin difference | #3 |
| adult patients vte | #3 |
| female hemorrhage humans | #3 |
| female humans inhibitors | #3 |
| primary rule | #3 |
| patients venography | #3 |
| capillary blood sample | #3 |
| patients proximalvein thrombosis | #3 |
| patients gastrointestinal cancer | #3 |
| endogenous apc | #3 |
| users incidence | #3 |
| stable acute | #3 |
| enoxaparin follow | #3 |
| hasbled | #3 |
| presenting location | #3 |
| death clinical studies | #3 |
| dvt hip | #3 |
| low probability models | #3 |
| incidental pulmonary embolism | #3 |
| einstein dvt | #3 |
| embolism‐related | #3 |
| 95 wells rule | #3 |
| ft4 risk | #3 |
| patients incidental vte | #3 |
| venous thromboembolism thrombophilia | #3 |
| prevalence hemostatic abnormalities | #3 |
| outcome venous | #3 |
| venous thrombosis travel | #3 |
| pad smokers | #3 |
| desogestrelcontaining | #3 |
| dvt primary | #3 |
| thiophenes venous | #3 |
| recurrent thromboembolic | #3 |
| diagnosis pulmonary embolism | #3 |
| knee factor | #3 |
| extensive screening | #3 |
| heparins cancer | #3 |
| ddimer assays | #3 |
| sensitivity compression | #3 |
| treatment lowmolecularweight heparin | #3 |
| strategies efficiency | #3 |
| revised geneva efficiency | #3 |
| thrombophilic defect | #3 |
| standard therapy treatment | #3 |
| discontinuation ufh | #3 |
| efficacy heparin | #3 |
| ventilation scan | #3 |
| outpatients dvt | #3 |
| ddimer threshold | #3 |
| time venous thrombosis | #3 |
| normal ctnt presentation | #3 |
| cardiac troponine | #3 |
| studies hemorrhage | #3 |
| oral hormonal cross | #3 |
| 3month incidence | #3 |
| vte major burden | #3 |
| warfarin subgroup | #3 |
| pph lmwh | #3 |
| age annual incidence | #3 |
| normal result | #3 |
| vein thrombosis | #3 |
| lowmolecularweight heparin placebo | #3 |
| 3month vte incidence | #3 |
| monoclonal replacement | #3 |
| combination wells score | #3 |
| dip placebo | #3 |
| venous thromboembolism | #3 |
| coagulation influence | #3 |
| vte denmark | #3 |
| intravenous loading dose | #3 |
| single diagnostic | #3 |
| older children vte | #3 |
| cancer patients ate | #3 |
| chemotherapy prophylaxis | #3 |
| prolactin controls | #3 |
| multiple comorbidities polypharmacy | #3 |
| subcutaneous lmwh | #3 |
| idrabiotaparinux | #3 |
| rnapc2 fviia | #3 |
| hf severity risk | #3 |
| axa activity | #3 |
| lmwh pph | #3 |
| coagulation air travel | #3 |
| patients venous | #3 |
| pulmonary embolism gestalt | #3 |
| administration rnapc2 | #3 |
| iii deficiency | #3 |
| idrabiotaparinux warfarin | #3 |
| composite stroke | #3 |
| heparin heparin | #3 |
| probability dimer | #3 |
| prevalence avws | #3 |
| incidence enoxaparin | #3 |
| plethysmography impedance | #3 |
| favour lmwh | #3 |
| 20210ga | #3 |
| cancer patients ipe | #3 |
| ipe cancer patients | #3 |
| 100 years year | #3 |
| vte low | #3 |
| recurrence thrombophlebitis | #3 |
| safety acenocoumarol | #3 |
| platelet agents | #3 |
| lowmolecularweight humans length | #3 |
| safely exclude | #3 |
| products follow | #3 |
| thrombophlebitis treatment | #3 |
| sankyo | #4 |
| protecht | #4 |
| primary pulmonary embolism | #4 |
| edoxaban patients | #4 |
| 3587 | #4 |
| diagnostic management strategies | #4 |
| thromboembolism treatment | #4 |
| lowmolecular weight heparins | #4 |
| patients fondaparinux | #4 |
| vte global burden | #4 |
| population rivaroxaban | #4 |
| embolism tomography | #4 |
| cancer vwf | #4 |
| clinically relevant bleeding | #4 |
| patients venous thromboembolism | #4 |
| hemostatic profile | #4 |
| patients edoxaban | #4 |
| patients submassive | #4 |
| nct00571649 | #4 |
| vte treatment patients | #4 |
| lmwhs standard heparin | #4 |
| apixaban efficacy | #4 |
| oral rivaroxaban | #4 |
| measurement abi | #4 |
| vte netherlands | #4 |
| thromboembolism arterial | #4 |
| patients alternative diagnosis | #4 |
| thrombosis ischemic stroke | #4 |
| postthrombotic symptoms | #4 |
| procoagulant factors | #4 |
| vte total | #4 |
| thrombosis symptomatic | #4 |
| vte global | #4 |
| death survey | #4 |
| lmwh cancer patients | #4 |
| travel thrombosis | #4 |
| arterial thrombotic | #4 |
| coagulation factors risk | #4 |
| venous thrombosis levels | #4 |
| prophylaxis lmwh | #4 |
| global disease burden | #4 |
| 0651 | #4 |
| fibrin generation test | #4 |
| patient category | #4 |
| embolism dimer | #4 |
| probability prospective | #4 |
| predilution postdilution | #4 |
| chemotherapy shr | #4 |
| 150 microg levonorgestrel | #4 |
| life duration | #4 |
| ageadjusted cutoff patients | #4 |
| proximal patients | #4 |
| idiopathic venous thrombosis | #4 |
| 10172 | #4 |
| rivaroxaban 20 | #4 |
| symptomatic deep | #4 |
| ultrasonography venous | #4 |
| vitamin antagonists | #4 |
| extended treatment | #4 |
| impedance plethysmography | #4 |
| patients primary healthcare | #4 |
| global burden vte | #4 |
| thrombosis air | #4 |
| daily netilmicin | #4 |
| “reversal | #4 |
| diagnosis uedvt | #4 |
| patients nonpermanent | #4 |
| episode venous | #4 |
| embolism roc | #4 |
| contraindications treatment | #4 |
| thromboembolism systematic | #4 |
| rfviia injection | #4 |
| risk occult cancer | #4 |
| serial impedance | #4 |
| patients crcl 60 | #4 |
| chinese korean ethnicity | #4 |
| chromogenic compounds | #4 |
| point dimer | #4 |
| diagnostic management | #4 |
| women apc resistance | #4 |
| clot resolution | #4 |
| bleeding anticoagulants | #4 |
| diagnostic prediction models | #4 |
| enoxaparin female humans | #4 |
| estrogen therapy patients | #4 |
| enoxaparin day | #4 |
| women normal levels | #4 |
| abdomen relationship | #4 |
| doac studies | #4 |
| lmwh female heparin | #4 |
| thromboembolism factor | #4 |
| thrombosis uedvt | #4 |
| chemotherapy vte prophylaxis | #4 |
| thromboembolism study | #4 |
| patients clinically | #4 |
| 335 patients | #4 |
| total vte | #4 |
| pregnancies carriers | #4 |
| coagulation endotoxin | #4 |
| warfarin 3 months | #4 |
| hyperhomocysteinemic relatives | #4 |
| ddimer assay patients | #4 |
| thrombophilic families | #4 |
| preexisting heparin | #4 |
| leiden carriers | #4 |
| vitamin antagonist treatment | #4 |
| chads2 p0001 | #4 |
| advanced cancer 95 | #4 |
| hemorr2hages | #4 |
| disease burden vte | #4 |
| cleavage sites apc | #4 |
| vitamin antagonists patients | #4 |
| 6 months prophylaxis | #4 |
| vka treatment | #4 |
| venous thromboembolism patients | #4 |
| recurrent vte months | #4 |
| dimer assays | #4 |
| series venograms | #4 |
| dose noacs | #4 |
| embolism background | #4 |
| patients dimer | #4 |
| activation fibrinolytic | #4 |
| noacs netherlands | #4 |
| refuted | #4 |
| lowmolecularweight heparin | #4 |
| noacs cancer patients | #4 |
| patient education treatment | #4 |
| thromboembolism vitamin | #4 |
| venography patients | #4 |
| 35±4 | #4 |
| primary failure rate | #4 |
| control anticoagulation | #4 |
| gramnegative bacteria humans | #4 |
| questionnaires venous | #4 |
| rule pulmonary | #4 |
| vte highincome countries | #4 |
| tinaquant | #4 |
| received warfarin | #4 |
| negative point | #4 |
| risk vkas | #4 |
| rviia thrombin generation | #4 |
| clot lysis patients | #4 |
| thromboembolism occurred | #4 |
| criteria dose reduction | #4 |
| disease vte | #4 |
| 150 microg desogestrel | #4 |
| safety pravastatin | #4 |
| treatment unfractionated heparin | #4 |
| netherlands pulmonary | #4 |
| serial impedance plethysmography | #4 |
| dutch orthopedic | #4 |
| mbe patients | #4 |
| amadeus trial | #4 |
| thrombophilia 95 | #4 |
| levels ft4 | #4 |
| thrombosis deep | #4 |
| coc pregnancy | #5 |
| phlebography plethysmography | #5 |
| thromboembolism thrombosis | #5 |
| low‐molecular‐weight | #5 |
| vte patients cancer | #5 |
| molecularweight heparin | #5 |
| outcome major | #5 |
| consensus strategy | #5 |
| thromboembolism | #5 |
| vte 6 | #5 |
| secondary venous thrombosis | #5 |
| previous venous thromboembolism | #5 |
| patients recurrent dvt | #5 |
| antithrombotic drug treatment | #5 |
| thrombosis primary | #5 |
| upper extremity thrombosis | #5 |
| asymptomatic carriers mutation | #5 |
| venous thromboembolism studies | #5 |
| thromboembolism studies | #5 |
| severe pph women | #5 |
| endotoxin chimpanzees | #5 |
| lmwh recommended | #5 |
| preschool contraceptives | #5 |
| patients superficial thrombophlebitis | #5 |
| bleeding cancer | #5 |
| southern latin america | #5 |
| recurrent dvt patients | #5 |
| deepvein thrombosis | #5 |
| normal ctpa | #5 |
| hokusai | #5 |
| patients parenteral anticoagulants | #5 |
| inhibition plasminogen activation | #5 |
| thrombosis leg | #5 |
| hirudin treatment | #5 |
| netilmicin patients | #5 |
| specificity thrombophlebitis | #5 |
| diagnosis questionnaire | #5 |
| suspected uedvt | #5 |
| 8491 | #5 |
| elevated plasma level | #5 |
| incidence prognostic significance | #5 |
| fh patients cvd | #5 |
| diagnostic strategies | #5 |
| vte factor | #5 |
| pregnancy pph | #5 |
| daiichi sankyo | #5 |
| cdr patients | #5 |
| cancer strategy | #5 |
| ventricular dysfunction echocardiography | #5 |
| pulmonary embolism patients | #5 |
| rivaroxaban enoxaparin vka | #5 |
| 8292 | #5 |
| efficiency patients | #5 |
| embolism reproducibility | #5 |
| 2 rules | #5 |
| fviia rnapc2 | #5 |
| clinical probability | #5 |
| ft4 level | #5 |
| secondary dvt | #5 |
| dimer combination | #5 |
| predilution | #5 |
| thrombosis upper | #5 |
| women warfarin | #5 |
| gestalt | #5 |
| compression ultrasound | #5 |
| endogenous activated | #5 |
| endotoxin testing | #5 |
| isolated calfvein thrombosis | #5 |
| coronary angioplasty angioplasty | #5 |
| factor leiden 95 | #5 |
| patients wells score | #5 |
| pad smoking | #5 |
| medea study | #5 |
| treatment acute dvt | #5 |
| transfusion blood loss | #5 |
| vka patients | #5 |
| patients subtherapeutic | #5 |
| dvt prevalence | #5 |
| thromboembolism idraparinux | #5 |
| low molecularweight humans | #5 |
| burden vte | #5 |
| clinical probability assessment | #5 |
| lmwh incidence | #5 |
| fviii families | #5 |
| adjusted dimer | #5 |
| treatment fondaparinux | #5 |
| heparin compared | #5 |
| outpatients hospital | #5 |
| panwards | #5 |
| thrombophlebitis ultrasonography | #5 |
| repeated ultrasonography | #5 |
| day rivaroxaban | #5 |
| risk prediction scores | #5 |
| exclusion venous thromboembolism | #5 |
| iii plasminogen | #5 |
| patients pulmonary embolism | #5 |
| sensitivity negative predictive | #5 |
| cgp 39393 | #5 |
| clinical presentation clinical | #5 |
| risk khorana score | #6 |
| levonorgestrel desogestrel | #6 |
| oral edoxaban | #6 |
| incidence recurrence | #6 |
| subcutaneous low | #6 |
| synthetic pentasaccharides | #6 |
| thromboembolism bleeding | #6 |
| thrombophilic defects | #6 |
| dalteparin dose | #6 |
| anticoagulants hemorrhage | #6 |
| outcome occurred | #6 |
| dvt trial | #6 |
| myocardial infarction ctni | #6 |
| severe antithrombin | #6 |
| effects ufh | #6 |
| embolism pulmonary | #6 |
| patients tests | #6 |
| arterial cardiovascular | #6 |
| recurrent pulmonary | #6 |
| 12month cumulative incidence | #6 |
| vte cancer | #6 |
| apixaban treatment dose | #6 |
| warfarin venous thromboembolism | #6 |
| rate major bleeding | #6 |
| symptomatic legs | #6 |
| antagonists treatment | #6 |
| treatment ufh | #6 |
| 393 patients | #6 |
| diagnostic workup | #6 |
| stressinduced hyperglycaemia | #6 |
| ultrasonography normal | #6 |
| wells rule | #6 |
| lmwh users users | #6 |
| patients pulmonary angiography | #6 |
| conventional therapy treatment | #6 |
| ft4 patients | #6 |
| vte controls | #6 |
| vka | #6 |
| standardized morbidity ratio | #6 |
| subcutaneous nadroparin | #6 |
| 049 95 | #6 |
| vte anticoagulant treatment | #6 |
| leiden | #6 |
| simplired dimer | #6 |
| proportion cancer patients | #6 |
| blood coagulation mechanism | #6 |
| venograms | #6 |
| anticoagulants female | #6 |
| combined utility | #6 |
| selective beta | #6 |
| oral anticoagulants dabigatran | #6 |
| perioperative blood loss | #6 |
| patients factor mutation | #6 |
| embolism ventricular | #6 |
| neoplasms pulmonary embolism | #6 |
| cancer primary patients | #6 |
| endotoxin assays | #6 |
| grade 1a ufh | #6 |
| c1173 | #6 |
| clinically relevant subgroups | #6 |
| factor leiden carriers | #6 |
| fixeddose regimen | #6 |
| dabigatran etexilate dabigatran | #6 |
| assay fibrin | #6 |
| pembqol questionnaire | #6 |
| patients suspected | #6 |
| fviia inhibition | #6 |
| symptoms intermittent claudication | #6 |
| isolated deficiencies | #6 |
| effects levonorgestrel | #6 |
| amplify | #6 |
| 39393 | #6 |
| anticoagulant treatment | #6 |
| low absolute risk | #6 |
| d‐dimer testing | #6 |
| repeatedly normal | #6 |
| severe dic | #6 |
| enoxaparin incidence | #6 |
| duration rivaroxaban | #6 |
| patients iohexol | #6 |
| compression stockings patients | #6 |
| subjects vte | #6 |
| daily gentamicin | #6 |
| patients diagnostic | #6 |
| treatment pulmonary embolism | #6 |
| efficiency proportion | #6 |
| funding bayer | #6 |
| 10±4 | #6 |
| probability pulmonary | #6 |
| endotoxininduced activation | #6 |
| dimer cut | #6 |
| elisapositive | #6 |
| treatment intermittent claudication | #6 |
| patients anticoagulation clinic | #6 |
| lmwh cancer | #6 |
| patients lowmolecularweight heparin | #6 |
| patients proximal | #6 |
| risk increasing levels | #6 |
| prevalence vte | #6 |
| svt extension | #6 |
| treatment svt | #6 |
| patients uedvt | #6 |
| initial heparin treatment | #6 |
| pulmonary embolism presence | #6 |
| edoxaban efficacy | #6 |
| thrombosis guidelines | #6 |
| women hyperhomocysteinemia | #6 |
| carriers defects | #7 |
| lung scan | #7 |
| embolism prospective | #7 |
| rates edoxaban | #7 |
| dvt ipg | #7 |
| deepvein thrombosis patients | #7 |
| tb402 | #7 |
| primary efficacy | #7 |
| vte cancer diagnosis | #7 |
| 220 dabigatran | #7 |
| pulmonary embolism sensitivity | #7 |
| major bleeding vkas | #7 |
| recurrent dvt | #7 |
| 597939 | #7 |
| spiral sensitivity | #7 |
| thromboembolism total | #7 |
| relation prolactin levels | #7 |
| etexilate oral | #7 |
| incidence recurrent vte | #7 |
| carriers venous thromboembolism | #7 |
| presence cteph | #7 |
| administration bsf | #7 |
| perelated death | #7 |
| heparin org | #7 |
| plasma levels ifngamma | #7 |
| ottawa score | #7 |
| factor female humans | #7 |
| thromboembolism vte | #7 |
| ufh treatment | #7 |
| 680 | #7 |
| relation levels | #7 |
| diagnostic suspicion | #7 |
| anticoagulant parameters | #7 |
| neoplasms pulmonary | #7 |
| statin treatment risk | #7 |
| inhibitor apixaban | #7 |
| blood coagulation humans | #7 |
| stockings control | #7 |
| coagulation humans | #7 |
| specific antidotes | #7 |
| thrombophlebitis adolescent | #7 |
| general practitioners guideline | #7 |
| day initial treatment | #7 |
| unselected women | #7 |
| aspirin combined | #7 |
| phenprocoumon polymorphism | #7 |
| major bleeding | #7 |
| negative predictive npv | #7 |
| antithrombin protein | #7 |
| combination ipg | #7 |
| tnf injection | #7 |
| diagnosis venous thrombosis | #7 |
| primary dvt | #7 |
| vitamin antagonists vka | #7 |
| noncompressibility | #7 |
| venous thrombosis treatment | #7 |
| rivaroxaban 10 | #7 |
| arterial cardiovascular disease | #7 |
| vka therapy | #7 |
| levels factor viii | #7 |
| proportion older patients | #7 |
| mpc1609 | #7 |
| mutations factor viii | #7 |
| doppler skin | #7 |
| leg ultrasonography | #7 |
| placebo rivaroxaban | #7 |
| silent pulmonary embolism | #7 |
| nondiagnostic lung scans | #7 |
| thrombophilia pregnancy loss | #7 |
| major bleeding rate | #7 |
| protein protein deficiencies | #7 |
| negative ddimer test | #7 |
| prothrombin risk | #7 |
| patients standard heparin | #7 |
| thromboembolism adult | #7 |
| treatment doac | #7 |
| 150 enoxaparin | #8 |
| occult cancer patients | #8 |
| low clinical probability | #8 |
| probability lung | #8 |
| patients excluded | #8 |
| discontinuation anticoagulant treatment | #8 |
| compression surveys | #8 |
| ufh initial treatment | #8 |
| pvoct | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| inr determination | #8 |
| treatment venous thrombosis | #8 |
| comorbidity polypharmacy | #8 |
| vitamin antagonists vkas | #8 |
| products humans | #8 |
| contrast venography | #8 |
| v617f jak2 | #8 |
| lmwh grade 1a | #8 |
| funding daiichi | #8 |
| analysis apixaban | #8 |
| leiden prothrombin | #8 |
| structured algorithm | #8 |
| enoxaparin vka | #8 |
| 0·2 | #8 |
| patients symptomatic vte | #8 |
| wells scores | #8 |
| persistent risk factors | #8 |
| initial heparin | #8 |
| dimer concentration | #8 |
| tests pulmonary | #8 |
| oac adherence | #8 |
| years cumulative incidence | #8 |
| recurrent vte bleeding | #8 |
| optimal intensity | #8 |
| normal computed | #8 |
| unprovoked vte patients | #8 |
| severe preeclampsia patients | #8 |
| dimer tests | #8 |
| consecutive outpatients | #8 |
| testing rule | #8 |
| bnp ctnt | #8 |
| oral glucocorticoids risk | #8 |
| vascular endothelial barrier | #8 |
| xii deficient | #8 |
| homocysteine markers | #8 |
| cancer pulmonary embolism | #8 |
| administration low | #8 |
| acute symptomatic vte | #8 |
| international organisations | #8 |
| anticoagulants antineoplastic | #8 |
| proximal deepvein thrombosis | #8 |
| 97 95 | #8 |
| oral apixaban | #8 |
| inr values patients | #8 |
| deficiency antithrombin | #8 |
| objectively confirmed | #8 |
| overt cancer | #8 |
| patients extended anticoagulation | #8 |
| vte score | #8 |
| point ultrasonography | #8 |
| nondiagnostic scan | #8 |
| prospective management | #8 |
| thrombosis prophylaxis | #8 |
| physicians stockings | #8 |
| risk employees | #8 |
| risks dvt | #8 |
| aged phlebography | #8 |
| current approach | #8 |
| levonorgestrelcontaining | #8 |
| warfarin hazard ratio | #8 |
| ageadjusted ddimer cutoff | #8 |
| chemotherapy low risk | #8 |
| euro55 | #8 |
| thrombosis adolescent | #8 |
| vka lmwh | #8 |
| proximal deep | #8 |
| duration treatment | #8 |
| recurrent vte mb | #8 |
| symptomatic deepvein thrombosis | #8 |
| arg506 factor | #8 |
| nafronyl | #8 |
| p0001 hasbled score | #8 |
| 1599 patients | #8 |
| heparin vitamin antagonists | #8 |
| prevention vte | #8 |
| anticoagulation unprovoked vte | #8 |
| carriers fvl | #8 |
| apixaban enoxaparin | #8 |
| agnelli | #8 |
| increased fibrinolytic | #8 |
| fxi aso | #8 |
| inherited thrombophilic | #8 |
| ultrasonogram | #9 |
| combination stroke | #9 |
| fxa inhibitor | #9 |
| thromboembolism cancer | #9 |
| iii concentrate | #9 |
| longterm treatment vte | #9 |
| patients fxa inhibitors | #9 |
| discontinuing anticoagulation | #9 |
| male oligosaccharides | #9 |
| fondaparinux cancer patients | #9 |
| lipoproteina women | #9 |
| placebo plasma levels | #9 |
| normal ddimer | #9 |
| diagnostic prediction model | #9 |
| incidental pulmonary | #9 |
| vte rcts | #9 |
| generation pill | #9 |
| abnormal vaginal | #9 |
| cancer factor | #9 |
| concomitant cancer | #9 |
| method enoxaparin | #9 |
| bled bleeding | #9 |
| cofact | #9 |
| thrombosis thromboinflammation | #9 |
| acute medical illnesses | #9 |
| apixaban oral factor | #9 |
| incidence postthrombotic syndrome | #9 |
| vte relatives | #9 |
| compression stockings prevention | #9 |
| büller | #9 |
| thrombosis compared | #9 |
| strategies dimer | #9 |
| tafi levels | #9 |
| diagnosis mdct | #9 |
| lmwh mortality | #9 |
| oral antithrombins | #9 |
| anticoagulant pathways | #9 |
| daiichisankyo | #9 |
| prothrombin 20210a | #9 |
| edoxaban major bleeding | #9 |
| postdilution | #9 |
| months efficacy | #9 |
| weight heparin | #9 |
| carriers factor leiden | #9 |
| patients active cancer | #9 |
| therapeutic dose patients | #9 |
| thrombosis venous thromboembolism | #9 |
| hemorr2hages atria | #9 |
| atiii concentrates | #9 |
| homocysteine women | #9 |
| factors thrombophlebitis | #9 |
| cancer episode | #9 |
| characteristics severity | #9 |
| treatment edoxaban | #9 |
| oral contraceptive pregnancy | #9 |
| heparin therapy patients | #9 |
| enoxaparin factor | #9 |
| crcl 60 | #9 |
| treatment prophylaxis | #9 |
| nonpermanent | #9 |
| cancer cell extravasation | #9 |
| comorbidities polypharmacy | #9 |
| major bleeding treatment | #9 |
| serotonin platelet | #9 |
| independent committee | #9 |
| embolism venous | #9 |
| schedule heparin | #10 |
| venous thromboembolic event | #10 |
| fii mutation | #10 |
| rates recurrent vte | #10 |
| wells | #10 |
| cvd fh patients | #10 |
| intimamedia thickness imt | #10 |
| crp test | #10 |
| fondaparinux risk | #10 |
| thr incidence | #10 |
| ddimer concentration | #10 |
| cancer patients lmwh | #10 |
| treatment vitamin | #10 |
| thrombophlebitis adult | #10 |
| embolism patients | #10 |
| aged antithrombin | #10 |
| gramnegative septicemia | #10 |
| oral thrombin inhibitor | #10 |
| treatment uedvt | #10 |
| subcutaneous metaanalysis | #10 |
| hypocoagulable state | #10 |
| 4470 | #10 |
| protein dic | #10 |
| rabbits administration | #10 |
| inherited thrombophilic factors | #10 |
| heparin nomogram | #10 |
| factor levels patients | #10 |
| vte efficacy | #10 |
| treatment aprotinin | #10 |
| incidence major bleeding | #10 |
| extremity deep | #10 |
| major bleeding crnmb | #10 |
| normohomocysteinemic | #10 |
| 100 years discontinuation | #10 |
| year years | #10 |
| incidence 1000 personyears | #10 |
| snp scores | #10 |
| patients endotoxemia | #10 |
| oral administration dabigatran | #10 |
| inr cases | #10 |
| vnv | #10 |
| 1215 patients | #10 |
| severity clinical | #10 |
| pregnancy carriers | #10 |
| asymptomatic pulmonary embolism | #10 |
| venous thrombosis | #10 |
| dvt lower extremity | #10 |
| probability pulmonary embolism | #10 |
| patients venous thrombosis | #10 |
| magellan trial | #10 |
| embolism clinical | #10 |
| thrombosis background | #10 |
| factor prevention | #10 |
| bled scores | #10 |
| retrospective study efficacy | #10 |
| lmwh studies | #10 |
| deficiencies antithrombin | #10 |
| 598 patients | #10 |
| ageadjusted cutoff | #10 |
| anticoagulants | #10 |
| simplified geneva | #10 |
| nadroparine | #10 |
| single loss | #10 |
| magellan study | #10 |
| rfviia blood loss | #10 |
| animal heparin | #10 |
| induced coagulation | #10 |
| cancer patients vte | #10 |
| injection avidin | #10 |
| cus diagnosis | #10 |
| leg veins | #10 |
| 30 microg ethinylestradiol | #11 |
| pregnancyrelated complications | #11 |
| org 10172 | #11 |
| patients anticoagulant treatment | #11 |
| lmwh pregnancies | #11 |
| recombinant human tnf | #11 |
| gps training | #11 |
| intensity anticoagulation | #11 |
| weight humans | #11 |
| ufh studies | #11 |
| d‐dimer levels | #11 |
| 750 μg | #11 |
| thromboembolism major | #11 |
| oral dabigatran | #11 |
| endotoxin assay | #11 |
| carriers factor | #11 |
| embolism recurrence | #11 |
| variation inr | #11 |
| patients probability | #11 |
| medical conferences | #11 |
| inhibitors hemorrhage | #11 |
| edoxaban | #11 |
| pyridines thiazoles | #11 |
| hospital lmwh | #11 |
| gentamicin treatment patients | #11 |
| sulfates dermatan | #11 |
| crnmb 95 | #11 |
| pulmonary angiography venography | #11 |
| factor venous | #11 |
| embolism prevalence | #11 |
| dvt | #11 |
| pulmonary embolism incidence | #11 |
| heparinoid org | #11 |
| clinical pretest | #11 |
| air travel | #11 |
| patients cancer vte | #11 |
| cancer patients evidence | #11 |
| screening cancer | #11 |
| incidence major | #11 |
| endotoxin pentoxifylline | #11 |
| levels prolactin | #11 |
| haemophilia vwd | #11 |
| cancer patients dvt | #11 |
| dabigatran enoxaparin | #11 |
| lmwh pregnancy | #11 |
| patients cvcs | #11 |
| adult anticoagulants | #11 |
| combination dimer | #11 |
| ldfr | #11 |
| knee clinical trials | #11 |
| reference testing | #11 |
| vte vwf | #11 |
| pcc dabigatran | #11 |
| fondaparinux hemorrhage | #11 |
| previous venous | #11 |
| 880 patients | #11 |
| mutations prevalence | #11 |
| warfarin therapy inr | #12 |
| vte recurrence risk | #12 |
| warfarin treated | #12 |
| annual incidence vte | #12 |
| outpatient management patients | #12 |
| venous thromboembolism incidence | #12 |
| 9702 | #12 |
| livebirth rate | #12 |
| proximal veins | #12 |
| crd42013003526 | #12 |
| topic venous | #12 |
| thrombin generation fibrinolysis | #12 |
| prevention venous thrombosis | #12 |
| thrombosis dvt | #12 |
| female heparin humans | #12 |
| vka noacs | #12 |
| patients lmwhs | #12 |
| 9295 | #12 |
| patients lupus anticoagulant | #12 |
| observation risk | #12 |
| peghirudin | #12 |
| 72 children | #12 |
| recurrent vte | #12 |
| doseadjustment | #12 |
| risk venous | #12 |
| noacs vka | #12 |
| perelated | #12 |
| paulin | #12 |
| bnp cardiac troponin | #12 |
| warfarin recurrent vte | #12 |
| factor leiden prothrombin | #12 |
| months primary | #12 |
| pioped study | #12 |
| anticoagulant factor | #12 |
| women factor | #12 |
| dvt treatment | #12 |
| concomitant disorders | #12 |
| hemodynamically stable | #12 |
| bayer schering pharma | #12 |
| nephro | #12 |
| stopping anticoagulation | #12 |
| safety efficiency | #12 |
| patients incidental | #12 |
| hirulog1 | #12 |
| event recurrence | #12 |
| subsegmental pulmonary emboli | #12 |
| control metaanalysis | #12 |
| thrombophilic | #12 |
| fondaparinux unfractionated heparin | #12 |
| ageadjusted ddimer | #12 |
| geneva score | #12 |
| anticoagulation unprovoked | #12 |
| outcomes venous thromboembolism | #12 |
| proximal vein | #12 |
| recurrent vte anticoagulation | #12 |
| treatment crt | #12 |
| humanized arthroplasty | #12 |
| deficient women | #12 |
| thrombosis young | #13 |
| bleeding events edoxaban | #13 |
| inferiority efficacy | #13 |
| marder score | #13 |
| vte 64 | #13 |
| antithrombin iii activity | #13 |
| groups inr | #13 |
| spiral computed tomography | #13 |
| continuous intravenous heparin | #13 |
| deepvein thrombosis dvt | #13 |
| obesity haemophilia patients | #13 |
| thrombosis acute | #13 |
| category studies | #13 |
| superficial thrombophlebitis | #13 |
| heparin low | #13 |
| dimer threshold | #13 |
| bayer healthcare | #13 |
| vte | #13 |
| plethysmograms | #13 |
| rivaroxaban thiophenes | #13 |
| prevention venous thromboembolism | #13 |
| association venous thrombosis | #13 |
| levels factor | #13 |
| dabigatran 220 | #13 |
| dimer testing | #13 |
| patients thrombophilia | #13 |
| factor viii apc | #13 |
| vte groups | #13 |
| randomized cross | #13 |
| plethysmography | #13 |
| dvt lower | #13 |
| dabigatran vte | #13 |
| concomitant antiplatelet therapy | #13 |
| daily subcutaneous | #13 |
| indication anticoagulation | #13 |
| arterial thromboembolism ate | #13 |
| arixtra | #13 |
| occult cancer | #13 |
| safety oral | #13 |
| vte recurrence 95 | #13 |
| conventional anticoagulants | #13 |
| nct00986154 | #13 |
| clinical decision rules | #13 |
| ufh dalteparin | #13 |
| inhibition tnf | #13 |
| hematologic pregnancy trimester | #13 |
| major hip | #13 |
| time prothrombin | #13 |
| pselectin patients | #13 |
| treatment venous thromboembolism | #13 |
| uedvt | #13 |
| vte female humans | #13 |
| vte major | #13 |
| 86 percent | #13 |
| recombinant hirudin rhirudin | #13 |
| safety doacs | #13 |
| 95 carriers | #13 |
| patients anticoagulant | #13 |
| selective testing | #13 |
| strain gauge plethysmography | #13 |
| factor leiden mutation | #13 |
| thromboembolism age | #14 |
| 17 placebo | #14 |
| standard heparin | #14 |
| limited screening | #14 |
| unprovoked vte vte | #14 |
| anticoagulant rivaroxaban | #14 |
| thrombosis | #14 |
| low molecular | #14 |
| patients acute vte | #14 |
| gastrointestinal bleeding patients | #14 |
| cancer patients anticoagulation | #14 |
| ultrasound strategies | #14 |
| patients dvt | #14 |
| vte months | #14 |
| effects hyperthyroidism | #14 |
| thrombophilia patients | #14 |
| dvt lower extremities | #14 |
| aspirin women | #14 |
| pregnancy venous | #14 |
| treated lmwh | #14 |
| treatment duration patients | #14 |
| lmwh vka | #14 |
| revised geneva | #14 |
| fvl carriers | #14 |
| factor viii levels | #14 |
| edoxaban warfarin | #14 |
| aged anticoagulants | #14 |
| higher ddimer levels | #14 |
| atiii deficiency | #14 |
| obstetric complications women | #14 |
| aged plethysmography | #14 |
| incidence severe pph | #14 |
| experimental endotoxaemia | #14 |
| plasminogen apoa | #14 |
| female fibrin | #14 |
| loss women | #14 |
| costs dvt | #14 |
| patients vka therapy | #14 |
| patients outpatients | #14 |
| vte statin | #14 |
| awareness pad | #14 |
| recurrent venous thromboembolism | #14 |
| placebo rfviia | #14 |
| cadherins endothelium | #14 |
| bolus intravenous injection | #14 |
| acute deep | #14 |
| riete score | #14 |
| 12 kg1 | #14 |
| edoxaban oral factor | #14 |
| safety edoxaban | #14 |
| recurrent venous | #14 |
| conventionaltherapy | #14 |
| crnm | #14 |
| symptomatic pulmonary | #14 |
| doseranging study | #14 |
| patients ctpa | #15 |
| established vte | #15 |
| doacs aspirin | #15 |
| lomoparan | #15 |
| experimental thrombosis | #15 |
| fondaparinux efficacy | #15 |
| antagonist vka | #15 |
| cardiovascular diseases thrombosis | #15 |
| activation contact | #15 |
| subcutaneous regimen | #15 |
| symptomatic events | #15 |
| pregnancy outcome pregnancy | #15 |
| factor leiden | #15 |
| probability assessment | #15 |
| edoxaban treatment | #15 |
| cteph incidence | #15 |
| arg506 | #15 |
| primary safety outcome | #15 |
| vitaminkantagonists | #15 |
| enoxaparin vte | #15 |
| inr patient | #15 |
| treatment 12 months | #15 |
| prophylaxis venous thromboembolism | #15 |
| diagnosis venous | #15 |
| thyroid hormone excess | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| clinically relevant endpoints | #15 |
| abdominal pelvic | #15 |
| thrombus growth | #15 |
| inr range | #15 |
| thrombinography | #15 |
| khorana score | #15 |
| generation oral | #15 |
| studies pulmonary | #15 |
| arg562 | #15 |
| thrombosis diagnosis | #15 |
| recombinant factor viia | #15 |
| oral direct factor | #15 |
| coc vte | #15 |
| lmwh ufh | #15 |
| control subjects prevalence | #15 |
| prior venous thromboembolism | #15 |
| subcutaneous enoxaparin | #15 |
| 500 pg | #15 |
| patients vitamin antagonists | #15 |
| anticoagulants patients | #15 |
| coagulation | #15 |
| venous thrombosis warfarin | #16 |
| recurrent symptomatic | #16 |
| vte khorana score | #16 |
| impaired fibrinolysis | #16 |
| thrombosis association | #16 |
| bleeding aged | #16 |
| dvt lmwh | #16 |
| cancer screening patients | #16 |
| cancer cancer patients | #16 |
| netilmicin gentamicin | #16 |
| major bleeding events | #16 |
| positivity threshold | #16 |
| factors major | #16 |
| warfarin acenocoumarol | #16 |
| vterelated death | #16 |
| viia activity | #16 |
| major bleeding anticoagulation | #16 |
| factor inhibitor | #16 |
| occult cancer detection | #16 |
| test clinical | #16 |
| subsequent pregnancy loss | #16 |
| combination clinical | #16 |
| patients acenocoumarol | #16 |
| arterial vascular events | #16 |
| 100 95 | #16 |
| thrombosis low | #16 |
| thrombosis haemostasis | #16 |
| abdomino | #16 |
| analysis rivaroxaban | #16 |
| avws patients | #16 |
| postthrombotic syndrome children | #16 |
| thromboembolism time | #16 |
| deep venous thrombosis | #16 |
| risk clinically | #16 |
| thrombosis adult | #16 |
| 6 months placebo | #16 |
| ddimer levels patients | #16 |
| women unexplained | #16 |
| compared enoxaparin | #17 |
| thrombosis clinical | #17 |
| topic hemorrhage humans | #17 |
| vte edoxaban | #17 |
| dimer assay | #17 |
| patients overt hypothyroidism | #17 |
| pharmo record linkage | #17 |
| ctscans | #17 |
| fragment f1 | #17 |
| mutation women | #17 |
| women mutation | #17 |
| 12 months patients | #17 |
| thromboembolism patients | #17 |
| 2688 | #17 |
| endotoxemia bacteremia | #17 |
| fibrinolysis treatment | #17 |
| anticoagulants drug | #17 |
| patients impedance | #17 |
| anticoagulants clinical | #17 |
| anticoagulant therapy patients | #17 |
| rivaroxaban oral factor | #17 |
| lmwhs patients | #17 |
| recurrent vte events | #17 |
| management crt | #17 |
| female humans vte | #17 |
| gentamicin netilmicin | #17 |
| factor monoclonal | #17 |
| hematoma heparin | #17 |
| excessive blood loss | #17 |
| factors venous | #17 |
| 516 patients | #17 |
| diagnosis svt | #17 |
| scan classification | #17 |
| dvt prevention | #17 |
| permanent patients | #17 |
| vkorc1 gene | #17 |
| incidence pts | #17 |
| lower specificity | #17 |
| prohemostatic | #17 |
| annual incidence | #18 |
| 023 | #18 |
| poc test | #18 |
| venous thromboembolism rivaroxaban | #18 |
| vka vte | #18 |
| lmwh doacs | #18 |
| thromboembolism venous | #18 |
| thrombosis pulmonary | #18 |
| outcome events | #18 |
| women pregnancy loss | #18 |
| treatment vkas | #18 |
| commercial airline pilots | #18 |
| patients strategy | #18 |
| stable anticoagulation | #18 |
| sanofi aventis | #18 |
| apc thrombin generation | #18 |
| relevant nonmajor | #18 |
| thrombosis total | #18 |
| vka edoxaban | #18 |
| intravenous heparin therapy | #18 |
| favor lmwh | #18 |
| warfarin hazard | #18 |
| proximal vein thrombosis | #18 |
| prothrombin g20210a | #18 |
| aptt heparin | #18 |
| cancer vte | #18 |
| antithrombotic treatment patients | #18 |
| weight adjusted | #18 |
| hivinfected patients cart | #18 |
| diagnostic strategy | #18 |
| simplired | #18 |
| combined form | #18 |
| edoxaban vte | #18 |
| 4 clinical | #18 |
| flight hours | #18 |
| dvt rivaroxaban | #19 |
| patients prevalence | #19 |
| recurrence vte | #19 |
| vwf vte | #19 |
| venous thromboembolism relatives | #19 |
| abnormal ultrasound | #19 |
| ufh lmwh | #19 |
| low platelets | #19 |
| adjusted dose | #19 |
| venography sensitivity | #19 |
| 56 95 | #19 |
| prognostic echocardiography | #19 |
| patients sspe | #19 |
| objective testing | #19 |
| oral dabigatran enoxaparin | #19 |
| lmwh patients | #19 |
| acute recurrent | #19 |
| antibodynegative | #19 |
| vitamin antagonist | #19 |
| coagulation studies | #19 |
| patients major bleeding | #19 |
| thromboembolism administration | #19 |
| fondaparinux enoxaparin | #19 |
| patients elevated biomarkers | #19 |
| doubleblinding | #19 |
| local angiogenesis | #19 |
| versions version | #19 |
| ddimer tests | #19 |
| fibrinolytic response | #19 |
| treatment heparin | #19 |
| systemic activation coagulation | #19 |
| retropubic prostatectomy | #19 |
| increased fibrinolytic activity | #19 |
| extended oral | #19 |
| endogenous fibrinolysis | #19 |
| active search | #19 |
| recurrent venous thrombosis | #19 |
| 35 women | #19 |
| edoxaban dose | #19 |
| subcutaneous dalteparin | #19 |
| patients derivation | #19 |
| studies factor | #19 |
| symptomatic dvt | #19 |
| ipdma | #19 |
| increased risk relatives | #19 |
| excluded patients | #20 |
| impedance plethysmography ipg | #20 |
| incidences death | #20 |
| patients ddimer testing | #20 |
| risk thrombophilia | #20 |
| diagnostic workup patients | #20 |
| symptomatic venous thrombosis | #20 |
| shr 95 | #20 |
| synthetic cross | #20 |
| intravenous injections | #20 |
| distance treatment | #20 |
| new agent | #20 |
| cancer severity | #20 |
| antagonists vkas | #20 |
| control situation | #20 |
| calf veins | #20 |
| subsegmental | #20 |
| anticoagulation clinic | #20 |
| malignancy time | #20 |
| life venous thrombosis | #20 |
| single criterion | #20 |
| portola | #20 |
| abi measurement | #20 |
| established atherosclerosis | #20 |
| nadroparin | #20 |
| carriers prothrombin | #20 |
| injections subcutaneous | #20 |
| therapy rivaroxaban | #20 |
| warfarin edoxaban | #20 |
| blindly | #20 |
| dabigatran 150 | #20 |
| statin vte | #20 |
| treatment vte | #20 |
| compared ufh | #20 |
| antitpo | #20 |
| proteins thrombin | #20 |
| standardtherapy hazard ratio | #20 |
| absolute risk | #20 |
| recurrence bleeding | #20 |
| ctnt bnp | #20 |
| residual venous | #20 |
| abi risk factors | #20 |
| prothrombin mutation | #20 |
| guidance ssc | #20 |
| pregnancyrelated vte | #20 |
| versions questionnaire | #20 |
| thrombosis ultrasonography | #20 |
| thrombophilia vte | #20 |
| distance quality | #21 |
| hemodynamically stable patients | #21 |
| deep venous | #21 |
| d‐dimer | #21 |
| hemostatic abnormalities | #21 |
| thromb | #21 |
| venogram | #21 |
| ddimer concentrations | #21 |
| outcome incidence | #21 |
| occult malignancy | #21 |
| carriers noncarriers | #21 |
| current standard treatment | #21 |
| disease ischemic | #21 |
| prothrombin 20210 | #21 |
| patients 3 months | #21 |
| doacs lmwhs | #21 |
| concomitant anti | #21 |
| thrombosis anticoagulants | #21 |
| treatment acenocoumarol | #21 |
| internists cardiologists | #21 |
| major bleeding patients | #21 |
| vte patients | #21 |
| risk cohort study | #21 |
| fibrinolysis inflammation | #21 |
| treatment apixaban | #21 |
| discriminatory performance | #21 |
| thrombophilia screening | #22 |
| acute vte | #22 |
| dichotomously | #22 |
| anticoagulants humans | #22 |
| venous thromboembolic | #22 |
| public awareness | #22 |
| host defense response | #22 |
| cmax ctrough | #22 |
| patients recurrent symptoms | #22 |
| dimer age | #22 |
| bleeding treatment | #22 |
| lpa plasminogen | #22 |
| hormonal cross | #22 |
| patients immobilization | #22 |
| dose subcutaneous | #22 |
| ttr inr | #22 |
| daily enoxaparin | #22 |
| patients severe hf | #22 |
| patientyears | #22 |
| anticoagulants heparin | #22 |
| alternative anticoagulation | #22 |
| safety treatment | #22 |
| treatment dvt | #22 |
| recurrent thromboembolism | #22 |
| time inr | #22 |
| riskbenefit ratio | #22 |
| vascular endotoxins | #22 |
| cttr | #22 |
| doppler venous thrombosis | #22 |
| hasbled score | #23 |
| vte studies | #23 |
| n1157 | #23 |
| 5392 | #23 |
| lower extremity amputation | #23 |
| 011 | #23 |
| thromboembolism anticoagulants | #23 |
| time platelet | #23 |
| life pulmonary embolism | #23 |
| recurrence venous | #23 |
| prevalence venous thromboembolism | #23 |
| fondaparinux | #23 |
| bidirectional relation | #23 |
| gentamicin patients | #23 |
| ambulatory cancer patients | #23 |
| rivaroxaban dosing | #23 |
| development dic | #23 |
| percentage increase | #23 |
| normal angiogram | #23 |
| 2 investigators | #23 |
| clotbound thrombin | #23 |
| odis | #23 |
| direct factor inhibitors | #23 |
| standardduration | #23 |
| venous arterial thrombosis | #23 |
| kakkar | #23 |
| elevated ctni | #23 |
| enoxaparin 40 | #23 |
| cancer patients risk | #23 |
| patients coagulation disorders | #23 |
| patients severe bleeding | #24 |
| prevalence deficiencies | #24 |
| thrombosis carriers | #24 |
| years episode | #24 |
| independent external validation | #24 |
| followup incidence | #24 |
| food drugs | #24 |
| therapy heparin | #24 |
| recurrent pulmonary embolism | #24 |
| predefined criteria | #24 |
| parameters fibrinolysis | #24 |
| bleeding complication | #24 |
| presence dvt | #24 |
| levels fviii | #24 |
| patients abnormal perfusion | #24 |
| viiic | #24 |
| lowmolecularweight humans | #24 |
| ufh patients | #24 |
| specific antidote | #24 |
| patients acute treatment | #24 |
| fondaparinux placebo | #24 |
| ddimer testing | #24 |
| rates venous thromboembolism | #24 |
| recurrent thromboembolism patients | #24 |
| safety fondaparinux | #24 |
| subtherapeutic | #24 |
| 049 | #24 |
| overt hyperthyroidism | #24 |
| desogestrel levonorgestrel | #24 |
| a21gly | #24 |
| month incidence | #24 |
| factors anticoagulants | #25 |
| lmwh treatment | #25 |
| fatima | #25 |
| patients gastrointestinal bleeding | #25 |
| expert radiologists | #25 |
| perfusion lung scan | #25 |
| thromboembolism acute | #25 |
| specificity efficiency | #25 |
| fibrinogen degradation | #25 |
| influence smoking | #25 |
| studies lmwh | #25 |
| anatomical extent | #25 |
| amadeus | #25 |
| sepsis intravascular coagulation | #25 |
| suggestions improvement | #25 |
| xii activity | #25 |
| vte clinical | #25 |
| f1 2 levels | #25 |
| cha2ds2vasc chads2 | #25 |
| willebrand factor adamts13 | #25 |
| treatment symptomatic | #25 |
| middeldorp | #25 |
| major bleeding bleeding | #26 |
| hormonal manipulation | #26 |
| patients cdr | #26 |
| venous thromboemboli | #26 |
| dalteparin ufh | #26 |
| ecq | #26 |
| treatment lmwh | #26 |
| specificity negative predictive | #26 |
| asymptomatic carriers | #26 |
| rate recurrent vte | #26 |
| 9715 | #26 |
| miscarriage stillbirth | #26 |
| edoxaban vka | #26 |
| viia complex | #26 |
| patients symptomatic dvt | #26 |
| rethoracotomy | #26 |
| failure rate | #26 |
| homozygous carriers | #26 |
| unprovoked vte | #26 |
| patients essential thrombocythaemia | #26 |
| events year | #26 |
| doacs vitamin antagonists | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| edoxaban versus | #26 |
| parameters risk | #26 |
| anticoagulants blood | #27 |
| cancer spread | #27 |
| thrombocytopenia antibodies | #27 |
| extremity venous | #27 |
| thrombophlebitis | #27 |
| patients elevated levels | #27 |
| perfusion lung | #27 |
| thrombosis venous | #27 |
| day 35 | #27 |
| current guidance | #27 |
| anticoagulants factor | #27 |
| airline pilots | #27 |
| patients major hemorrhage | #27 |
| vte doacs | #27 |
| venous thromboembolism carriers | #27 |
| 0·63 | #27 |
| low molecularweight heparin | #27 |
| nonmajor | #27 |
| noncarriers 95 | #27 |
| female heterozygote | #27 |
| combined training | #27 |
| months studies | #27 |
| enoxaparin female | #27 |
| lmwh prophylaxis | #27 |
| vte thr | #27 |
| treating physician | #27 |
| training gps | #27 |
| npv patients | #27 |
| unprovoked venous | #27 |
| lowmolecularweight heparin patients | #27 |
| patients 50 | #27 |
| rfviia placebo | #28 |
| tests diagnostic | #28 |
| apc plasma | #28 |
| pph severe pph | #28 |
| embolism retrospective | #28 |
| monitoring therapy | #28 |
| objective tests | #28 |
| cancer venous thromboembolism | #28 |
| vitamin aged | #28 |
| 2½ | #28 |
| presentation followup | #28 |
| specific reversal agent | #28 |
| anticoagulation women | #28 |
| anticoagulants compared | #28 |
| vte 6 months | #28 |
| unexplained | #28 |
| pembqol | #28 |
| coagulation tissue factor | #28 |
| factors recurrent | #28 |
| acutely medical patients | #28 |
| 4650 | #28 |
| therapeutic doses | #28 |
| patients unprovoked | #28 |
| receiving rivaroxaban | #28 |
| hirudin therapy | #28 |
| g20210a mutation | #29 |
| major bleeding rivaroxaban | #29 |
| acenocoumarol patients | #29 |
| pulmonary angiography | #29 |
| patients avws | #29 |
| plateletactivating antibodies | #29 |
| 8240 | #29 |
| dvt pulmonary embolism | #29 |
| septicemia | #29 |
| direct oral anticoagulants | #29 |
| blind trials | #29 |
| current management strategies | #29 |
| authors incidence | #29 |
| aspirin placebo | #29 |
| aged morpholines | #29 |
| recurrence svt | #29 |
| spread cancer | #29 |
| pulmonary embolism death | #29 |
| dutch famine | #29 |
| aminoglycoside therapy | #29 |
| thrombosis 95 | #29 |
| thrombo | #29 |
| diagnosis dvt | #29 |
| prediction scores | #29 |
| pulmonary embolism recurrence | #29 |
| oral glucocorticoids | #29 |
| 1000 individuals | #29 |
| sex‐specific differences | #29 |
| pbac score | #29 |
| heparin versus | #29 |
| cindexes | #29 |
| patients standard therapy | #29 |
| dabigatran pcc | #29 |
| years year | #29 |
| thrombosis treatment | #29 |
| bleeding increased | #29 |
| resistance activated protein | #29 |
| vte coc | #30 |
| subcutaneous heparin | #30 |
| 1000 personyears incidence | #30 |
| residual thrombosis | #30 |
| rule patients | #30 |
| 95 risk | #30 |
| new anticoagulants | #30 |
| markers coagulation activation | #30 |
| ufh vte | #30 |
| thromboembolism warfarin | #30 |
| costs diagnosis | #30 |
| embolism risk | #30 |
| xii factor | #30 |
| administration pentoxifylline | #30 |
| support techniques | #30 |
| direct oral factor | #30 |
| f1 2 | #30 |
| patients vte | #30 |
| prevention venous | #30 |
| cancer venous | #30 |
| doac vka | #30 |
| 0206 | #31 |
| vte ufh | #31 |
| experimental endotoxemia | #31 |
| ufh fondaparinux | #31 |
| patients deepvein thrombosis | #31 |
| thromboembolism adolescent | #31 |
| dvt pulmonary | #31 |
| incidence pph | #31 |
| rhir | #31 |
| iii activity | #31 |
| ventilation scintigraphy | #31 |
| bled | #31 |
| analysis reviewers | #31 |
| activation blood coagulation | #31 |
| imaging sensitivity specificity | #31 |
| dimer cutoff | #31 |
| rfviia novoseven | #31 |
| recurrent episode | #31 |
| standardtherapy | #31 |
| incidence cteph | #31 |
| thromboprophylaxis risk | #31 |
| placebo observation | #31 |
| antithrombotic therapies | #31 |
| inhibitor edoxaban | #31 |
| 8755 | #31 |
| events 95 | #31 |
| recurrent vte patients | #31 |
| 2 antiplasmin | #31 |
| prevalence probability | #31 |
| apixaban placebo | #31 |
| extended prophylaxis | #31 |
| term risk | #31 |
| pharmacological prophylaxis | #31 |
| women recurrent miscarriage | #31 |
| recurrent patients | #31 |
| year 95 | #32 |
| normal genotype | #32 |
| treatment anticoagulants | #32 |
| leiden mutation | #32 |
| factor female | #32 |
| resistance activated | #32 |
| negative dimer | #32 |
| warfarin vte | #32 |
| parenteral anticoagulants | #32 |
| netherlands predictive | #32 |
| khorana score patients | #32 |
| negative septicemia | #32 |
| varicosis | #32 |
| parenteral anticoagulation | #32 |
| ufh | #32 |
| generation patients | #32 |
| suspected patients | #32 |
| age adjusted | #32 |
| low clinical | #32 |
| international society thrombosis | #32 |
| factors thrombolytic | #32 |
| apixaban treatment | #33 |
| pulmonary angiogram | #33 |
| active implementation | #33 |
| nephrotoxicity gentamicin | #33 |
| additional tests | #33 |
| unitage | #33 |
| rhirudin | #33 |
| thromboembolism young | #33 |
| mega study | #33 |
| factor viii patients | #33 |
| cancer patients diagnosis | #33 |
| subcutaneous male | #33 |
| low probability | #33 |
| prophylaxis vte | #33 |
| warfarin risks | #33 |
| chapter patients | #33 |
| data meta | #33 |
| heparin lmwh | #33 |
| activation factors | #33 |
| anticoagulant protein | #33 |
| anticoagulant | #34 |
| vte thrombophilia | #34 |
| hemorrhage heparin humans | #34 |
| lmwh unfractionated heparin | #34 |
| plasmin alpha | #34 |
| 10 95 | #34 |
| deficiency protein | #34 |
| bilateral venography | #34 |
| pregnancy loss women | #34 |
| 3 months treatment | #34 |
| warfarin adult | #34 |
| subsegmental pulmonary embolism | #34 |
| grade 1a | #34 |
| 9241 | #34 |
| reocclusion patients | #34 |
| compare efficacy | #34 |
| apcsr | #34 |
| thrombosis lower | #34 |
| 590 | #34 |
| phytonadione | #34 |
| control trials | #34 |
| vte compared | #34 |
| anticoagulants benzimidazoles | #35 |
| surgery hip | #35 |
| weekly subcutaneous | #35 |
| rviia | #35 |
| embolism | #35 |
| 36 95 | #35 |
| patients efficiency | #35 |
| pph blood loss | #35 |
| enoxaparin prevention | #35 |
| statin association | #35 |
| radiologists diagnosis | #35 |
| prevention model | #35 |
| neoplasms venous | #35 |
| activation coagulation | #35 |
| risk members | #35 |
| lung scanning | #35 |
| venous thromboembolic disease | #36 |
| catheterrelated infection | #36 |
| iii antithrombin | #36 |
| regular monitoring | #36 |
| fibrinogen depletion | #36 |
| peripheral endovascular | #36 |
| venous thromboembolism dabigatran | #36 |
| fibrinolytic activation | #36 |
| 287 patients | #36 |
| acute symptomatic | #36 |
| novoseven | #36 |
| inherited risk factors | #36 |
| treatment acute vte | #36 |
| levels coagulation | #36 |
| hellp patients | #36 |
| factors travel | #36 |
| dose reduction patients | #36 |
| riskbenefit | #36 |
| thrombophilia venous | #36 |
| studies echocardiography | #36 |
| 1698 | #36 |
| 4139 | #36 |
| viii levels | #36 |
| screening occult | #37 |
| anticoagulant action | #37 |
| genotype 95 | #37 |
| suspected venous | #37 |
| magellan | #37 |
| excluding | #37 |
| factors thrombophilia | #37 |
| perelated mortality | #37 |
| risk factors pts | #37 |
| warfarin 95 | #37 |
| thrombosis humans | #37 |
| vte increased | #37 |
| anticoagulants prevention | #37 |
| cumulative incidence vte | #37 |
| tat complexes | #37 |
| ctpa patients | #37 |
| lwmh | #37 |
| bagsvaerd | #37 |
| venography | #37 |
| risk venous thrombosis | #37 |
| ototoxicity nephrotoxicity | #37 |
| pad studies | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| prophylactic heparin | #37 |
| outcome composite | #37 |
| recombinant hirudin | #37 |
| vte cancer patients | #38 |
| vte bleeding | #38 |
| catheterrelated thrombosis | #38 |
| nonmajor bleeding | #38 |
| anticoagulants female humans | #38 |
| 10 total | #38 |
| coagulation protein | #38 |
| patients ddimer levels | #38 |
| 3306 | #38 |
| recurrence day | #38 |
| congenital deficiencies | #38 |
| restenosis reocclusion | #38 |
| doac lmwh | #38 |
| 2835 | #38 |
| age recurrence | #38 |
| submassive pulmonary | #38 |
| fetal loss women | #38 |
| sensitivity biomarkers | #38 |
| rivaroxaban placebo | #38 |
| fibrin fibrinogen | #39 |
| low molecular weight | #39 |
| compression stocking | #39 |
| time compression | #39 |
| incidence patients | #39 |
| continued treatment | #39 |
| doacs | #39 |
| specificity patients | #39 |
| heparins lmwhs | #39 |
| enoxaparin placebo | #39 |
| submassive | #39 |
| embolus | #39 |
| subcutaneous intention | #39 |
| septic syndrome | #39 |
| superficial vein thrombosis | #39 |
| incidence cancer | #39 |
| 277 patients | #39 |
| children familial hypercholesterolemia | #39 |
| diagnostic prediction | #39 |
| systemic inflammatory responses | #39 |
| common femoral vein | #40 |
| ambulatory cancer | #40 |
| episode venous thromboembolism | #40 |
| bleeding | #40 |
| arterial vascular | #40 |
| day 6 months | #40 |
| standardized definition | #40 |
| anticoagulant therapy | #40 |
| tfmp | #40 |
| activatable fibrinolysis | #40 |
| patients normal | #40 |
| dalteparin treatment | #40 |
| international clinical | #40 |
| pemb | #40 |
| thrombinantithrombin complexes | #40 |
| clotting activation | #40 |
| anticoagulation therapy patients | #40 |
| fviiic | #40 |
| therapeutic dosages | #40 |
| grade 1a patients | #40 |
| endotoxininduced | #40 |
| anticoagulated patients | #41 |
| dabigatran etexilate | #41 |
| triage tests | #41 |
| endotoxin induced | #41 |
| 95 genotype | #41 |
| cancer lmwh | #41 |
| lung scintigraphy | #41 |
| 7268 | #41 |
| risk recurrent vte | #41 |
| heparin therapy | #41 |
| placebo 6 months | #41 |
| submassive pulmonary embolism | #41 |
| calf vein thrombosis | #41 |
| lowmolecularweight heparins | #41 |
| pentasaccharides | #41 |
| stroke thrombosis | #42 |
| patients prospective | #42 |
| neoplasms thrombosis | #42 |
| netilmicin | #42 |
| 8101 | #42 |
| anticoagulation risk | #42 |
| patients silent | #42 |
| type graft | #42 |
| major contributor | #42 |
| standardization committee | #42 |
| prophylaxis venous | #42 |
| thrombosis administration | #42 |
| patients vasopressors | #42 |
| cell extravasation | #42 |
| warfarin anticoagulants | #43 |
| initial treatment | #43 |
| post‐thrombotic syndrome | #43 |
| venous thrombosis thrombophilia | #43 |
| 543 patients | #43 |
| cancer adjusted | #43 |
| draft document | #43 |
| ischemic events | #43 |
| heparin risk | #43 |
| patients vte risk | #43 |
| venous thromboembolism vte | #43 |
| monthly incidence | #43 |
| vkas patients | #43 |
| rtap | #43 |
| probability patients | #43 |
| fetal loss | #43 |
| recurrent vte 95 | #44 |
| enoxaparin risk | #44 |
| protein sepsis | #44 |
| efficiency models | #44 |
| nonvka oral anticoagulants | #44 |
| 10–14 | #44 |
| patients tinzaparin | #44 |
| 95 pulmonary embolism | #44 |
| uedvt patients | #44 |
| role coagulation | #44 |
| experimental venous thrombosis | #44 |
| mild hyperhomocysteinaemia | #44 |
| rate venous | #44 |
| indications patients | #44 |
| factors thromboembolism | #44 |
| 20 30 | #44 |
| restoration euthyroidism | #44 |
| edoxaban therapy | #44 |
| expert physicians | #44 |
| wells score | #45 |
| venous thrombotic | #45 |
| coumarin therapy | #45 |
| treated warfarin | #45 |
| dvt patients | #45 |
| coagulation activation | #45 |
| patients bnp | #45 |
| revascularisation procedures | #45 |
| 95 warfarin | #45 |
| oral direct | #45 |
| fondaparinux patients | #45 |
| dose adjusted | #45 |
| dose lmwh | #45 |
| years algorithm | #45 |
| extended duration | #46 |
| prothrombin fragment f1 | #46 |
| percent confidence | #46 |
| bleeding rivaroxaban | #46 |
| day levels | #46 |
| pioped | #46 |
| standard therapy | #46 |
| major bleeding placebo | #46 |
| treatment model | #46 |
| stroke risk assessment | #46 |
| abtpo | #46 |
| patients unprovoked vte | #46 |
| management venous | #46 |
| daily rivaroxaban | #46 |
| hospital outpatients | #46 |
| healthcare settings | #46 |
| ssc isth | #46 |
| ruling | #46 |
| bristol myers squibb | #47 |
| mechanical prophylaxis | #47 |
| outcome vitamin | #47 |
| central venous lines | #47 |
| iiia receptors | #47 |
| episode vte | #47 |
| roccurve | #47 |
| mutation pregnancy | #47 |
| boehringer ingelheim | #47 |
| plasma ddimer levels | #47 |
| new oral anticoagulant | #47 |
| ambulatory anticoagulants | #47 |
| male methimazole | #47 |
| rivaroxaban compared | #48 |
| intermediate risk risk | #48 |
| factors rivaroxaban | #48 |
| diagnosis physicians | #48 |
| small studies | #48 |
| thromboprophylactic | #48 |
| daiichi | #48 |
| fondaparinux heparin | #48 |
| risk recurrent | #48 |
| patients pulmonary | #48 |
| subcommittee | #48 |
| recurrence venous thromboembolism | #48 |
| travel risk | #48 |
| elevated plasma levels | #48 |
| patients acute dvt | #48 |
| thrombotic burden | #48 |
| calf vein | #49 |
| factor viii deficiency | #49 |
| levels protein | #49 |
| women aspirin | #49 |
| vte diagnosis | #49 |
| enoxaparin | #49 |
| lowmolecularweight heparin lmwh | #49 |
| rivaroxaban prevention | #49 |
| buller | #50 |
| intensity treatment | #50 |
| cardiac surgery mortality | #50 |
| etexilate | #50 |
| vitamink antagonists | #50 |
| outpatient therapy | #50 |
| acute respiratory insufficiency | #50 |
| nonselective betablockers | #50 |
| thromboembolism aged | #50 |
| incidence venous thromboembolism | #50 |
| prospective diagnostic | #50 |
| transient risk factor | #50 |
| dvt diagnosis | #50 |
| atria patients | #50 |
| treatment threshold | #50 |
| acenocoumarol | #51 |
| protein deficiencies | #51 |
| effects coagulation | #51 |
| 95 apixaban | #51 |
| discrimination model | #51 |
| global disease | #51 |
| strategies treatment | #51 |
| patients 11 | #51 |
| normal perfusion | #51 |
| tomography pulmonary | #51 |
| previous survey | #51 |
| factor vte | #51 |
| patients comorbid conditions | #52 |
| unnecessarily | #52 |
| doacs vka | #52 |
| hematologic malignancies patients | #52 |
| apixaban vte | #52 |
| svt patients | #52 |
| inhibitors heparin | #52 |
| vte major bleeding | #52 |
| pdvt | #52 |
| free thyroxine ft4 | #52 |
| 1·12 | #52 |
| risk venous thromboembolism | #52 |
| 3 month | #52 |
| lung scans | #52 |
| lmwh fondaparinux | #52 |
| 1522 | #53 |
| hemostatic balance | #53 |
| 479 patients | #53 |
| cross study | #53 |
| versus enoxaparin | #53 |
| reported incidence | #53 |
| thrombophilic factors | #53 |
| postthrombotic syndrome | #53 |
| thromboembolism prevention | #53 |
| absolute risks | #53 |
| patients initially | #53 |
| warfarintreated patients | #53 |
| preference patients | #53 |
| suspected venous thromboembolism | #53 |
| 40 daily | #53 |
| acquired risk factors | #54 |
| 2537 | #54 |
| familial thrombophilia | #54 |
| 378 patients | #54 |
| major bleeds | #54 |
| antithrombotic drug | #54 |
| male pulmonary embolism | #54 |
| endocrine disorders | #54 |
| pai1 levels patients | #54 |
| bled score | #54 |
| vte mortality | #54 |
| prethrombotic | #54 |
| chads2 cha2ds2vasc | #54 |
| thromboembolism death | #54 |
| patients incidence | #54 |
| 034 | #54 |
| patients obese | #54 |
| long term risk | #55 |
| insurances | #55 |
| biological pan | #55 |
| dosereduction | #55 |
| unfractionated heparin ufh | #55 |
| methods randomized | #55 |
| compared lmwh | #55 |
| rivaroxaban | #55 |
| legs patients | #55 |
| unfractionated heparin | #55 |
| nondeficient | #55 |
| proximal extent | #55 |
| treatment thresholds | #55 |
| anticoagulants arthroplasty replacement | #55 |
| vitamin warfarin | #56 |
| tromboembólica | #56 |
| vte death | #56 |
| weight heparins | #56 |
| enoxaparin rivaroxaban | #56 |
| inr values | #56 |
| major bleeding apixaban | #56 |
| physicians guidelines | #56 |
| risk major bleeding | #56 |
| time event | #56 |
| vasopressors | #56 |
| venous outflow obstruction | #56 |
| deficiency prevalence | #56 |
| preeclampsia hellp syndrome | #56 |
| 20210a | #56 |
| level mortality | #56 |
| reduced capacity | #56 |
| seventh accp conference | #56 |
| enoxaparin patients | #56 |
| calf dvt | #57 |
| subsegmental pulmonary | #57 |
| ctscan | #57 |
| risk factors vte | #57 |
| clinical models | #57 |
| antithrombin iii heparin | #57 |
| inhibitors female humans | #57 |
| levels survival | #57 |
| unfractionated heparin patients | #58 |
| fibrinolysis humans | #58 |
| inhibitors female | #58 |
| doacs patients | #58 |
| lowmolecular weight heparin | #58 |
| malignancy mortality | #58 |
| spiral computed | #58 |
| pharmo | #58 |
| ruled | #58 |
| thrombin activatable | #58 |
| incidence symptomatic | #59 |
| bias trial | #59 |
| mutation prothrombin | #59 |
| heterozygous factor | #59 |
| aventis | #59 |
| risk vte | #59 |
| thrombosis aged | #59 |
| risk factors sensitivity | #59 |
| factor generation | #59 |
| warfarin treatment | #59 |
| acute venous thromboembolism | #59 |
| direct oral | #59 |
| risk periods | #59 |
| clot lysis time | #59 |
| safety warfarin | #59 |
| fixeddose | #60 |
| women difference | #60 |
| constans | #60 |
| prevalence pulmonary | #60 |
| pulmonary embolism 95 | #60 |
| hemorrhage humans | #60 |
| anticoagulants treatment | #60 |
| atrial fibrillation metaanalysis | #60 |
| pediatric venous thromboembolism | #60 |
| target inr | #60 |
| 079 95 | #60 |
| acute pulmonary embolism | #60 |
| awareness risk factors | #60 |
| dvt 95 | #61 |
| free thyroxine | #61 |
| long‐term treatment | #61 |
| month surgery | #61 |
| amuse | #61 |
| tests prevalence | #61 |
| hypocoagulable | #61 |
| perfusion ventilation | #61 |
| benzimidazoles dabigatran | #61 |
| 3633 | #61 |
| rosendaal | #61 |
| association protein | #61 |
| cdr score | #61 |
| combined contraceptives oral | #62 |
| 250 patients | #62 |
| activated partial | #62 |
| protein fibrinogen | #62 |
| human endotoxemia | #62 |
| procoagulant state | #62 |
| general practitioners patients | #62 |
| informatizado | #62 |
| 273 patients | #62 |
| ttr patients | #62 |
| post thrombotic | #62 |
| patients administration | #62 |
| management anticoagulation | #63 |
| quantitative test | #63 |
| vte thromboprophylaxis | #63 |
| women mutations | #63 |
| physicians predictive | #63 |
| cvrs | #63 |
| factor leiden risk | #63 |
| rivaroxaban lmwh | #63 |
| smoking smoking cessation | #63 |
| 33 women | #63 |
| injection endotoxin | #63 |
| common odds ratio | #63 |
| symptoms dvt | #63 |
| venous thromboembolisms | #63 |
| treatment network | #63 |
| revised geneva score | #63 |
| factor inhibitors | #64 |
| cancer noncancer patients | #64 |
| patients aortic valve | #64 |
| postthrombotic | #64 |
| acute pulmonary | #64 |
| blinded trial | #64 |
| heparin fondaparinux | #64 |
| superficial vein | #64 |
| vkas treatment | #64 |
| selfadjustment | #64 |
| oral thrombin | #64 |
| bleeding events patients | #64 |
| decision rules | #64 |
| dvts | #64 |
| prior vte | #64 |
| thrombophilic risk | #64 |
| ultrasonograms | #65 |
| accuracy diagnostic tests | #65 |
| fvl vte | #65 |
| prevalence abnormalities | #65 |
| prothrombin g20210a mutation | #65 |
| treatment pad | #65 |
| stroke thromboembolism | #65 |
| 95 bleeding | #66 |
| death classification | #66 |
| newer anticoagulants | #66 |
| statin therapy risk | #66 |
| rapid triage | #66 |
| axa | #66 |
| risk factor thrombosis | #66 |
| elfa | #66 |
| female heparin | #66 |
| 0 points | #66 |
| dvt sensitivity | #66 |
| apixaban | #67 |
| patients tertiles | #67 |
| patients factor | #67 |
| standard therapy patients | #67 |
| 1127 | #67 |
| atrial fibrillation stroke | #67 |
| rate major | #67 |
| patients bnp levels | #68 |
| ranging study | #68 |
| academic medical centre | #68 |
| 1894 | #68 |
| perioperative blood | #68 |
| fibrinolytic | #68 |
| 3594 | #68 |
| coagulation fibrinolysis | #68 |
| 20210g | #68 |
| 05 95 | #68 |
| patients benefits | #68 |
| recurrent thrombosis patients | #69 |
| ionis | #69 |
| postphlebitic | #69 |
| thrombosis blood | #69 |
| certoparin | #69 |
| heparin ufh | #69 |
| suspected | #69 |
| plasma interleukin | #69 |
| justify | #69 |
| enfermedad tromboembólica | #69 |
| rivaroxaban treatment | #70 |
| major bleeding complications | #70 |
| 8190 | #70 |
| gramnegative sepsis | #70 |
| thrombosis recurrence | #70 |
| patients protein | #70 |
| withhold | #70 |
| vwfrco | #70 |
| α2ap | #70 |
| fixed dose | #70 |
| elevated cardiac | #70 |
| mantelhaenszel | #70 |
| cutoff levels | #70 |
| ischemic events patients | #70 |
| aged predictive | #70 |
| test patients | #70 |
| thromboprophylaxis | #71 |
| diagnostic sensitivity specificity | #71 |
| levels vwf | #71 |
| asymptomatic atherosclerosis | #71 |
| unfractionated | #71 |
| tests prospective | #71 |
| topic costs | #71 |
| vte vka | #71 |
| clopidogrel placebo | #71 |
| plasminogen plg | #71 |
| complications hematologic | #72 |
| overt hypothyroidism | #72 |
| elevated factor | #72 |
| antithrombin iii iii | #72 |
| pooled rate | #72 |
| versus vitamin | #72 |
| viia factor | #72 |
| new anticoagulant | #72 |
| hf studies | #72 |
| activation prothrombin | #72 |
| trifurcation | #72 |
| ddimer values | #72 |
| patients lmwh | #72 |
| analysis diagnostic | #73 |
| noacs | #73 |
| prolongations | #73 |
| 12 months 95 | #73 |
| reversal agent | #73 |
| soluble fibrin | #73 |
| ingelheim | #73 |
| ddimer measurement | #73 |
| tomography spiral | #73 |
| female hemorrhage | #74 |
| longterm risk | #74 |
| prethrombotic state | #74 |
| 2124 | #74 |
| carriers | #74 |
| 5395 | #74 |
| proteins patients | #74 |
| dvt study | #74 |
| suspected dvt | #74 |
| study selection | #74 |
| experimental metastasis | #74 |
| 2550 | #74 |
| soluble thrombomodulin | #74 |
| 1732 | #74 |
| postoperative dvt | #75 |
| 8492 | #75 |
| 2904 | #75 |
| carotid femoral arteries | #75 |
| retrospective follow | #75 |
| 1334 | #75 |
| incidence bleeding events | #75 |
| thrombolytic therapy patients | #75 |
| selective factor | #75 |
| duration thromboprophylaxis | #76 |
| extended anticoagulation | #76 |
| early time | #76 |
| tests primary | #76 |
| combined contraceptives | #76 |
| oral combined contraceptives | #76 |
| angiography ctpa | #76 |
| risk thrombosis | #76 |
| factor xii deficiency | #76 |
| individual patient | #77 |
| social aspects | #77 |
| boehringer | #77 |
| thrombosis pregnancy | #77 |
| p023 | #77 |
| patients secondary | #77 |
| women thrombophilia | #78 |
| elevated dimer | #78 |
| female fibrinolysis | #78 |
| arterial wall thickness | #78 |
| arterial thromboembolism | #78 |
| 20 daily | #78 |
| ipg | #78 |
| unprovoked | #78 |
| vte fvl | #79 |
| efficacy agents | #79 |
| topic heparin | #79 |
| time therapeutic | #79 |
| 2486 | #79 |
| humans pulmonary | #79 |
| vkas | #79 |
| limulus test | #79 |
| suspected acute | #79 |
| factor adult | #79 |
| validation models | #80 |
| suspected cancer | #80 |
| thromboembolism incidence | #80 |
| subhazard ratio | #80 |
| 95 05 | #80 |
| patient data | #80 |
| bleeding mortality | #80 |
| heterozygous deficiency | #80 |
| vte rate | #80 |
| daily bid | #80 |
| alife | #80 |
| sspe patients | #80 |
| vascular events | #81 |
| systemic inflammatory | #81 |
| walking distance | #81 |
| weitz | #81 |
| test evaluation | #81 |
| lmwh vte | #81 |
| topic risk | #81 |
| prothrombin complex concentrate | #81 |
| outpatient basis | #81 |
| knee arthroplasty patients | #81 |
| common practice | #82 |
| clinical sign | #82 |
| thrombolytic drugs | #82 |
| 3month followup | #82 |
| 50 micrograms | #82 |
| thrombosis incidence | #82 |
| prospective validation | #82 |
| placebo women | #82 |
| symptomatic carriers | #82 |
| mammography patients | #82 |
| heparin prevention | #82 |
| crnmb | #82 |
| thrombosis thrombophilia | #82 |
| posthoc analysis | #82 |
| timeperiods | #82 |
| 287 | #83 |
| bleeding women | #83 |
| 2213 | #83 |
| inhibitor dabigatran | #83 |
| elective coronary | #83 |
| bistro | #83 |
| patients thrombi | #83 |
| dimer patients | #83 |
| duration therapy | #84 |
| heparin treatment | #84 |
| inhibitor rivaroxaban | #84 |
| prophylactic dose | #84 |
| healthcare setting | #84 |
| inherited thrombophilia | #84 |
| screening humans | #84 |
| normotensive patients | #84 |
| diagnostic outcome | #84 |
| peripheral vascular diseases | #85 |
| asymptomatic dvt | #85 |
| venous thrombosis patients | #85 |
| antithrombin iii protein | #85 |
| normal levels | #85 |
| anticoagulants antiphospholipid | #85 |
| endotoxins | #85 |
| thrombosis svt | #85 |
| 75 microg | #86 |
| 4576 | #86 |
| major bleeding warfarin | #86 |
| venovenous hemofiltration | #86 |
| elevated ddimer levels | #86 |
| rhapc | #86 |
| dabigatran vka | #86 |
| 10⁶ | #86 |
| contact activation | #87 |
| acute venous | #87 |
| patients 28 | #87 |
| 95 100 | #87 |
| ≤50 | #87 |
| post‐hoc analysis | #87 |
| vidas | #87 |
| avws | #87 |
| clinical impact | #87 |
| obstetric patients | #87 |
| 3319 | #88 |
| cdr | #88 |
| lmwhs | #88 |
| washout period | #88 |
| internist | #88 |
| 4 points | #88 |
| venographic | #88 |
| treatment statins | #88 |
| treatment incidence | #88 |
| activation factor | #88 |
| aged multicenter | #88 |
| unexplained recurrent | #89 |
| costs patient | #89 |
| anticoagulants dabigatran | #89 |
| tests test | #89 |
| beta blockers | #89 |
| smoking incidence | #89 |
| reversal strategies | #89 |
| adequate treatment | #89 |
| cytokine release | #89 |
| matisse | #89 |
| vte venous thromboembolism | #89 |
| rates major bleeding | #89 |
| safety noacs | #89 |
| ventilation lung | #89 |
| ddimer | #89 |
| severe hf | #89 |
| stroke bleeding | #89 |
| thrombophilic risk factors | #90 |
| primary thromboprophylaxis | #90 |
| fibrinolytic factors | #90 |
| vka dabigatran | #90 |
| outweighs | #90 |
| venous thrombosis risk | #90 |
| new patients | #90 |
| popliteal vein | #90 |
| 2293 | #90 |
| pediatric venous | #90 |
| agents hemorrhage | #91 |
| thromboembolism pregnancy | #91 |
| cdrs | #91 |
| 20210 | #91 |
| 60 95 | #91 |
| perfusion ratio | #91 |
| inconvenience | #91 |
| pyridines pyridones | #91 |
| anticoagulants doacs | #91 |
| thrombosis women | #91 |
| prophylaxis incidence | #92 |
| thrombotic disease | #92 |
| combined clinical | #92 |
| single intravenous | #92 |
| 95 years | #93 |
| anticoagulation reversal | #93 |
| scenario analyses | #93 |
| rivaroxaban edoxaban | #93 |
| incidence knee | #93 |
| direct thrombin inhibitors | #93 |
| compression patients | #93 |
| patients symptomatic | #94 |
| hf severity | #94 |
| 125 patients | #94 |
| children vte | #94 |
| heparins | #94 |
| test result | #94 |
| atherogenic lipid | #94 |
| vte surgery | #94 |
| 1027 | #94 |
| direct oral anticoagulant | #95 |
| viia rfviia | #95 |
| european consensus statement | #95 |
| 2 levels | #95 |
| risk symptomatic | #96 |
| fondaparinux treatment | #96 |
| efficacy rivaroxaban | #96 |
| symptomatic vte | #96 |
| 6 12 months | #96 |
| randomised crossover study | #96 |
| xii deficiency | #96 |
| ddimer level | #96 |
| invasive testing | #97 |
| doacs risk | #97 |
| symptomatic pulmonary embolism | #97 |
| pyrazoles pyridones | #97 |
| tpa release | #97 |
| haemophilia patients | #97 |
| fibrin generation | #97 |
| abnormal perfusion | #97 |
| studies evaluated | #97 |
| difference rates | #97 |
| supervised exercise therapy | #98 |
| pregnancy postpartum period | #98 |
| activated protein apc | #98 |
| 16slice | #98 |
| essential thrombocythaemia | #98 |
| major bleed | #98 |
| simplify | #98 |
| hypercoagulable | #98 |
| 2875 | #98 |
| risk arterial | #99 |
| hirudin | #99 |
| 2·0 | #99 |
| perfusion scintigraphy | #99 |
| acute dvt | #99 |
| probast | #99 |
| unselected | #99 |
| lmwh warfarin | #99 |
| prevention recurrent | #100 |
| fatty foods | #100 |
| 1116 | #100 |
| previews | #100 |
| increasing levels | #100 |
| patient groups | #100 |
| 3 trials | #100 |
| gbd 2010 | #100 |
| warfarin patients | #100 |
| doubleblind trial | #100 |
| aptts | #101 |
| factor viia | #101 |
| morpholines | #101 |
| factor vii factor | #101 |
| venous thromboembolism women | #102 |
| 40 microg | #102 |
| enoxaparin fondaparinux | #102 |
| 265 patients | #102 |
| low pretest probability | #102 |
| pts patients | #102 |
| alternative diagnosis | #102 |
| arthroscopic anterior | #103 |
| pregnancy puerperium | #103 |
| therapeutic consequences | #103 |
| cteph patients | #103 |
| doppler method | #103 |
| endogenous thrombin | #103 |
| adjudicated | #103 |
| 338 | #103 |
| recurrence women | #104 |
| fibrin degradation products | #104 |
| diagnostic imaging humans | #104 |
| apparent increase | #104 |
| oral factor | #104 |
| heparin pregnancy | #104 |
| partial restoration | #104 |
| separate analyses | #104 |
| term treatment | #104 |
| absolute increase | #104 |
| assay variation | #104 |
| antithrombin iii | #104 |
| 7 children | #105 |
| embryo loss | #105 |
| 1089 | #105 |
| conventional therapy patients | #105 |
| 2479 | #106 |
| hospitalized patients hf | #106 |
| thrombosis age | #106 |
| thrombophilia | #106 |
| essentials | #106 |
| 314 | #106 |
| fibrinolytic systems | #106 |
| elevated levels | #106 |
| study total | #106 |
| chest ray | #106 |
| blind double | #106 |
| thromboprophylaxis patients | #106 |
| simplified version | #107 |
| vte risk | #107 |
| survival cancer patients | #107 |
| definition classification | #107 |
| ddimer levels | #107 |
| thromboembolic | #107 |
| topic recurrence | #107 |
| post thrombotic syndrome | #108 |
| cardiovascular death stroke | #108 |
| grade 1c | #108 |
| human volunteers | #108 |
| patients cancer | #108 |
| specific subgroups | #108 |
| noncancer patients | #108 |
| evaluation studies | #109 |
| routine coagulation | #109 |
| viia | #109 |
| embolism treatment | #109 |
| synthetic pentasaccharide | #109 |
| thrombin antithrombin | #109 |
| 500μg | #109 |
| factor mutation | #109 |
| anticoagulants cohort | #109 |
| 1235 | #109 |
| 039 | #109 |
| inferiority trial | #110 |
| thrombosis treated | #110 |
| cancer activity | #110 |
| primary safety | #110 |
| vka doac | #110 |
| embolism quality | #110 |
| subsequent pregnancy | #110 |
| antiplasmin | #110 |
| anticoagulants biomarkers | #111 |
| treatment risk factors | #111 |
| humans intermittent | #111 |
| negative predictive 100 | #111 |
| predefined | #111 |
| comparison control | #111 |
| siset | #111 |
| obstetric complications | #111 |
| recurrence treatment | #112 |
| efficacy prevention | #112 |
| thromboembolic diseases | #112 |
| patients ventricular dysfunction | #112 |
| chromogenic | #112 |
| patients 70 | #112 |
| topic guidelines | #112 |
| risk rivaroxaban | #112 |
| emergency situations | #112 |
| rivaroxaban enoxaparin | #112 |
| publication anticoagulants | #112 |
| epidemiology risk factors | #112 |
| nonionic contrast | #113 |
| metabolic response | #113 |
| inappropriate treatment | #113 |
| lmwh risk | #113 |
| heterozygous carriers | #113 |
| patients nephrotoxicity | #113 |
| dialysers | #114 |
| postphlebitic syndrome | #114 |
| 0·0 | #114 |
| total knee replacement | #114 |
| cancerassociated vte | #114 |
| patients intermediate | #114 |
| study centre | #114 |
| patients recurrent | #115 |
| 393 | #115 |
| global public | #115 |
| fibrinogen vwf | #115 |
| hyperhomocysteinaemia | #115 |
| positive predictive values | #115 |
| major bleeding 95 | #116 |
| topic dabigatran | #116 |
| effects tnf | #116 |
| heparin warfarin | #116 |
| life treatment | #116 |
| agents heparin | #116 |
| vte data | #116 |
| reference standard | #116 |
| anticoagulants arthroplasty | #116 |
| computed tomography patients | #116 |
| women severe preeclampsia | #116 |
| vte complications | #117 |
| protein resistance | #117 |
| protein inhibitor pci | #117 |
| vte children | #117 |
| arthroscopies | #117 |
| women caesarean | #117 |
| 2460 | #117 |
| fibrinolytic parameters | #117 |
| proximal dvt | #118 |
| autopsyconfirmed | #118 |
| 4118 | #118 |
| arterial thrombosis patients | #118 |
| 2744 | #118 |
| patients extensive | #118 |
| incidence pulmonary embolism | #119 |
| compression stockings | #119 |
| humans leg | #119 |
| compared warfarin | #119 |
| patients doac | #119 |
| lactoferrin leukocyte | #120 |
| healthy humans | #120 |
| rivaroxaban patients | #120 |
| months follow | #120 |
| dabigatran factor | #120 |
| thrombosis study | #120 |
| previous vte | #120 |
| mortality diseases | #120 |
| acquired deficiency | #120 |
| risk thromboembolism | #120 |
| patients prostatic cancer | #121 |
| thrombocytopenia thrombosis | #121 |
| anti factor | #122 |
| studies venous | #122 |
| patients 6 | #122 |
| fatal pulmonary embolism | #122 |
| oral hormonal | #122 |
| placebo standard | #123 |
| 100 patients | #123 |
| venous thromboembolism pregnancy | #123 |
| minor bleeding | #123 |
| factor xia | #123 |
| acute infection | #123 |
| heparin hirudin | #123 |
| heparin | #123 |
| early dynamics | #123 |
| statin risk | #124 |
| treatment data | #124 |
| thrombophilia pregnancy | #124 |
| ft4 levels | #124 |
| vte lmwh | #124 |
| association level | #124 |
| atherogenic lipid profile | #124 |
| nonsignificantly | #125 |
| puerperal disorders | #125 |
| bayer | #125 |
| skin perfusion | #125 |
| fibrinolysis inhibitor | #125 |
| intravenous heparin | #125 |
| peripheral arterial disease | #125 |
| thromboembolism recurrence | #125 |
| incidence thrombosis | #125 |
| treatment indication | #125 |
| diseases mortality | #125 |
| elevated liver enzymes | #125 |
| upper extremity | #126 |
| doacs treatment | #126 |
| distal dvt | #126 |
| thromboprophylaxis lmwh | #127 |
| performance scores | #127 |
| patients ventilation | #127 |
| unacceptably | #127 |
| occurrence vte | #127 |
| marder | #127 |
| patients permanent | #127 |
| resistance apc | #128 |
| venous thromboembolism risk | #128 |
| treatment months | #128 |
| development vte | #128 |
| patients conventional therapy | #128 |
| 50 age | #128 |
| prevention | #128 |
| direct factor | #128 |
| elevated biomarkers | #129 |
| riete registry | #129 |
| mortality cancer patients | #129 |
| 1041 | #129 |
| 060 | #129 |
| ctrough | #129 |
| plaster cast | #130 |
| internists | #130 |
| day 10 | #130 |
| patients episode | #130 |
| anticoagulants antithrombins | #130 |
| hospital discharge records | #130 |
| 194 patients | #130 |
| 220 | #130 |
| obviating | #131 |
| tests specificity | #131 |
| pooled incidence | #131 |
| 05 patients | #131 |
| long‐term clinical outcomes | #131 |
| linear interpolation | #131 |
| hoc analysis | #132 |
| hypocoagulability | #132 |
| postpartum period women | #132 |
| rivaroxaban versus | #132 |
| avidin | #133 |
| fxa inhibitors | #133 |
| enoxaparin treatment | #133 |
| direct inhibitors | #133 |
| 80 anticoagulants | #133 |
| started | #133 |
| cha2ds2vasc | #133 |
| rco vwf | #134 |
| risk pad | #134 |
| embolism acute | #134 |
| pulmonary angiography patients | #134 |
| instituted | #134 |
| selectin levels | #134 |
| activator plasminogen | #135 |
| bnp concentration | #135 |
| prevalence dvt | #135 |
| anticoagulant prophylaxis | #135 |
| 0056 | #136 |
| months anticoagulation | #136 |
| thrombotic syndrome | #136 |
| followup patients | #136 |
| apixaban edoxaban | #136 |
| severe pph | #136 |
| east asian patients | #136 |
| clinical prediction | #136 |
| point‐of‐care | #137 |
| 99 patients | #137 |
| acquired thrombophilia | #137 |
| phase 3 trials | #137 |
| diagnostic work | #137 |
| factor prothrombin | #137 |
| sequential application | #137 |
| 2283 | #137 |
| national guidelines | #138 |
| complete inhibition | #138 |
| intravascular coagulation dic | #138 |
| bleeding warfarin | #138 |
| antidote | #138 |
| enhanced factor | #138 |
| studies mortality | #138 |
| risk fatal | #139 |
| factor viii factor | #139 |
| patients comparison | #139 |
| reproducibility risk | #139 |
| 2465 | #139 |
| 95 major bleeding | #139 |
| direct inhibitor | #139 |
| 3 weeks | #139 |
| oral anticoagulant treatment | #139 |
| 12 95 | #140 |
| 0114 | #140 |
| human activated | #140 |
| 20 iu | #140 |
| distal deep | #140 |
| vwf rco | #140 |
| ottawa | #140 |
| 80 cohort | #140 |
| dvt incidence | #140 |
| antidotes | #141 |
| thromboembolic disorders | #141 |
| pharmacy records | #141 |
| carriership | #142 |
| thrombin potential | #142 |
| points 95 | #143 |
| warfarin administration | #143 |
| active malignancy | #143 |
| ischaemic events | #143 |
| treatment pulmonary | #143 |
| escherichia humans | #143 |
| geneva | #143 |
| jugular veins | #143 |
| management vte | #144 |
| fatal pulmonary | #144 |
| topic practice patterns | #144 |
| doac treatment | #144 |
| compared treatment | #144 |
| postoperative venous | #144 |
| pregnancy female humans | #144 |
| hyperthyroxinemia | #145 |
| thrombosis model | #145 |
| patient populations | #145 |
| serial testing | #145 |
| referred patients | #145 |
| filters venous | #145 |
| dose rivaroxaban | #145 |
| protein factor | #146 |
| death cancer patients | #146 |
| derived microvesicles | #146 |
| months treatment | #146 |
| tissue factor pathway | #147 |
| personal fees | #147 |
| 10 years patients | #148 |
| partial thromboplastin | #148 |
| long‐acting | #148 |
| embolism diagnosis | #148 |
| 2076 | #148 |
| rebuttal | #148 |
| intention treat | #148 |
| antithrombotic drugs | #148 |
| acute medical illness | #148 |
| 0·45 | #149 |
| individual patient data | #149 |
| risk subgroups | #149 |
| procoagulant | #149 |
| vte hospitalization | #149 |
| thrombocyte | #149 |
| relevant publications | #149 |
| diagnostic score | #149 |
| dimer level | #150 |
| humans injections | #151 |
| enoxaparin unfractionated heparin | #151 |
| additional imaging | #151 |
| coagulation dic | #151 |
| bleeding patients | #152 |
| patient eligibility | #152 |
| patients primary outcome | #152 |
| longterm treatment | #152 |
| continuous venovenous | #152 |
| hypercoagulable state | #153 |
| extracorporeal circuit | #153 |
| thrombosis prevention | #153 |
| cardiopulmonary bypass surgery | #153 |
| point systems | #153 |
| bleeding scores | #154 |
| angioplasty patients | #154 |
| activity mortality | #154 |
| dimer levels | #154 |
| thrombosis factor | #154 |
| direct thrombin | #154 |
| active cancer | #154 |
| curve sensitivity | #155 |
| fiia | #155 |
| states venous | #155 |
| drug factor | #155 |
| warfarin apixaban | #155 |
| thromboembolic event | #155 |
| tomography patients | #155 |
| patients gastrointestinal | #156 |
| 09 | #156 |
| daily oral | #156 |
| coagulant activity | #156 |
| enoxaparin dose | #156 |
| fvl | #156 |
| vte treatment | #156 |
| stockings | #156 |
| recurrent symptoms | #156 |
| hemodynamically | #157 |
| cross‐sectional survey | #157 |
| increased thrombin | #157 |
| prophylaxis patients | #157 |
| 97 | #158 |
| underlying malignancy | #158 |
| 2126 | #158 |
| dfl | #158 |
| months chemotherapy | #158 |
| duration anticoagulation | #158 |
| increased risk thrombosis | #159 |
| adjusted relative risk | #159 |
| schering | #160 |
| plasma dimer | #160 |
| antithrombotic efficacy | #160 |
| children fh | #160 |
| guidelines prevention | #160 |
| thrombotic disorders | #160 |
| 145 patients | #160 |
| 120 minutes | #160 |
| pvo | #161 |
| prophylactics | #161 |
| antagonists patients | #161 |
| patients imaging | #162 |
| incidence vte | #162 |
| women time | #162 |
| lysine analogues | #162 |
| 2206 | #162 |
| 198 patients | #163 |
| rates vte | #163 |
| increased plasma levels | #163 |
| lmwh therapy | #163 |
| strain gauge | #163 |
| imaging test | #163 |
| venous thrombus | #163 |
| factors bleeding | #163 |
| coagulation blood | #163 |
| inborn humans | #164 |
| 028 | #164 |
| age comorbidity | #164 |
| justified | #164 |
| observer variability | #164 |
| relatives patients | #165 |
| subhazard | #165 |
| patients enoxaparin | #165 |
| mutation factor | #165 |
| phlebography | #166 |
| stockings compression | #166 |
| viii factor | #166 |
| pravastatin therapy | #166 |
| management venous thromboembolism | #166 |
| strategies patients | #166 |
| microvascular thrombosis | #166 |
| 3658 | #167 |
| recurrent thrombosis | #167 |
| ankle brachial abi | #167 |
| thrombin venous | #167 |
| treatment 3 months | #168 |
| syndrome pts | #168 |
| recurrent acute | #168 |
| current clinical practice | #168 |
| warfarin | #168 |
| double heterozygosity | #168 |
| cvcs | #168 |
| cstatistics | #168 |
| 3 12 | #169 |
| patients infections | #169 |
| preexistent | #169 |
| fold increased | #169 |
| postthrombotic syndrome pts | #169 |
| therapeutic range | #169 |
| risk profile | #169 |
| thrombosis cancer | #170 |
| heavy menstrual bleeding | #170 |
| cart patients | #170 |
| interobserver agreement | #170 |
| postoperative blood loss | #170 |
| recombinant factor | #171 |
| venous thrombotic events | #171 |
| aged algorithms | #171 |
| adamts‐13 | #171 |
| 57 years | #171 |
| clinical trials patients | #172 |
| patients blood transfusion | #172 |
| pulmonology | #172 |
| risk factors patients | #172 |
| lmw heparin | #172 |
| antifibrinolytic | #172 |
| vaginal bleeding | #172 |
| inr | #173 |
| pulmonary | #173 |
| hospitalized medical patients | #173 |
| bleeds | #173 |
| bleeding tendency | #174 |
| clinically bleeding | #174 |
| arterial occlusions | #174 |
| patients initial | #174 |
| laboratory monitoring | #174 |
| data control | #175 |
| fragment 1 | #175 |
| reocclusion | #175 |
| arterial venous | #175 |
| vte common | #175 |
| picotamide | #177 |
| prothrombin | #177 |
| mitsubishi | #177 |
| short‐ | #178 |
| intention analysis | #178 |
| hyperthyroidism hypothyroidism | #178 |
| 122 | #178 |
| aspirin ticlopidine | #178 |
| baseline day | #179 |
| vte event | #179 |
| noninferior | #179 |
| oral female humans | #179 |
| concomitance | #179 |
| ventilation perfusion | #180 |
| isth | #180 |
| patients deficiency | #180 |
| additional risk factors | #180 |
| thromboplastin time | #180 |
| referral bias | #180 |
| aged partial | #181 |
| painkillers | #182 |
| testing patients | #182 |
| acute episode | #182 |
| antithrombin | #182 |
| biological variation | #183 |
| hyperhomocysteinemic | #183 |
| patients major | #183 |
| 2–4 | #183 |
| n110 | #184 |
| subsequent diagnosis | #184 |
| prognosis pulmonary | #184 |
| treat analysis | #184 |
| antithrombin iii atiii | #184 |
| incidental | #184 |
| pregnancy vte | #184 |
| thromboinflammation | #184 |
| coagulation factors | #184 |
| risk bleeding | #184 |
| 4150 | #184 |
| vte age | #185 |
| deficient patients | #185 |
| symptomatic | #186 |
| brain natriuretic | #186 |
| studies heparin | #186 |
| patients intensive units | #186 |
| live birth rate | #186 |
| hemostatic effects | #186 |
| anticoagulated | #186 |
| patients thromboprophylaxis | #186 |
| patients haemophilia | #187 |
| risk composite | #187 |
| antifibrinolytic agents | #187 |
| cutoff level | #187 |
| safety apixaban | #187 |
| humans international | #188 |
| 926 | #188 |
| spontaneous rupture | #188 |
| absolute rate | #188 |
| ratio inr | #188 |
| prevalence cancer | #188 |
| doacs vkas | #188 |
| heparin administration | #189 |
| 64slice | #189 |
| fibrinolysis | #189 |
| clinical validity | #189 |
| riete | #189 |
| patients netherlands | #189 |
| viia female | #189 |
| willebrand factor antigen | #189 |
| blood loss patients | #189 |
| current views | #190 |
| thrombosis patients | #190 |
| ccus | #190 |
| ischemic event | #190 |
| anticoagulant drugs | #190 |
| score patients | #191 |
| 07 | #191 |
| acute thrombosis | #191 |
| attending physicians | #191 |
| venous outflow | #191 |
| gogh | #191 |
| 058 | #192 |
| stroke systemic | #192 |
| 1495 | #192 |
| endothelial cell activation | #193 |
| coagulation assays | #193 |
| blood coagulation | #194 |
| 070 | #194 |
| heparin patients | #194 |
| prothrombin activation | #194 |
| anticoagulation | #194 |
| antagonist treatment | #195 |
| 65 months | #195 |
| recurrent ischemic events | #195 |
| antixa levels | #195 |
| risk major | #195 |
| target range | #195 |
| coagulation status | #196 |
| abnormal test | #196 |
| 29 95 | #196 |
| complications cardiovascular | #196 |
| vii rfviia | #198 |
| difference treatment | #198 |
| sew2871 | #198 |
| vwf adamts13 | #198 |
| treatment groups patients | #198 |
| ate | #198 |
| cachectin | #199 |
| patient diagnosis | #199 |
| coagulation monitoring | #199 |
| patients 12 months | #200 |
| obese controls | #200 |
| screening patients | #200 |
| incidence cardiovascular events | #200 |
| vte incidence | #201 |
| thromboembolic disease | #201 |
| thrombin factor | #201 |
| patients abnormal | #201 |
| validation sets | #201 |
| arterial thrombosis | #202 |
| johnson | #202 |
| 17 95 | #202 |
| peritoneovenous | #202 |
| heparin dose | #203 |
| induced activation | #203 |
| symptomatic pad | #203 |
| worldwide survey | #203 |
| invitees | #203 |
| levonorgestrel | #204 |
| antithrombotic agents | #204 |
| 0 95 | #205 |
| thrombophilia risk | #205 |
| period time | #205 |
| extended thromboprophylaxis | #205 |
| stroke systemic embolism | #205 |
| low incidence | #205 |
| varese | #206 |
| data synthesis | #206 |
| fgt | #206 |
| patients anticoagulant therapy | #206 |
| venous ultrasonography | #206 |
| fviii | #207 |
| platelet activation patients | #207 |
| algorithms anticoagulants | #207 |
| death female humans | #207 |
| methods consecutive | #207 |
| objectively | #207 |
| imt patients | #207 |
| desogestrel | #207 |
| 06 | #207 |
| cardiologist | #207 |
| systematic review studies | #207 |
| thrombocythaemia | #208 |
| bleeding compared | #208 |
| patients hypothyroidism | #208 |
| deficiency risk | #209 |
| free protein | #209 |
| hirudins | #210 |
| tgt | #210 |
| women frequency | #210 |
| antixa activity | #210 |
| systemic embolism patients | #211 |
| stocking | #211 |
| toxaemia | #211 |
| ioxaglate | #211 |
| atrial fibrillation study | #212 |
| anticoagulation management | #212 |
| plasminogen activator activity | #213 |
| heparitin sulfate | #213 |
| topic practice | #214 |
| correct interpretation | #214 |
| dabigatran dose | #214 |
| thrombin inhibition | #215 |
| factors vte | #215 |
| standard duration | #215 |
| current developments | #215 |
| studies rivaroxaban | #215 |
| community hospital | #216 |
| deamino | #216 |
| betatg | #216 |
| warfarin stroke | #216 |
| duplex venous | #216 |
| obviates | #217 |
| diagnostic algorithm | #217 |
| mildest | #217 |
| studies difference | #217 |
| undergoing total | #217 |
| cstatistic | #218 |
| conclusive evidence | #218 |
| g20210a | #218 |
| npv 100 | #218 |
| plasminogen activator inhibitor | #218 |
| deamino arginine | #219 |
| 077 95 | #219 |
| patients cart | #219 |
| cancer | #219 |
| hip replacement surgery | #220 |
| vii factor | #220 |
| data extraction | #220 |
| techniques female | #220 |
| viii female | #220 |
| heparin humans | #221 |
| postoperative vte | #221 |
| healthy human subjects | #221 |
| hmvec | #221 |
| preventive measures | #221 |
| apc resistance | #222 |
| proximally | #222 |
| vte events | #222 |
| 1 january | #223 |
| 1541 | #223 |
| pulmonologists | #223 |
| substantial proportion | #223 |
| engl | #223 |
| protein pathway | #224 |
| subsequent cancer | #224 |
| topic factor | #224 |
| thromboendarterectomy | #224 |
| org | #225 |
| neoplasms prospective | #225 |
| balloon coronary anticoagulants | #225 |
| thrombosis warfarin | #225 |
| kruskalwallis | #225 |
| extremity amputation | #226 |
| vascular events patients | #226 |
| 16 95 | #226 |
| inr monitoring | #226 |
| 0·67 | #226 |
| 35 ± | #227 |
| acute medical | #227 |
| tests diagnosis | #227 |
| haemostasis | #227 |
| mild hyperhomocysteinemia | #228 |
| ipe | #228 |
| dalteparin | #229 |
| scant | #229 |
| cgp | #229 |
| residual thrombus | #229 |
| advocated | #230 |
| 037 | #230 |
| resource utilisation | #231 |
| equinox | #231 |
| ft4 | #231 |
| major orthopaedic surgery | #231 |
| habitual abortion | #231 |
| 6 studies | #231 |
| thiazoles | #231 |
| urosepsis | #231 |
| patients discontinuation | #231 |
| severe preeclampsia | #231 |
| patients warfarin | #232 |
| aspirin dipyridamole | #232 |
| endogenous thrombin potential | #233 |
| cancer prevalence | #233 |
| dimer | #233 |
| surgical embolectomy | #233 |
| recurrence risk factors | #233 |
| humans netherlands | #233 |
| anticoagulant effects | #233 |
| effective alternative | #234 |
| doac | #235 |
| prothrombotic state | #235 |
| graduated compression | #235 |
| humans meta | #236 |
| brain natriuretic peptide | #236 |
| venous thromboembolic events | #236 |
| myocardial infarction 95 | #237 |
| treatment continuation | #237 |
| oral anticoagulants | #237 |
| 009 | #238 |
| 6500 | #238 |
| predictive tests | #238 |
| patients vkas | #238 |
| factor viii fviii | #239 |
| anticoagulants aspirin | #239 |
| rational approach | #239 |
| crossover study | #239 |
| factor tnf | #239 |
| arterial venous thrombosis | #240 |
| patients initial treatment | #240 |
| aspirin heparin | #241 |
| hip knee arthroplasty | #241 |
| 045 | #241 |
| time therapeutic range | #242 |
| bleeding incidence | #242 |
| patients intermittent claudication | #243 |
| prothrombin fragment | #243 |
| pivotal trials | #243 |
| iohexol | #244 |
| n89 | #245 |
| vte risk factors | #245 |
| thrombogenesis | #246 |
| children neonates | #246 |
| casecontrol | #246 |
| vte cases | #246 |
| warfarin aged | #247 |
| antithrombotic | #247 |
| 23 95 | #247 |
| lipoproteina levels | #247 |
| committees | #248 |
| coronary anticoagulants | #248 |
| patients solid tumours | #248 |
| treatment compared | #248 |
| anti activity | #248 |
| diagnostic models | #249 |
| score risk | #249 |
| multiple comorbidities | #249 |
| bleeding rates | #249 |
| fv leiden | #250 |
| ioxaglic | #250 |
| ischemic strokes | #250 |
| protein risk | #250 |
| patients contraindications | #251 |
| finalized | #251 |
| microthrombosis | #251 |
| 8595 | #251 |
| simplification | #252 |
| somit | #252 |
| vkas doacs | #252 |
| thrombin thrombosis | #253 |
| incidence | #253 |
| agents anticoagulants | #254 |
| treatment duration | #254 |
| fibrinolytic activity | #255 |
| palga | #255 |
| activation humans | #256 |
| medea | #256 |
| haul | #256 |
| cost‐effectiveness | #257 |
| activity assay | #257 |
| clinical utility | #257 |
| continuous intravenous | #257 |
| bleeding risk | #257 |
| q24h | #257 |
| fibrin degradation | #258 |
| patient subgroups | #258 |
| ctpa | #258 |
| unpublished data | #259 |
| 30 50 | #259 |
| sspe | #260 |
| dvt risk | #260 |
| toxicosis | #261 |
| thrombus size | #261 |
| heparin dosing | #261 |
| noncarriers | #261 |
| patients hospitalization | #262 |
| risk pulmonary | #263 |
| optimal duration | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| einstein | #267 |
| pbac | #267 |
| statins risk | #268 |
| endotoxaemia | #268 |
| malignancy patients | #269 |
| propeptide | #269 |
| randomised cross | #269 |
| relation time | #269 |
| lysis time | #269 |
| versus aspirin | #269 |
| protein patients | #270 |
| exclusion | #270 |
| discontinuing | #270 |
| single test | #270 |
| hormonal replacement therapy | #271 |
| protein apc | #271 |
| thrombosis inflammation | #271 |
| 3·0 | #271 |
| platelet serotonin | #271 |
| orthopaedic patients | #271 |
| groups levels | #272 |
| clopidogrel ticlopidine | #272 |
| bleeding patient | #272 |
| vte recurrence | #272 |
| patients combination | #272 |
| ankle brachial | #273 |
| efficacy analysis | #273 |
| months 12 | #274 |
| risk levels | #274 |
| cleavage sites | #274 |
| prevalence pad | #274 |
| parenteral nutrition patients | #275 |
| performance score | #275 |
| international normalized | #275 |
| antithrombotic agent | #276 |
| fourth quartile | #276 |
| time aptt | #277 |
| smoking hypertension | #277 |
| normalized ratio | #278 |
| imaging sensitivity | #278 |
| dose reduction | #278 |
| rco | #279 |
| blood test | #279 |
| aptt | #279 |
| obviate | #280 |
| hospitalized medical | #280 |
| partial thromboplastin time | #280 |
| intracranial hemorrhage patients | #280 |
| propositi | #280 |
| exclusion criteria | #280 |
| patients presence | #281 |
| thromboplastin | #282 |
| diagnostic test | #282 |
| diagnostic sensitivity | #283 |
| thyroid diseases | #283 |
| presentation patients | #283 |
| neutrophil degranulation | #283 |
| puerperal | #283 |
| favor | #284 |
| test characteristics | #284 |
| animals anticoagulants | #284 |
| noninferiority margin | #284 |
| outpatient treatment | #284 |
| departments | #284 |
| major orthopaedic | #285 |
| patients apixaban | #286 |
| plasma bnp | #286 |
| gentamicin treatment | #286 |
| 2630 | #286 |
| subdistribution | #287 |
| disseminated intravascular | #287 |
| levels measured | #287 |
| clinically | #287 |
| patients pancreatic cancer | #287 |
| oral combined | #288 |
| md patients | #288 |
| 227 | #288 |
| premature atherosclerosis | #288 |
| substantiation | #289 |
| clot lysis | #289 |
| cvt patients | #289 |
| vte rates | #289 |
| vte women | #289 |
| n59 | #290 |
| 0·50 | #290 |
| thrombin time | #290 |
| current clinical | #291 |
| carriers mutation | #291 |
| extracted data | #291 |
| oral contraceptives | #291 |
| 016 | #291 |
| 1603 | #292 |
| willebrand disease vwd | #292 |
| activator inhibitor | #292 |
| 2 studies | #292 |
| pentasaccharide | #293 |
| patients dabigatran | #293 |
| 1000 personyears | #293 |
| plasmin activity | #293 |
| adverse outcome patients | #293 |
| patients rivaroxaban | #294 |
| lower extremities | #294 |
| cardiac troponin ctnt | #294 |
| tissuetype plasminogen activator | #294 |
| extremity dvt | #295 |
| 1025 | #295 |
| scenario analysis | #295 |
| peripheral vascular | #296 |
| classified | #296 |
| coagulation factor viii | #296 |
| routine monitoring | #297 |
| observer agreement | #297 |
| recurrent miscarriage | #298 |
| thrombocytes | #298 |
| episode patients | #298 |
| specificity npv | #298 |
| patients inr | #299 |
| inferiority | #300 |
| 041 | #301 |
| heparitin | #301 |
| toxemia | #302 |
| thromboglobulin | #302 |
| 155 patients | #302 |
| subclinical thyroid dysfunction | #302 |
| aged neoplasms | #302 |
| absolute difference | #304 |
| 1214 | #304 |
| rivaroxaban dabigatran | #305 |
| prophylactic administration | #306 |
| medline embase | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| thrombotic | #310 |
| surgery day | #310 |
| hematologic pregnancy | #310 |
| vte pregnancy | #310 |
| percentage points | #311 |
| 105 patients | #311 |
| clinical presentation | #311 |
| antithrombins blood | #311 |
| patients 100 | #311 |
| leg male | #312 |
| 598 | #312 |
| hereditary thrombophilia | #313 |
| vte 95 | #313 |
| negative reactions | #313 |
| obesity risk factor | #313 |
| diagnosis | #314 |
| funding | #315 |
| puerperium | #315 |
| cardiologists | #315 |
| postpartum haemorrhage | #315 |
| heparin aspirin | #315 |
| apixaban versus | #316 |
| therapeutic dose | #316 |
| adjudicators | #317 |
| patients followup | #317 |
| 0·92 | #318 |
| deciding | #318 |
| failure rates | #319 |
| safety outcomes | #319 |
| decision model | #319 |
| patients pregnancy | #320 |
| combined administration | #320 |
| catheter thrombosis | #320 |
| bnp levels | #320 |
| influenza infections | #320 |
| 1731 | #320 |
| ventricular dysfunction patients | #321 |
| intermediate phenotype | #322 |
| additional data | #322 |
| patients noacs | #322 |
| difference risk | #322 |
| peripheral arterial | #324 |
| inrs | #324 |
| glaxosmithkline | #324 |
| mortality odds ratio | #325 |
| convincing evidence | #325 |
| mechanical heart valves | #326 |
| blood coagulation factor | #326 |
| 122 patients | #326 |
| pulmonary embolus | #326 |
| surgery trauma | #327 |
| clinical | #327 |
| association vte | #329 |
| thrombotic event | #331 |
| pregnancy outcome women | #331 |
| vitamin administration | #331 |
| incidence bleeding | #331 |
| new oral | #332 |
| n69 | #333 |
| analysis trials | #333 |
| 95 percent | #333 |
| embase databases | #333 |
| incidences | #334 |
| 95 confidence limits | #334 |
| minor effects | #334 |
| complicate | #334 |
| fibrillation benzimidazoles | #335 |
| patients healthy volunteers | #335 |
| rationale design | #335 |
| central venous catheter | #336 |
| pulmonary perfusion | #336 |
| septicaemia | #336 |
| 065 | #337 |
| total hip replacement | #337 |
| plethysmographic | #337 |
| 035 | #337 |
| 2 points | #337 |
| recurrent | #337 |
| outpatient management | #338 |
| fatal bleeding | #338 |
| aged netherlands | #338 |
| coagulation abnormalities | #338 |
| placebo trials | #339 |
| noacs warfarin | #339 |
| prospective clinical study | #339 |
| patients 12 | #340 |
| 024 | #340 |
| antithrombotic effects | #340 |
| 217 | #341 |
| activatable | #341 |
| coagulation markers | #341 |
| noac patients | #342 |
| knee arthroscopy | #342 |
| pretest | #344 |
| patients covid19 infection | #344 |
| rfviia | #345 |
| splanchnic vein thrombosis | #345 |
| antithrombotic strategies | #345 |
| vte prevention | #345 |
| embolisms | #346 |
| diagnosis vte | #346 |
| 073 | #347 |
| activated protein resistance | #347 |
| patients thrombosis | #347 |
| cochrane central | #348 |
| 044 | #348 |
| bsf | #349 |
| chads2 | #349 |
| 2575 | #349 |
| tafia | #350 |
| randomized studies | #350 |
| trousseau | #350 |
| brain predictive | #350 |
| 013 | #351 |
| factor viii | #351 |
| versus warfarin | #351 |
| dermatan sulphate | #352 |
| selection bias | #352 |
| factor activation | #352 |
| anticoagulants noacs | #352 |
| relative efficacy | #353 |
| 1590 | #353 |
| vein | #353 |
| 5075 | #353 |
| oral anticoagulant therapy | #353 |
| international normalized ratio | #354 |
| aged pulmonary | #354 |
| patients gp | #355 |
| studies diagnostic accuracy | #355 |
| protein deficiency | #356 |
| tests prospective studies | #357 |
| categorised | #357 |
| post hoc | #357 |
| intestinal microbiome | #357 |
| 127 patients | #358 |
| pilots | #360 |
| sucra | #360 |
| intermittent claudication | #361 |
| treatment risk | #362 |
| consensus agreement | #362 |
| anticoagulation patients | #364 |
| humans risk | #365 |
| conventional therapy | #365 |
| topic female | #366 |
| bleeding rate | #366 |
| prediction models | #367 |
| time recurrence | #368 |
| infrainguinal | #368 |
| patients 3 | #368 |
| thrombin inhibitor | #369 |
| influenza infection | #370 |
| 6week | #370 |
| patients acl reconstruction | #370 |
| venous stasis | #371 |
| endotoxin infusion | #371 |
| 055 | #372 |
| 803 | #372 |
| clinical suspicion | #373 |
| recombinant activated | #373 |
| knee surgery | #373 |
| aprotinin blood | #373 |
| patients svt | #373 |
| helical computed tomography | #374 |
| human cytomegalovirus infection | #374 |
| patients scores | #374 |
| hmb | #375 |
| subcutaneous | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| contraceptives oral | #380 |
| stroke venous | #380 |
| ethinyloestradiol | #381 |
| tafi | #381 |
| antitnf | #382 |
| prefilter | #383 |
| reassessed | #384 |
| thromboembolic complications | #384 |
| 0·8 | #384 |
| multivariate regression analysis | #384 |
| standardized questionnaire | #384 |
| alpha2m | #385 |
| systemic activation | #385 |
| surrogate outcome | #386 |
| conference proceedings | #386 |
| bleeding events | #386 |
| cumulative incidences | #387 |
| sensitivity npv | #387 |
| antithrombins | #387 |
| delegates | #388 |
| major orthopedic | #388 |
| systemic embolism | #389 |
| 880 | #389 |
| safety rivaroxaban | #389 |
| referred | #389 |
| tinzaparin | #390 |
| vitt | #390 |
| apixaban warfarin | #390 |
| abi | #391 |
| increased bleeding | #391 |
| drug prescription | #391 |
| postop | #391 |
| biosis | #391 |
| comparison patients | #391 |
| time presentation | #392 |
| patients chest | #392 |
| topic female humans | #392 |
| factors thrombosis | #393 |
| kappa values | #393 |
| pulmonary emboli | #394 |
| clinical score | #394 |
| injections intravenous | #394 |
| background patients | #394 |
| 007 | #395 |
| 95 12 | #396 |
| bleeding event | #396 |
| popliteal | #396 |
| replacement surgery | #397 |
| factors factor | #397 |
| 665 | #397 |
| embolic events | #397 |
| hirudins humans | #397 |
| risk score patients | #399 |
| risk factors asthma | #400 |
| echography | #400 |
| heparin induced | #400 |
| patients risk | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| dabigatran | #403 |
| increased risk vte | #403 |
| controversy | #403 |
| massive pulmonary embolism | #405 |
| 2215 | #406 |
| treatment patient | #406 |
| 075 | #406 |
| thrombolytic agents | #406 |
| oral anticoagulant | #408 |
| factor levels | #408 |
| biologic effects | #410 |
| safety combination | #411 |
| patients assigned | #411 |
| noacs patients | #411 |
| fviii levels | #411 |
| 20 microg | #412 |
| transfusion patients | #412 |
| major risk factor | #412 |
| maastricht | #414 |
| euthyroidism | #414 |
| coagulation patients | #414 |
| hypocortisolism | #415 |
| xii | #415 |
| aged odds | #415 |
| pai1 levels | #416 |
| deserve | #416 |
| dose heparin | #416 |
| intravascular coagulation | #416 |
| comparable | #417 |
| 95 10 | #417 |
| data risk | #417 |
| 95 | #418 |
| pretest probability | #418 |
| carotid femoral | #418 |
| 269 | #419 |
| risk factors thrombosis | #419 |
| dermatan | #419 |
| ototoxicity | #420 |
| xia | #420 |
| fibrillation risk | #421 |
| 2850 | #422 |
| tests radiography | #422 |
| fibrillation clinical | #422 |
| 1989 | #422 |
| fibrinolysin | #423 |
| fviia | #424 |
| subanalysis | #424 |
| prevalence patients | #425 |
| randomised double | #426 |
| adjunct | #426 |
| fii | #426 |
| cancer cohort | #426 |
| consecutive | #427 |
| activated factor | #427 |
| excessive bleeding | #428 |
| daily practice | #428 |
| plg | #428 |
| conferences | #428 |
| idiopathic myelofibrosis | #429 |
| daily clinical practice | #429 |
| undergoing elective | #429 |
| patients testing | #429 |
| prolactin levels | #429 |
| 1904 | #430 |
| heparinoids | #431 |
| rule | #431 |
| bleeding complications | #431 |
| 04 | #432 |
| incidence length | #433 |
| outpatients | #433 |
| patients systematic review | #434 |
| ncb | #434 |
| firstdegree relatives patients | #436 |
| blood cultures | #436 |
| bolus injection | #437 |
| 059 | #437 |
| dose adjustment | #439 |
| women compared | #439 |
| proven | #439 |
| composite point | #439 |
| prostatic cancer | #439 |
| highrisk populations | #441 |
| concomitant medications | #441 |
| 074 | #442 |
| rate vte | #442 |
| standard therapies | #444 |
| –control study | #444 |
| prespecified | #445 |
| febrile patients | #446 |
| patients atrial fibrillation | #446 |
| female fibrinolytic | #447 |
| utrecht | #449 |
| hellp | #449 |
| 58 | #449 |
| patients parenteral nutrition | #449 |
| prevalence distribution | #450 |
| 3 12 months | #450 |
| stigmatisation | #451 |
| category | #451 |
| pipecolic | #452 |
| noninvasive tests | #453 |
| fatal disease | #453 |
| thrombin generation | #453 |
| aspirin risk | #453 |
| 30 40 | #454 |
| portal blood | #454 |
| placebo day | #454 |
| factor xii | #454 |
| microthrombi | #455 |
| 026 | #455 |
| 12week | #455 |
| fviii vwf | #456 |
| dichotomized | #456 |
| dicumarol | #457 |
| squibb | #457 |
| onwards | #457 |
| anti levels | #458 |
| iii complexes | #458 |
| hazard ratio 95 | #458 |
| svt | #460 |
| recommend | #460 |
| plasma lipoprotein | #460 |
| gastrointestinal cancer | #461 |
| factor fxa | #461 |
| expert consensus document | #462 |
| curve biomarkers | #462 |
| hip arthroplasty replacement | #462 |
| guidelines patients | #463 |
| haemolysis | #463 |
| studies ultrasonography | #464 |
| gp iib | #464 |
| patients values | #464 |
| month follow | #465 |
| diabetes stroke | #466 |
| cancerassociated thrombosis | #466 |
| accuracy detection | #467 |
| thrombin formation | #467 |
| patients nsaids | #468 |
| prophylaxis | #468 |
| intimamedia thickness | #468 |
| bmi≥30 | #469 |
| teaching hospitals | #469 |
| eligible studies | #469 |
| hemihepatectomy | #470 |
| 077 | #470 |
| roc analysis | #470 |
| inr patients | #470 |
| test probability | #470 |
| placebo recipients | #471 |
| hypercoagulability | #472 |
| prophylactic anticoagulation | #472 |
| case control study | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| intermittent pneumatic | #475 |
| heterozygote humans | #475 |
| endotoxemia | #475 |
| patients heparin | #475 |
| plethysmograph | #475 |
| 15 95 | #475 |
| atria | #477 |
| patients score | #479 |
| 08 | #479 |
| haemophiliacs | #479 |
| versus standard | #480 |
| thrombosis cvt | #481 |
| acutely | #481 |
| hit patients | #481 |
| postoperative blood | #482 |
| transportability | #482 |
| advisory | #482 |
| 1162 | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| patients hematologic malignancies | #485 |
| diagnostic efficacy | #485 |
| awaited | #486 |
| secondary prophylaxis | #487 |
| composite scores | #487 |
| silent | #488 |
| travel | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| treatment period | #493 |
| new therapy | #493 |
| residual risk | #493 |
| pan troglodytes | #493 |
| p00007 | #493 |
| hemophilic | #493 |
| vcf | #494 |
| activated protein | #495 |
| replacement hip arthroplasty | #496 |
| favour | #496 |
| dose oral | #496 |
| heterozygote | #496 |
| topic risk factors | #497 |
| 271 | #497 |
| blockages | #498 |
| discriminative ability | #498 |
| risk factors stroke | #498 |
| willebrand disease | #498 |
| hip knee | #501 |
| ptp | #502 |
| nri | #502 |
| deficiencies | #503 |
| subcategories | #503 |
| ft4 tsh | #503 |
| rapid decrease | #504 |
| complications pulmonary | #505 |
| patients referred | #505 |
| nondiagnostic | #505 |
| 1107 | #505 |
| 310 | #506 |
| net clinical | #506 |
| nonionic | #507 |
| oftentimes | #507 |
| day surgery | #507 |
| inhibitors rivaroxaban | #508 |
| guidelines diagnosis | #509 |
| coagulation tests | #509 |
| aminocaproates | #509 |
| contraceptives | #509 |
| 13 95 | #509 |
| angiography patients | #510 |
| degradation products | #510 |
| thrombosis animals | #510 |
| new oral anticoagulants | #510 |
| viii fviii | #511 |
| 019 | #512 |
| epiphenomenon | #512 |
| serial | #513 |
| highintensity | #514 |
| interim analysis | #514 |
| 056 | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| sensitivity diagnosis | #518 |
| thrombotic diseases | #518 |
| protein antithrombin | #518 |
| bleeding outcomes | #518 |
| thrombophilia thrombosis | #518 |
| groups treatment | #519 |
| treatment cancer patients | #519 |
| study sensitivity | #520 |
| duration intensity | #521 |
| 8090 | #521 |
| 1599 | #521 |
| warfarin therapy | #524 |
| fixed doses | #525 |
| general practitioner | #525 |
| 062 | #527 |
| cancer age | #528 |
| cindices | #528 |
| convincing | #529 |
| 923 | #529 |
| 051 | #529 |
| 378 | #529 |
| fatal | #530 |
| health female | #530 |
| betaalanine | #531 |
| humans postoperative | #531 |
| thrombosis hemostasis | #531 |
| medically patients | #531 |
| ≥50 years | #532 |
| 068 | #532 |
| thrombosis risk | #532 |
| intensive units icu | #532 |
| therapy cancer | #534 |
| factor thrombin | #534 |
| 730 | #536 |
| factor pathway | #537 |
| humans neoplasms | #538 |
| patients idiopathic | #538 |
| 449 | #538 |
| concise | #539 |
| ddavp | #539 |
| cbo | #539 |
| comprehensive search | #539 |
| diagnostic accuracy studies | #540 |
| clinical review | #540 |
| diagnosis acute | #540 |
| thrombotic risk | #543 |
| 234 | #543 |
| bleeding episodes | #543 |
| vascular obstruction | #543 |
| patients eligible | #543 |
| conventional treatment | #543 |
| coagulative | #544 |
| jak2 mutation | #544 |
| pad abi | #544 |
| 00 | #544 |
| prospective cohort study | #545 |
| perc | #545 |
| hellp syndrome | #545 |
| v617f | #545 |
| association statin | #546 |
| screening strategies | #546 |
| prothrombin complex | #547 |
| bureau | #547 |
| primary | #548 |
| adequate | #549 |
| 95 difference | #549 |
| overt | #549 |
| conduction anesthesia | #550 |
| cancer type | #550 |
| platelet inhibitors | #550 |
| 1103 | #550 |
| reviewers | #550 |
| percent patients | #550 |
| management bleeding | #552 |
| day patients | #552 |
| careful | #552 |
| 500 patients | #552 |
| amsterdam | #552 |
| studies sensitivity | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| factor vii | #558 |
| 66 patients | #558 |
| vivo treatment | #558 |
| bleeding time | #559 |
| orthopedic surgery | #559 |
| limulus | #561 |
| risk development | #563 |
| patients transfusion | #563 |
| board directors | #563 |
| female humans tests | #563 |
| anamnesis | #564 |
| appears | #564 |
| hip replacement | #564 |
| increasing risk | #565 |
| hyperfibrinolysis | #565 |
| cardiac troponins | #566 |
| solid tumours | #566 |
| withholding | #566 |
| patients 2 years | #568 |
| n46 | #568 |
| roc curves | #568 |
| levothyroxine | #571 |
| alpha1antitrypsin | #571 |
| aggravation | #572 |
| ctnt | #573 |
| cutoff point | #574 |
| menstrual bleeding | #574 |
| revascularization procedures | #574 |
| major bleedings | #575 |
| women proportion | #575 |
| subcutaneously | #575 |
| progression cancer | #577 |
| endothelial barrier | #578 |
| patients vka | #578 |
| endotoxin | #579 |
| thiophenes | #579 |
| pharma | #579 |
| 99 | #580 |
| notice | #580 |
| diagnostic tools | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| unselected patients | #584 |
| dummy | #584 |
| 094 | #585 |
| coagulation disorders | #585 |
| chondroitin sulfates | #586 |
| feasibility safety | #588 |
| major orthopedic surgery | #588 |
| helminth proteins | #589 |
| thrombophilias | #590 |
| healthy human | #590 |
| malignancy | #590 |
| beta alanine | #590 |
| reversal agents | #590 |
| conventional management | #592 |
| doppler ultrasound | #592 |
| massive pulmonary | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| ldf | #597 |
| patency rates | #597 |
| severe bleeding | #597 |
| replacement knee | #597 |
| major hemorrhage | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| loss surgical | #600 |
| tests sensitivity | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| events occurred | #604 |
| clinical characteristics patients | #604 |
| comorbid conditions | #604 |
| diagnostic studies | #606 |
| activated coagulation | #607 |
| 0·3 | #607 |
| patients antibodies | #607 |
| initial increase | #607 |
| treatment acute | #608 |
| pfizer | #609 |
| tissue factor | #609 |
| arbitrage | #609 |
| airline | #610 |
| benefit risk | #610 |
| 100 years | #610 |
| patients death | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| reluctant | #615 |
| patients bariatric surgery | #615 |
| leg | #615 |
| complications risk | #616 |
| treatment rivaroxaban | #617 |
| arterial disease | #617 |
| 467 | #618 |
| occurred | #618 |
| stroke atrial fibrillation | #618 |
| fh patients | #620 |
| compared placebo | #620 |
| advisory committees | #621 |
| patients elevated | #621 |
| 1002 | #622 |
| thyrotoxic | #623 |
| sgs | #623 |
| thrombocytopenia hit | #623 |
| cochrane central register | #625 |
| peptide bnp | #625 |
| stopped | #626 |
| topic practice guidelines | #626 |
| stroke warfarin | #627 |
| women risk factors | #628 |
| warfarin risk | #628 |
| 66 | #628 |
| 5000 | #628 |
| diagnostic algorithms | #629 |
| physical training | #629 |
| referral patients | #629 |
| human subjects | #629 |
| sanofi | #630 |
| absolute | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| outweigh | #635 |
| uneventful | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 95 allcause mortality | #640 |
| 14 95 | #640 |
| study quality | #641 |
| proceedings | #641 |
| 3050 | #642 |
| predictive performance | #642 |
| neutrophilia | #643 |
| threatening bleeding | #643 |
| association mortality | #647 |
| primary outcome measure | #647 |
| statin treatment | #648 |
| necessitating | #648 |
| studies efficacy | #648 |
| fixed | #651 |
| 036 | #651 |
| thrombolysis patients | #651 |
| organisations | #652 |
| troglodytes | #652 |
| fxa | #653 |
| hemorrhagic stroke | #653 |
| 127 | #655 |
| patients review | #657 |
| 69 | #659 |
| coronary stent implantation | #659 |
| bleeding death | #659 |
| haematoma | #660 |
| coagulation proteins | #661 |
| physical examination | #661 |
| tertiles | #661 |
| haemophilia | #662 |
| clinical presentations | #662 |
| 1028 | #663 |
| 95 studies | #663 |
| long term treatment | #664 |
| provoked | #664 |
| sepsis shock | #665 |
| deep | #666 |
| phase iii studies | #666 |
| guideline adherence | #667 |
| patients completed | #667 |
| onethird | #667 |
| presence patients | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| patients cteph | #673 |
| elevated plasma | #673 |
| managing | #674 |
| hospitalization hf | #674 |
| inhibitor 1 | #675 |
| clotting factors | #675 |
| il6 levels | #675 |
| prothrombotic | #676 |
| highincome countries | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| medicine humans | #681 |
| pulmonary endarterectomy | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| ambulatory patients | #692 |
| patients bleeding | #692 |
| activator pa | #693 |
| myocardial infarctions | #693 |
| graduated | #693 |
| administer | #694 |
| precise mechanisms | #694 |
| intracranial bleeding | #694 |
| composite outcome | #694 |
| 1718 | #695 |
| combined oral contraceptives | #696 |
| moyamoya | #696 |
| stroke prevention patients | #696 |
| participant data | #698 |
| difference 95 | #698 |
| ratio male | #698 |
| compression devices | #700 |
| episode | #700 |
| diagnostic errors | #702 |
| therapeutic management | #702 |
| prothrombin gene | #702 |
| patients confirmed | #703 |
| veins venous | #703 |
| surgery risk | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| directors | #709 |
| clinical expression | #709 |
| starters | #711 |
| 048 | #712 |
| gynaecology | #712 |
| medical patients | #712 |
| gastrointestinal bleeding | #712 |
| radionuclide imaging | #713 |
| rate death | #714 |
| 1098 | #714 |
| neurosurgical patients | #714 |
| intravenous bolus | #715 |
| menstrual period | #716 |
| rivaroxaban stroke | #716 |
| cancer groups | #717 |
| adequately | #717 |
| 10 30 | #718 |
| falsely | #718 |
| solid cancer | #718 |
| reagent kits | #719 |
| plasminogen | #719 |
| pulmonary medicine | #720 |
| accp | #721 |
| clinical judgment | #721 |
| pyrazoles pyridines | #721 |
| nordisk | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| follow period | #726 |
| abnormal | #726 |
| 59 patients | #727 |
| gentamicins | #727 |
| orthopaedic surgery | #728 |
| diagnostic therapeutic | #728 |
| diagnostic tests | #730 |
| leeches | #732 |
| gentamicin | #732 |
| oral contraception | #733 |
| tumor necrosis factor | #733 |
| relative risk 95 | #734 |
| patients levels | #735 |
| hull | #735 |
| disease pad | #735 |
| tests retrospective studies | #736 |
| clinical prediction rule | #736 |
| atrial fibrillation risk | #736 |
| post hoc analysis | #739 |
| 6 12 | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| 040 | #742 |
| unclear | #742 |
| early pregnancy loss | #742 |
| topic predictive | #743 |
| illness time factors | #744 |
| betathromboglobulin | #744 |
| molecular weight | #744 |
| 285 | #746 |
| antithrombin activity | #746 |
| patients 50 years | #746 |
| etp | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| advisable | #754 |
| fibrin formation | #754 |
| primary patients | #755 |
| hf risk | #756 |
| 95 combination | #756 |
| pneumatic compression | #756 |
| answer | #756 |
| 95 risk factors | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| loe | #759 |
| 85 | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| 435 | #763 |
| proportion women | #763 |
| cprs | #764 |
| start treatment | #764 |
| hip surgery | #765 |
| 689 | #767 |
| risk pregnancy | #767 |
| aspirin clopidogrel | #767 |
| 732 | #768 |
| method drug | #769 |
| relevant | #770 |
| groups patients | #770 |
| 566 | #770 |
| graft patency | #772 |
| baseline values | #772 |
| patients criteria | #773 |
| bmi patients | #774 |
| subcutaneous injections | #774 |
| 1·5 | #776 |
| 992 | #777 |
| dose warfarin | #778 |
| patients 65 years | #778 |
| study groups | #778 |
| dose intravenous | #778 |
| miscarriage | #779 |
| 066 | #780 |
| patients hyperthyroidism | #780 |
| plasmin generation | #780 |
| thromboembolism prophylaxis | #780 |
| age ≥ | #782 |
| factor ixa | #785 |
| onefifth | #785 |
| abnormalities patients | #786 |
| 100 personyears | #787 |
| general practitioners | #787 |
| cteph | #787 |
| polypharmacy | #787 |
| topic disease models | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| mechanical heart | #793 |
| recombinant tissue | #793 |
| inactivators | #795 |
| 047 | #795 |
| risk factors risk | #795 |
| patient years | #796 |
| patency | #796 |
| eligible | #797 |
| netherlands | #797 |
| studies prevalence | #797 |
| lupus anticoagulant | #798 |
| femoropopliteal | #798 |
| patients lower | #799 |
| estrogen therapy | #799 |
| theme | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| randomized patients | #804 |
| subclinical | #804 |
| anticoagulant agents | #805 |
| microvesicles | #805 |
| fibrillation blood | #806 |
| adverse outcomes patients | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| hypertension cteph | #809 |
| efficacy patients | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| flights | #816 |
| factor vwf | #816 |
| 0·4 | #818 |
| irrespective | #820 |
| vehicle control | #820 |
| health predictive | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| reduction mortality | #823 |
| prevention patients | #823 |
| coc | #824 |
| single administration | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| gp | #828 |
| cardioembolic stroke | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| 93 | #833 |
| myers | #833 |
| antithrombotic treatment | #833 |
| abortion habitual | #835 |
| plough | #836 |
| oral adult | #836 |
| noac | #837 |
| versus placebo | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| 49 | #846 |
| antithrombotic therapy | #846 |
| 072 | #847 |
| multidetector row | #847 |
| advise | #848 |
| recurrence risk | #849 |
| patients diagnosis | #850 |
| caesarean | #850 |
| area roc curve | #852 |
| reference method | #853 |
| pre‐eclampsia | #853 |
| 30 patients | #853 |
| advanced prostate | #854 |
| clopidogrel aspirin | #855 |
| fibrin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| 6 month | #870 |
| pyridones | #870 |
| longterm clinical outcomes | #872 |
| individual participant | #872 |
| tasman | #873 |
| favoring | #873 |
| targeted inhibition | #874 |
| imaging reproducibility | #874 |
| thromboembolic pulmonary | #874 |
| plasminogen activation | #875 |
| titles | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| risk thromboembolic | #878 |
| dabigatran rivaroxaban | #878 |
| anticoagulants atrial | #879 |
| 57 | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| 084 | #894 |
| domiciliary | #894 |
| male mexico | #894 |
| loading dose | #896 |
| p011 | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| factor activity | #908 |
| 064 | #908 |
| subcutaneous administration | #909 |
| documented | #911 |
| patients clinical trials | #911 |
| initially | #912 |
| haemostatic | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| combined approach | #916 |
| haemodialysis patients | #916 |
| 317 | #917 |
| 022 | #918 |
| thromboembolic events | #918 |
| chronic thromboembolic | #919 |
| standard patients | #920 |
| antagonist oral | #920 |
| randomeffects model | #920 |
| loss patients | #921 |
| optimal dose | #921 |
| ultrasound examination | #921 |
| practise | #923 |
| estimate male | #923 |
| study medication | #925 |
| multifactorial disease | #925 |
| total hip | #926 |
| 902 | #928 |
| safer | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| wording | #934 |
| treatment placebo | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| 60 patients | #938 |
| subgroup patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| women preeclampsia | #944 |
| echocardiographically | #944 |
| stroke atrial | #944 |
| emboli | #945 |
| ssc | #946 |
| predictive values | #946 |
| anticoagulation treatment | #947 |
| knee replacement | #948 |
| extensive disease | #948 |
| diagnostic | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| cancer humans | #956 |
| dic | #956 |
| network metaanalysis | #956 |
| registro | #956 |
| venous insufficiency | #957 |
| reassuring | #957 |
| day1 | #958 |
| efficacy | #958 |
| retropubic | #961 |
| combined oral | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| inhibitor1 | #966 |
| reference lists | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| hoc | #973 |
| risk allcause mortality | #973 |
| prevalence characteristics | #973 |
| antiplatelet | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| female fibrinogen | #976 |
| vascular humans | #976 |
| fvii | #978 |
| false negative | #979 |
| onset aged aged | #980 |
| 071 | #980 |
| 50 100 | #980 |
| early gestation | #984 |
| 426 | #986 |
| prophylactic treatment | #987 |
| randomised trials | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| rises | #991 |
| missed | #991 |
| seminar | #992 |
| academic medical center | #992 |
| counteracted | #993 |
| normal lung | #993 |
| treatment bleeding | #994 |
| aged | #999 |
| 226 | #999 |
| lower extremity | #1000 |
| justification | #1000 |
| thromboembolic risk | #1000 |
| tissue type | #1001 |
| rivaroxaban apixaban | #1002 |
| parenteral administration | #1002 |
| eclamptic | #1003 |
| extended | #1005 |
| hyperprolactinaemia | #1005 |
| interleukin 6 | #1005 |
| pyridines | #1006 |
| orthosis | #1007 |
| easier | #1007 |
| 50 patients | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| pounds | #1018 |
| ticlopidine | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| cha2ds2 vasc | #1023 |
| years risk | #1023 |
| international prospective | #1024 |
| humans randomized | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| firstdegree relatives | #1030 |
| decision analysis | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| risk hemorrhage | #1033 |
| cardiovascular event | #1033 |
| relatives | #1033 |
| 052 | #1035 |
| male netherlands | #1037 |
| graft occlusion | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| patients severe asthma | #1047 |
| vwf levels | #1047 |
| patients massive | #1050 |
| examiner | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| mean±sd | #1054 |
| 221 | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| birth rate | #1060 |
| coagulant | #1060 |
| 179 | #1060 |
| pad | #1061 |
| 610 | #1061 |
| published literature | #1062 |
| primary data | #1062 |
| false | #1064 |
| prekallikrein | #1065 |
| 150 | #1065 |
| 101 | #1066 |
| 00008 | #1066 |
| live birth | #1066 |
| cut | #1067 |
| lysosphingolipid | #1067 |
| pmol | #1068 |
| 95 increased risk | #1070 |
| register controlled | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| thorax | #1074 |
| laboratory diagnosis | #1074 |
| systematic search | #1078 |
| 063 | #1080 |
| advocate | #1080 |
| drawbacks | #1082 |
| f1 | #1087 |
| longterm therapy | #1087 |
| bandages | #1089 |
| stopping | #1095 |
| clarifications | #1095 |
| mandated | #1096 |
| diagnostic utility | #1096 |
| idarucizumab | #1096 |
| 083 | #1099 |
| 1223 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| fourfold | #1105 |
| blueprint | #1105 |
| peptide brain | #1107 |
| clinical protocols | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| bypass grafts | #1116 |
| haemodialysis | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| probands | #1123 |
| resistance factor | #1123 |
| new developments | #1124 |
| advised | #1125 |
| 445 | #1126 |
| new perspectives | #1126 |
| cip | #1127 |
| heparininduced thrombocytopenia | #1127 |
| patients pad | #1128 |
| judged | #1132 |
| discretion | #1132 |
| statistic | #1133 |
| ≤10 | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| 635 | #1141 |
| superior efficacy | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| roc curve | #1150 |
| refusal | #1150 |
| medline | #1151 |
| medical records | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| anticoagulation therapy | #1156 |
| blood loss | #1156 |
| patients influenza | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| bristol | #1163 |
| published guidelines | #1163 |
| viii | #1164 |
| hyperhomocysteinemia | #1164 |
| intermittent | #1164 |
| stable angina | #1164 |
| safety concerns | #1164 |
| thromboembolism risk | #1165 |
| age 65 years | #1165 |
| angiogram | #1167 |
| crossover design | #1172 |
| atherosclerotic disease | #1172 |
| glucocorticoid treatment | #1172 |
| perioperative bleeding | #1172 |
| occlusive diseases | #1173 |
| practice guideline | #1173 |
| macroglobulin | #1176 |
| 5 years patients | #1176 |
| findings patients | #1178 |
| analysis studies | #1178 |
| 79 | #1179 |
| concealed | #1181 |
| conceive | #1181 |
| hospitalized patients | #1182 |
| patients obesity | #1182 |
| unaware | #1182 |
| conclusive | #1186 |
| combined therapy | #1186 |
| occult | #1189 |
| degree relatives | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| cardiotonic agents | #1199 |
| mandate | #1199 |
| international society | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| quantitative trait locus | #1204 |
| categorized | #1204 |
| 015 | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| multicenter randomized | #1214 |
| pph | #1214 |
| 103 | #1218 |
| warranted | #1221 |
| scores patients | #1221 |
| patient treatment | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| 64 patients | #1224 |
| peak levels | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| sixfold | #1227 |
| blind | #1227 |
| consensus guidelines | #1228 |
| metabolic syndrome patients | #1228 |
| trial background | #1229 |
| radionuclide | #1229 |
| peptide hydrolases | #1229 |
| 65 patients | #1230 |
| doubles | #1232 |
| rules | #1232 |
| aspirin | #1234 |
| coronary angiography patients | #1238 |
| postoperative hemorrhage | #1238 |
| milliliter | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| subgroups | #1252 |
| ml1 | #1252 |
| matter lesions | #1252 |
| artery pulmonary | #1254 |
| oral vitamin | #1257 |
| search strategy | #1257 |
| extensive | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| entity | #1266 |
| visiting | #1266 |
| troponins | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| intensive patients | #1274 |
| equally | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| statin users | #1281 |
| routine screening | #1281 |
| 75 years | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| scan | #1295 |
| janssen | #1295 |
| perfusion defects | #1295 |
| hemofiltration | #1297 |
| predictive | #1297 |
| insufficiently | #1298 |
| low prevalence | #1299 |
| cardiovascular complications | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| 61 | #1303 |
| pf4 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| apoa | #1312 |
| 1st | #1312 |
| risk difference | #1312 |
| cyproterone | #1312 |
| adamts13 activity | #1313 |
| tests severity | #1314 |
| 0·7 | #1314 |
| current strategies | #1314 |
| claudication | #1316 |
| atrial fibrillation | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| glycoprotein gpiib | #1325 |
| lipoproteina | #1325 |
| patients coronavirus disease | #1326 |
| vascular diseases | #1329 |
| antibodies monoclonal antibodies | #1329 |
| beneficial | #1329 |
| low moderate | #1330 |
| plasminogen activators | #1330 |
| thyroid disorders | #1330 |
| 6 months patients | #1331 |
| coagulation cascade | #1331 |
| 77 | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| 91 | #1342 |
| likelihood ratio | #1342 |
| venous catheters | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| surgical trauma | #1347 |
| antitrypsin | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| allcause mortality 95 | #1359 |
| experimental model | #1359 |
| 15 patients | #1359 |
| vwf | #1363 |
| arsenal | #1363 |
| limb salvage | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| noninferiority | #1385 |
| dl1 | #1385 |
| 224 | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| patients control subjects | #1400 |
| record linkage | #1400 |
| 82 | #1402 |
| equipoise | #1402 |
| antisense oligonucleotide | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| patients advanced cancer | #1405 |
| 1886 | #1405 |
| obese patients | #1406 |
| pregnancy loss | #1406 |
| categories | #1408 |
| 515 | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| thrombotic complications | #1419 |
| 3 6 | #1419 |
| 6 weeks | #1419 |
| 7 weeks | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| university hospitals | #1422 |
| followup data | #1422 |
| 061 | #1424 |
| daily | #1424 |
| ≥55 | #1424 |
| eightfold | #1425 |
| 080 | #1427 |
| randomised controlled trials | #1427 |
| casecontrol study | #1430 |
| rgs | #1430 |
| outcome pregnancy | #1438 |
| 096 | #1439 |
| imaging radiopharmaceuticals | #1439 |
| 78 | #1443 |
| principal | #1443 |
| 1123 | #1445 |
| outcome studies | #1446 |
| drug levels | #1446 |
| weight bmi | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| confusion | #1454 |
| population patients | #1454 |
| platelet factor | #1455 |
| aged blood | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| actual | #1466 |
| funded | #1466 |
| avoided | #1468 |
| 0·9 | #1468 |
| heart failure hf | #1469 |
| 26 patients | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| 1215 | #1473 |
| prevalences | #1473 |
| centrally | #1474 |
| systemic infection | #1477 |
| probability | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| cushing syndrome | #1485 |
| analysis randomized | #1485 |
| phase iii trials | #1486 |
| methodologic | #1486 |
| general practice | #1491 |
| patients control | #1495 |
| procoagulant activity | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| adverse outcome | #1514 |
| growing body | #1514 |
| proximal | #1516 |
| patients 10 | #1520 |
| ganz | #1520 |
| pregnancy postpartum | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| contraindicated | #1527 |
| thrombotic events | #1527 |
| time study | #1529 |
| score | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| patients severe sepsis | #1552 |
| live births | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| pfa | #1564 |
| enfermedad | #1564 |
| iii topic | #1565 |
| treatment prevention | #1566 |
| topic | #1566 |
| deficient | #1568 |
| 95ci | #1568 |
| cushings syndrome | #1568 |
| hyperlipoproteinemia type | #1568 |
| aged biomarkers | #1571 |
| 36 | #1575 |
| plasminogen activator | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| cocs | #1586 |
| study entry | #1586 |
| activation markers | #1586 |
| thyroid dysfunction | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| 1·1 | #1594 |
| total mortality | #1594 |
| translates | #1597 |
| noncancer | #1598 |
| placebo | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| 162 | #1613 |
| general surgery | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| postpartum period | #1616 |
| positive effects | #1616 |
| tests reproducibility | #1616 |
| factors tomography | #1616 |
| prospective cohort studies | #1616 |
| 155 | #1618 |
| perinatal outcome | #1618 |
| female hemostasis | #1619 |
| imaging tomography | #1619 |
| cvd patients | #1619 |
| proportion | #1620 |
| 12month followup | #1621 |
| uncertain | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| pa patients | #1632 |
| venous disease | #1632 |
| incidentally | #1632 |
| fresh frozen plasma | #1633 |
| clinical patients | #1633 |
| study outcomes | #1639 |
| double | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| stroke prevention | #1644 |
| ctni | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| 997 | #1651 |
| dorsiflexion | #1651 |
| ≤4 | #1652 |
| 35 years | #1652 |
| thrombin activity | #1653 |
| studies data | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| homocysteine levels | #1670 |
| disease adult | #1670 |
| thrombi | #1674 |
| inpatient treatment | #1676 |
| daily dosing | #1676 |
| plasma level | #1677 |
| deficiency | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| steroidal anti | #1686 |
| unreliable | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| 033 | #1712 |
| yielded | #1712 |
| hemorheology | #1715 |
| intravenous | #1715 |
| hematologic malignancies | #1720 |
| bronchospasm | #1720 |
| diagnostic evaluation | #1721 |
| mb | #1721 |
| female femoral | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| conference | #1726 |
| 107 | #1726 |
| derived microparticles | #1729 |
| volunteer | #1730 |
| 021 | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| east asian | #1735 |
| clinical scores | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| table | #1745 |
| 691 | #1745 |
| patients ventricular | #1745 |
| profession | #1746 |
| hyperinsulinaemia | #1747 |
| risk cardiovascular events | #1747 |
| apc | #1749 |
| turp | #1749 |
| pselectin | #1750 |
| replacement | #1750 |
| homozygosity | #1750 |
| 128 | #1752 |
| 133 | #1753 |
| intracranial hemorrhages | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| assessor | #1760 |
| treatment recommendations | #1760 |
| audiometry | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| human insulin | #1764 |
| fx | #1764 |
| duplicate | #1769 |
| hemorrhage | #1770 |
| initial management | #1770 |
| arteriosclerosis | #1770 |
| 2 6 | #1774 |
| allcause death | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| clinical consequences | #1790 |
| selfmanagement | #1790 |
| microparticle | #1793 |
| reid | #1793 |
| cardiac troponin | #1794 |
| vascular surgical | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| 020 | #1802 |
| aggregation inhibitors | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| 95 specificity | #1812 |
| tumor necrosis | #1812 |
| slc6a4 | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| economic evaluation | #1819 |
| conjoint | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| preference | #1825 |
| screening middle | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| compressibility | #1837 |
| definite | #1837 |
| cushing | #1838 |
| kaplanmeier estimate | #1838 |
| severe sepsis | #1839 |
| central venous | #1842 |
| 1 week | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| hydroxyethyl starch | #1852 |
| explanations | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| diagnostic techniques | #1892 |
| thromboses | #1892 |
| shrs | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 5 10 | #1897 |
| 067 | #1897 |
| contraindications | #1900 |
| diagnostic testing | #1901 |
| tnf | #1901 |
| extremity | #1901 |
| clt | #1905 |
| hazard ratio | #1906 |
| plaster | #1906 |
| induced thrombocytopenia | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| efficacy treatment | #1910 |
| referral | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 13 patients | #1920 |
| 793 | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| stroke 95 | #1923 |
| 868 | #1923 |
| 55 years | #1924 |
| biotin | #1924 |
| trials patients | #1926 |
| venous pressure | #1926 |
| μg | #1927 |
| intracranial hemorrhage | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| glucocorticoid | #1934 |
| nonfatal | #1934 |
| relative risks | #1935 |
| 3months | #1935 |
| acute | #1936 |
| 17 | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| safety effectiveness | #1950 |
| femoral vein | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| observer | #1962 |
| investigators | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| surgical blood | #1973 |
| fibrin clot | #1973 |
| 48 hours | #1973 |
| potent inhibitor | #1976 |
| renewed | #1976 |
| topic clinical trials | #1978 |
| specificity ultrasonography | #1981 |
| hyperaldosteronism | #1981 |
| 771 | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| treatment cancer | #1986 |
| 1·0 | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| prospero | #1992 |
| 018 | #1992 |
| cmax | #1994 |
| drug drug therapy | #1994 |
| cvt | #1995 |
| computerized | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| 3 months patients | #2000 |
| clinical severity | #2000 |
| transient increase | #2000 |
| autopsy | #2000 |
| 53 | #2003 |
| 7 patients | #2006 |
| pneumonia patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| mongrel | #2017 |
| angina unstable | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| 097 | #2033 |
| patients lung | #2033 |
| pertechnetate | #2036 |
| medical record | #2041 |
| costs cost | #2041 |
| abstracts | #2042 |
| undergoing major | #2042 |
| questioned | #2043 |
| thrice | #2045 |
| prediction rule | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| superior vena cava | #2051 |
| quartiles | #2051 |
| inadequately | #2052 |
| 277 | #2053 |
| pregnancy trimester | #2053 |
| controversial | #2055 |
| adherence guidelines | #2056 |
| stent implantation | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| varies | #2063 |
| requested | #2063 |
| clinical indications | #2064 |
| biological neoplasms | #2064 |
| hemostatics | #2070 |
| national institute | #2074 |
| 188 | #2074 |
| mcnemar | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| media thickness | #2087 |
| bypasses | #2087 |
| 03 | #2089 |
| versions | #2091 |
| square distribution | #2092 |
| 114 | #2092 |
| tissue plasminogen | #2093 |
| preformed | #2099 |
| reference range | #2099 |
| 038 | #2100 |
| lifetime risk | #2101 |
| 59 | #2101 |
| desmopressin | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| 1966 | #2109 |
| 031 | #2109 |
| substantial | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| unnecessary | #2118 |
| independently | #2118 |
| exists | #2119 |
| initial | #2119 |
| development validation | #2120 |
| 11 | #2122 |
| clinicaltrialsgov | #2122 |
| coronary stent | #2122 |
| original | #2125 |
| acl reconstruction | #2125 |
| patients cardiovascular disease | #2127 |
| topic surveys | #2127 |
| controlled | #2129 |
| chose | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| protamines | #2134 |
| congress | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| clot | #2145 |
| live | #2145 |
| professionals | #2146 |
| bodyweight | #2146 |
| pancreatic cancer patients | #2157 |
| oestrogens | #2160 |
| committee | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| 674 | #2183 |
| advanced cancer | #2183 |
| giant cell arteritis | #2185 |
| fifty | #2185 |
| 2 × | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| increased patients | #2205 |
| pravastatin | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| diagnosis differential | #2212 |
| neutrophil elastase | #2212 |
| doubled | #2213 |
| pao2 | #2219 |
| 364 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| differential female | #2225 |
| 94 | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| hivinfected patients | #2257 |
| clots | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| hyperthyroidism | #2265 |
| stroke aged | #2265 |
| 12 | #2266 |
| metaanalysis | #2267 |
| 6 months | #2267 |
| reverses | #2273 |
| patients developed | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| setting | #2284 |
| based case | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| metaanalysis studies | #2314 |
| tests | #2314 |
| nephelometry | #2316 |
| initial therapy | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| method female | #2324 |
| humans myocardial | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| lacked | #2344 |
| inhibitor | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| 099 | #2375 |
| risk bias | #2375 |
| patients active | #2376 |
| hemostasis | #2377 |
| predictable | #2377 |
| enrolling | #2379 |
| acute coronary syndromes | #2379 |
| 187 | #2381 |
| anticardiolipin | #2382 |
| dosing regimen | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| patients liver cirrhosis | #2401 |
| 757 | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| periodicals | #2413 |
| protein | #2413 |
| postinjection | #2413 |
| risk estimates | #2414 |
| 22 | #2415 |
| sphingosine1 | #2415 |
| internal medicine | #2424 |
| study drug | #2424 |
| 32 | #2425 |
| guidelines | #2426 |
| sensitivity 100 | #2426 |
| legs | #2430 |
| 0048 | #2430 |
| coagulants | #2430 |
| 002 | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| ptca | #2434 |
| prolonging | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| turbidimetry | #2448 |
| 719 | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| prognostic patients | #2464 |
| watchful | #2464 |
| potential benefits | #2466 |
| nephrotoxic | #2468 |
| therapy acute | #2468 |
| comprised | #2469 |
| 477 | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| current review | #2476 |
| cancer population | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| pathway inhibitor | #2485 |
| 648 | #2485 |
| treatment efficacy | #2489 |
| 829 | #2490 |
| 1015 | #2490 |
| duration | #2493 |
| chest | #2493 |
| 25 | #2495 |
| illness tomography | #2503 |
| 616 | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| drug female humans | #2516 |
| 479 | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| neutrophil extracellular traps | #2521 |
| 463 | #2521 |
| accurate diagnosis | #2523 |
| 152 | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 164 | #2537 |
| 0046 | #2537 |
| 874 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| haematology | #2560 |
| hydroxyethyl | #2560 |
| hours | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| 73 | #2574 |
| kits | #2574 |
| humans logistic | #2574 |
| prevalence | #2575 |
| pill | #2575 |
| patients total | #2577 |
| translate | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| 591 | #2585 |
| efficacious | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| manifest | #2605 |
| burden disease | #2605 |
| metaregression | #2606 |
| parenteral | #2606 |
| fatal outcome | #2608 |
| patients 2 | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| cost analysis | #2620 |
| aviation | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| coincided | #2635 |
| chondroitin | #2635 |
| trials rcts | #2635 |
| 10 day | #2637 |
| attractive | #2641 |
| 345 | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| c677 | #2662 |
| benzimidazoles | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| outcome ultrasonography | #2683 |
| 516 | #2683 |
| initial dose | #2685 |
| iii | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| 594 | #2691 |
| aso | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| management strategies | #2732 |
| dose low | #2732 |
| cart | #2736 |
| 595 | #2737 |
| classifications | #2739 |
| 427 | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| predetermined | #2746 |
| 848 | #2746 |
| patients asthma | #2747 |
| baseline characteristics | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| management acute | #2768 |
| 143 | #2768 |
| confounded | #2769 |
| alpha animals | #2772 |
| antithyroid | #2772 |
| expert consensus | #2772 |
| active control | #2775 |
| thrombomodulin | #2776 |
| inpatient | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| consecutive series | #2802 |
| 402 | #2802 |
| reaching | #2805 |
| cirrhosis patients | #2805 |
| international | #2809 |
| secondary | #2811 |
| standardized | #2811 |
| embolic | #2812 |
| follow studies | #2813 |
| 406 | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| bid | #2826 |
| antiplatelet drugs | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| recurrence rate | #2835 |
| contacting | #2835 |
| ketoprostaglandin | #2836 |
| helminth | #2836 |
| crossover | #2839 |
| kruskal | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| doppler ultrasonography | #2852 |
| iii trials | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| new treatment | #2857 |
| post discharge | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| excessive | #2880 |
| trimester pregnancy | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| systematic review metaanalysis | #2897 |
| 21 | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| feasible | #2903 |
| severe asthma | #2903 |
| slight | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| lowrisk patients | #2917 |
| leading death | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| 993 | #2928 |
| proportions | #2928 |
| clear | #2932 |
| risk stratification patients | #2934 |
| 2400 | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 270 | #2960 |
| 010 | #2960 |
| 20 | #2961 |
| followup | #2962 |
| exercise therapy | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| declare | #2984 |
| lecture | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| point | #2991 |
| pneumatic | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| antigen levels | #3015 |
| factors surveys | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| nested case | #3025 |
| early recognition | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 419 | #3040 |
| 50 years | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| nomogram | #3063 |
| 80 | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| subsequently | #3076 |
| 2 4 | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| angioplasty | #3088 |
| chronic renal failure | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| benchmark | #3110 |
| trimester | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| oac | #3122 |
| wallis | #3122 |
| lifelong | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 136 | #3134 |
| 12 months | #3134 |
| meta‐analysis | #3137 |
| levels risk | #3142 |
| 082 | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| idiopathic | #3153 |
| 507 | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| pregnancy women | #3194 |
| diethylstilbestrol | #3194 |
| pacientes | #3197 |
| plasmin | #3198 |
| 945 | #3198 |
| tenth | #3199 |
| therapy risk | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| cancer types | #3219 |
| suggested | #3219 |
| 153 | #3223 |
| intravenous infusion | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| meetings | #3241 |
| recombinant | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| bivalirudin | #3251 |
| 198 | #3251 |
| hypothyroid | #3253 |
| 29 | #3253 |
| scoring | #3255 |
| judgement | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| tumor markers | #3289 |
| coumarin | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| 465 | #3330 |
| reduces | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| cerebrovascular disease | #3344 |
| inpatients | #3344 |
| 362 | #3349 |
| evaluating | #3349 |
| spontaneous abortion | #3354 |
| diagnosing | #3354 |
| 273 | #3355 |
| diagnosis cancer | #3356 |
| common complication | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| 301 | #3379 |
| humans lower | #3379 |
| concluded | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| calf | #3389 |
| function patients | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| 553 | #3403 |
| tunica | #3403 |
| acute treatment | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| randomisation | #3419 |
| preventive | #3419 |
| hypothesised | #3420 |
| surgical patients | #3420 |
| study risk | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| 168 | #3452 |
| prevalence incidence | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| 34 | #3470 |
| differ | #3470 |
| intensive chemotherapy | #3471 |
| patients receive | #3472 |
| pregnancy complications | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| antiphospholipid | #3485 |
| cancer metastasis | #3485 |
| increased morbidity | #3486 |
| asymptomatic | #3487 |
| lower leg | #3487 |
| paradox | #3490 |
| personyears | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| treat | #3506 |
| inhibitors | #3506 |
| hemorrhagic complications | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| discusses | #3522 |
| confirmed | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| lupus | #3533 |
| human cytomegalovirus | #3533 |
| areas covered | #3537 |
| guidance | #3541 |
| societies | #3541 |
| 113 | #3544 |
| current practice | #3551 |
| gastro | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| necessity | #3596 |
| prognosis prospective | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| treated | #3619 |
| platelet function | #3619 |
| interval | #3622 |
| platelet activation | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| q3 | #3629 |
| kappa | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| homozygote | #3642 |
| undergo | #3642 |
| bypass surgery | #3642 |
| p006 | #3645 |
| externally | #3645 |
| occlusions | #3646 |
| 30 | #3649 |
| 1960 | #3649 |
| interindividual variability | #3651 |
| fibrillation | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| outcome administration | #3671 |
| optimal management | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| drug monitoring | #3721 |
| diagnostic process | #3721 |
| inhibitors humans | #3725 |
| pharmacodynamics | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| effective | #3739 |
| humans intracranial | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| deterioration | #3754 |
| randomised | #3754 |
| objectives | #3759 |
| subgroup analyses | #3762 |
| 8 patients | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| computed ultrasonography | #3774 |
| clinicians patients | #3774 |
| inherited | #3775 |
| 517 | #3778 |
| interpretable | #3778 |
| 483 | #3782 |
| total knee arthroplasty | #3789 |
| aminoglycosides | #3789 |
| thyroid hormones | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| compelling | #3804 |
| vessel wall | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| 330 | #3815 |
| patients lung cancer | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| irs | #3856 |
| meeting | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| acquired resistance | #3860 |
| review data | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| optimisation | #3884 |
| cancer survival | #3884 |
| record | #3885 |
| sensitivity | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| difference | #3890 |
| 184 | #3890 |
| 351 | #3890 |
| 10000 | #3902 |
| methylamines | #3903 |
| halflives | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| specificity tomography | #3915 |
| angiography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| case fatality | #3946 |
| 405 | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| p004 | #3961 |
| dichotomy | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| uncontrolled | #3970 |
| risk cancer | #3970 |
| austrian | #3971 |
| behalf | #3971 |
| cardiovascular events | #3972 |
| 2nd | #3975 |
| data studies | #3975 |
| quality assurance | #3980 |
| pregnancy | #3982 |
| 986 | #3982 |
| continuous infusion | #3983 |
| flying | #3986 |
| unstable | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| 296 | #4045 |
| introduction | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| bariatric | #4077 |
| pcc | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| oligosaccharides | #4089 |
| natriuretic peptide | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| activation | #4099 |
| cutoff | #4099 |
| indications | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| 008 | #4137 |
| withdrawn | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| patients prostate cancer | #4171 |
| 2030 | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 411 | #4212 |
| 485 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 289 | #4226 |
| 121 | #4226 |
| trough | #4229 |
| crosssectional analysis | #4230 |
| p0005 | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| patients mortality | #4242 |
| cox regression | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 102 | #4340 |
| 455 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| managed | #4350 |
| potential risk factors | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| rapid | #4383 |
| minutes | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| slice | #4394 |
| concurrently | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| negative | #4407 |
| bowel diseases | #4407 |
| general | #4407 |
| 71 | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| lacking | #4417 |
| splanchnic | #4417 |
| dose aspirin | #4419 |
| immunoassays | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| 192 | #4459 |
| vascular surgery | #4459 |
| cytomegalovirus infection | #4461 |
| proband | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| cd18 | #4486 |
| clinical manifestations | #4486 |
| pancreatic cancer | #4487 |
| inadequate | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| activation platelet | #4503 |
| comprises | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| cerebrovascular disorders | #4571 |
| calculating | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| attenuating | #4594 |
| preserves | #4594 |
| eventually | #4595 |
| gradual | #4595 |
| 204 | #4596 |
| simplified | #4596 |
| 4000 | #4601 |
| 4 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| acetylsalicylic acid | #4613 |
| vii | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| hospital costs | #4640 |
| risks benefits | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| habitual | #4658 |
| 003 | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| 171 | #4670 |
| myelofibrosis | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| day | #4680 |
| fh | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| unchanged | #4698 |
| ranging | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| baseline patients | #4775 |
| chronic renal | #4775 |
| acute coronary | #4784 |
| 44 | #4785 |
| scheduled | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| definition | #4861 |
| acl | #4861 |
| efficiency | #4869 |
| gpiib | #4870 |
| nonvalvular atrial fibrillation | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| antiplatelet therapy | #4891 |
| total | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| preparations | #4906 |
| tests prognosis | #4906 |
| served | #4910 |
| chlamydophila | #4913 |
| fmd | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| manufacturers | #4976 |
| dose | #4976 |
| orthopedics | #4982 |
| albeit | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| 389 | #5006 |
| references | #5006 |
| reminder | #5009 |
| epoprostenol | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| 156 | #5040 |
| screening test | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| evaluable | #5089 |
| regarded | #5089 |
| relation | #5090 |
| hip fractures | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| vivo studies | #5124 |
| bay | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| 0018 | #5130 |
| ischaemic stroke | #5130 |
| female | #5131 |
| 131 | #5131 |
| transfused | #5134 |
| balancing | #5136 |
| contrast media | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| shortly | #5157 |
| disagreement | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| predispose | #5170 |
| 11 patients | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| articles | #5233 |
| emergencies | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| pooling | #5289 |
| 365 | #5289 |
| aware | #5300 |
| thrombus | #5301 |
| 36 patients | #5301 |
| urokinase | #5302 |
| atherogenesis | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| reagent | #5341 |
| acute ischemic stroke | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| schedule drug | #5363 |
| male | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| occurrences | #5490 |
| 247 | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| patient risk | #5497 |
| 260 | #5497 |
| discomfort | #5499 |
| continuing | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| erythema | #5539 |
| limitation | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| receptor1 | #5563 |
| established | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| 46 | #5573 |
| reduce risk | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| circulating levels | #5598 |
| equivalent | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| reclassification | #5644 |
| 80 years | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| semiquantitative | #5771 |
| milder | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| mpo | #5804 |
| incidence rates | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| aircraft | #5819 |
| 1000 | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| true | #5852 |
| atrial | #5852 |
| 088 | #5854 |
| attending | #5856 |
| women pregnancy | #5857 |
| 290 | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| reliable | #5894 |
| occurrence | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| aged platelet | #5928 |
| 22 patients | #5928 |
| graded | #5934 |
| revision | #5938 |
| premenopause | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| rcts | #5962 |
| 43 | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| topics | #6101 |
| type iii | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| generation | #6160 |
| ffa | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| terminated | #6228 |
| mortality morbidity | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| colleagues | #6273 |
| practitioners | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 135 | #6340 |
| 63 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| roche | #6405 |
| factor gene | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| accuracy | #6501 |
| peripheral artery disease | #6501 |
| incidence risk | #6502 |
| cancer cell | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| triiodothyronine | #6524 |
| washout | #6524 |
| 318 | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| increased incidence | #6532 |
| cochrane | #6532 |
| highrisk patients | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| bowel | #6538 |
| exogenous | #6538 |
| thirteen | #6540 |
| aspirin patients | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| pancreatic neoplasms | #6641 |
| genetic testing | #6641 |
| complications | #6650 |
| individual | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| hazard ratios | #6729 |
| recognised | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| 385 | #6766 |
| body temperature | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| defined | #6780 |
| 2 groups | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| reached | #6803 |
| premedication | #6803 |
| response relationship | #6807 |
| plasma proteins | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| adverse event | #6912 |
| disturbances | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| 246 | #6976 |
| intensity | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| 222 | #6995 |
| shock septic | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| betacoronavirus covid19 | #7104 |
| computed | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| 5year | #7204 |
| withdrawal | #7204 |
| acting | #7210 |
| cardiovascular disease cvd | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| treatment children | #7250 |
| vldl | #7250 |
| hematocrit | #7255 |
| retrospective cohort study | #7257 |
| 199 | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| sensitivity analysis | #7290 |
| modest | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| ischemic stroke | #7338 |
| pectoris | #7338 |
| interleukin6 | #7352 |
| 1c | #7352 |
| standardised | #7356 |
| myocardial infarction | #7356 |
| p0001 | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| angina | #7522 |
| urgently | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| cinahl | #7578 |
| 191 | #7578 |
| comorbid | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| epidemiological studies | #7647 |
| 29 patients | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| 18 | #7705 |
| medical conditions | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| 110 | #7802 |
| manufacturer | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| 31 patients | #7828 |
| hormone replacement | #7828 |
| label | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| academic | #7878 |
| tramadol | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| urogenital | #7939 |
| highrisk | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| 600 | #8051 |
| preventable | #8051 |
| medical | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| patients heart | #8120 |
| training | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| imaging studies | #8141 |
| investigational | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| confidence | #8204 |
| parenteral nutrition | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| renal function | #8228 |
| impairment | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lowest | #8250 |
| lists | #8250 |
| version | #8260 |
| 125i | #8264 |
| activated | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| postulated | #8338 |
| endothelium vascular | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| absence presence | #8382 |
| 2 years | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| occur | #8415 |
| 28 patients | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| procedures operative | #8463 |
| transient ischemic | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| evaluate | #8501 |
| covariate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| adolescent | #8582 |
| 146 | #8582 |
| row | #8590 |
| carotid arteries | #8596 |
| thirty | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| 15 years | #8624 |
| fish oil | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| 1 2 | #8723 |
| hold | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| cardiovascular | #8756 |
| practical | #8756 |
| endovascular | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| convenient | #8837 |
| hydroxymethylglutaryl | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| planned | #8914 |
| micrograms | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| proportional hazards | #8945 |
| signs symptoms | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| options | #9002 |
| patients placebo | #9002 |
| chemoprevention | #9005 |
| comprise | #9005 |
| clinical events | #9007 |
| societies medical | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| diagnose | #9080 |
| mps | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| valve prosthesis | #9147 |
| time points | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| dyspnea | #9230 |
| pci | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| illness surveys | #9264 |
| hazards | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| rabbit | #9286 |
| positive | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| p0004 | #9355 |
| patients negative | #9355 |
| preceded | #9376 |
| loss | #9378 |
| 014 | #9380 |
| higher incidence | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| kidney failure | #9638 |
| primary point | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| precise | #9817 |
| easily | #9817 |
| coa reductase | #9828 |
| nmol | #9828 |
| classification | #9836 |
| 212 | #9839 |
| craniotomy | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| nonhuman primates | #9871 |
| heterozygotes | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| degradation | #9941 |
| 2003 | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| casecontrol studies | #9997 |
| pancreatic | #9997 |
| 12 hours | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| obstacles | #10045 |
| protective | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| cell activation | #10199 |
| investigations | #10199 |
| cardiovascular risk factors | #10209 |
| clinical data | #10213 |
| medical therapy | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| blood transfusion | #10293 |
| hospitalization | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| 032 | #10336 |
| dilution | #10336 |
| 667 | #10337 |
| worldwide | #10337 |
| aorta | #10352 |
| greatly | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| p0003 | #10408 |
| outcome measures | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| circulation | #10432 |
| reductase inhibitors | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| patients age | #10461 |
| priority | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| activity levels | #10489 |
| increased prevalence | #10489 |
| style | #10491 |
| 1991 | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| patients moderate | #10570 |
| ray | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| recurrences | #10583 |
| antisense | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| 159 | #10605 |
| microvascular | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| held | #10674 |
| concerned | #10674 |
| pulmonary vascular | #10690 |
| term | #10697 |
| discriminate | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| diagnoses | #10903 |
| airways | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| neutropenia | #11057 |
| ischemic | #11057 |
| ethical | #11062 |
| summarizes | #11062 |
| attained | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| inability | #11108 |
| location | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| cerebrovascular | #11281 |
| humans kidney | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| occlusion | #11533 |
| placebo treatment | #11533 |
| multicenter study | #11542 |
| outflow | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| baseline | #11624 |
| younger patients | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| dietary intake | #12057 |
| thirds | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| lung | #12208 |
| causality | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| inflammatory response | #12409 |
| switzerland | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| requires | #12540 |
| guide | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| 45 | #12708 |
| prostatic | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| instance | #13041 |
| oral administration | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| cancer risk | #13107 |
| escalation | #13107 |
| vomiting | #13112 |
| physical | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| pulmonary hypertension | #13563 |
| accurate | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| vascular | #13708 |
| competence | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| explanation | #13773 |
| pelvic | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| members | #14033 |
| risk death | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| focus | #14084 |
| situations | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| min1 | #14391 |
| 6 patients | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| statistics | #14637 |
| renal insufficiency | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| validity | #14787 |
| independent predictor | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| copd | #15201 |
| decrease | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| disorders | #15278 |
| drug | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| randomised controlled trial | #15474 |
| women age | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| examination | #15813 |
| effectively | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| discuss | #15997 |
| severely | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| prevented | #16513 |
| develop | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| lung neoplasms | #17262 |
| cooperative | #17262 |
| estimated | #17274 |
| largest | #17288 |
| acute phase | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| ventricular function | #18296 |
| metastases | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| 2002 | #20050 |
| gestational | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| elisa | #20562 |
| persistent | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| operative | #21137 |
| attenuated | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| 139 | #21894 |
| majority | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| adverse | #23767 |
| naive | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| commonly | #27411 |
| mass bmi | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
Bericht ausführen | |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| Bekannt für Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines |
KOL-Index: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| Bekannt für Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| Bekannt für Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range |
KOL-Index: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| Bekannt für Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized |
KOL-Index: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| Bekannt für Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors |
KOL-Index: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| Bekannt für Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| Bekannt für Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score |
KOL-Index: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| Bekannt für Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio |
KOL-Index: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| Bekannt für Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome |
KOL-Index: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| Bekannt für Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months |
KOL-Index: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| Bekannt für Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients |
KOL-Index: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| Bekannt für Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| Bekannt für Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections |
KOL-Index: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| Bekannt für Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval |
Schlüsselpersonen für Pulmonary Embolism
Top -Kols der Welt
Wählen Sie einen Suchphrase aus pulmonary embolism , pulmonary embolism patients , pulmonary embolism 95 , pulmonary embolism diagnosis , pulmonary embolism treatment
Harry Roger Büller:Expertenwirkung
Konzepte für welcheHarry Roger Büllerhat direkten Einfluss:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:KOL -Auswirkungen
Konzepte im Zusammenhang mit der Arbeit anderer Autoren, für diefor which Harry Roger Büller hat Einfluss:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
Ist das dein Profil? Fordern Sie Ihr Profil an URL kopieren Einbetten Sie den Link zu Ihrem Profil ein |